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Abstract 
 
 
Schizophrenia is a chronic illness which has severe consequences for the lives of patients and 
their families. The costs associated with treating individuals with schizophrenia are 
considerable. This thesis examined the relationship between non-adherence to medication, 
patient-, environmental- and medication-related factors and the costs associated with health 
and social care services used and the wider societal costs in treating individuals with 
schizophrenia. Analysis was undertaken of data from the 1993-4 and 2000 Psychiatric 
Morbidity Surveys and the Quality of Life following Adherence Therapy for People Disabled 
by Schizophrenia and their Carers study. 
 
An individual’s level of education, having had a recent inpatient stay and alcohol abuse were 
found to be associated with a greater likelihood of non-adherence in individuals taking 
antipsychotics. These results were not observed in analyses of individuals taking 
antidepressants. Common factors associated with non-adherence across individuals taking 
antipsychotics and antidepressants included experiencing side-effects and severity of illness. 
 
Community-based services were found to be used more by individuals with interruptions in 
their antipsychotic medication. In this group there may also be additional costs in 
hospitalisations and overall health and social care services attributable to non-adherence. 
Benefits to patients may be accrued by enabling health and social care professionals, 
particularly those working in the community, to encourage medication adherence in 
individuals with schizophrenia and to provide information on new interventions that are cost-
effective in improving adherence.    
 
National Institute of Clinical Excellence (NICE) guidelines for treating individuals with 
schizophrenia, revised in 2009, address some key findings in my analyses, such as 
emphasising the role of carers and family members in successful management of the illness, 
the potentially adverse impact that illicit drug use can have on therapeutic effects and issues 
around service provision to individuals from ethnic minorities. 
 
Further analysis of data from long-term studies is required to determine the clinical, economic 
and personal consequences of non-adherence. 
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Chapter 1 
 
Introduction 
 
 
 
 
OK. All right. Listen. 
Let me join up some of the dots for you. 
Let me do some of the maths for you: 
Schizophrenia is the worst pariah. 
One of the last great taboos... 
  
It is not treatable with glamorous and intriguing 
wonderdrugs like Prozac or Viagra. 
It isn’t newsworthy. 
It isn’t curable. 
It isn’t heroin or ecstasy. 
 
It is not the preserve of rock stars and supermodels and hip young authors... 
They make movies about junkies and alcoholics and  
gangsters and men who drink too much, fall over 
and beat their woman until bubbles come out of her 
nose but Schizophrenia my friend is just not in the phone book. 
 
Blue/Orange, Act II 
Joe Penhall, 2000 
 
 
 
 
The quote above, from the play ‘Blue/Orange’, captures many of the difficulties that surround 
schizophrenia – the lack of a cure, the stigma attached to the illness, the degree of isolation 
potentially felt by people with the illness and the unparalleled lack of understanding of the 
illness amongst the general public.  
 
Schizophrenia is a severe mental disorder, characterized by profound disruptions in thinking, 
affecting language, perception, and the sense of self. It often includes psychotic experiences, 
such as hearing voices or delusions. A recent study estimated that the number of individuals 
in England suffering from schizophrenia was over 120,000 (Mangalore and Knapp 2007). The 
World Health Organisation estimated that globally, in the year 2000, schizophrenia was the 
seventh leading cause of years-of-life lived in disability (WHO 2001). An idea of the difficult 
lives led by those with schizophrenia is further illustrated by a recent sample of individuals 
suffering from the illness in Britain. Bebbington et al (2005) found that nearly one-half had 
 12 
attempted suicide or self-harm, a third had at some point been homeless and one in seven had 
been in prison. 
 
 
1.1 Overview 
 
It is evident from research in the UK and elsewhere that the majority of people with 
schizophrenia need and use a range of health and other services, resulting in high costs to the 
public purse and (often) to others. One area that significantly impacts on costs is the 
experience of side effects and non-adherence with treatment. Antipsychotic medications have 
a high incidence of unwanted side effects associated with poor quality of life, high rates of 
non-adherence or discontinuation of therapy, and several important comorbidities. Substantial 
health care resources are used in both managing side effects and managing the consequences 
of non-adherence or discontinuation of antipsychotic medications. 
 
Weiden and Olfsen (1995) estimated that non-adherence accounts for approximately 40% of 
rehospitalisation costs for patients with schizophrenia in the two years after discharge from in-
patient treatment. Meta-analyses of data from a number of countries concluded that a 50% 
improvement in adherence would decrease one-year rehospitalisation rates by 12% (Weiden 
and Olfson 1995). Also, given that anywhere from 25% to 80% of patients at some point in 
their treatment do not adhere to their medications (Battaglia 2001; Conley and Kelly 2001), 
the system-wide costs of non-adherence could be substantial. 
 
Schizophrenia patients often require support in daily activities due to the poor personal and 
social functioning associated with the illness. Patients are likely to have difficulty in finding 
and holding onto jobs. This also has implications for their families and society at large, as 
they will be called upon to support patients. Other societal costs accrue from the lost 
productivity of schizophrenia patients and criminal justice costs associated with violent 
behaviours that may result from the condition. 
 
So in addition to the clinical and quality of life effects attributable to non-adherence, there are 
substantial resource implications in the form of higher service use levels and costs that result 
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from non-adherence. Interventions that are successful in reducing non-adherence rates, 
including new medications, will have considerable benefit for patients, their families, and the 
health and social care systems. To date, the majority of pharmaceutical, psychological therapy 
and psychosocial interventions have been judged based on the degree to which they improve 
adherence without consideration of their cost-effectiveness (Zygmunt, Olfson et al. 2002).  
Healey et al (1998) conducted a cost-effectiveness evaluation of adherence therapy and 
included health, social care and criminal justice costs in their analyses, but this study was 
limited by a small sample size at the end-point of the study as a result of sample attrition. 
Hughes et al (2001) highlight the need for more information on the cost consequences of non-
adherence to allow economic evaluations to reflect its potential impact. Additionally, 
evaluations of interventions that may have an impact on non-adherence require a period of 
observation long enough to allow for adequate assessments of their influence on adherence 
rates. 
 
This thesis aims to establish factors that contribute to non-adherence in schizophrenia, 
examine the pattern of health care service use associated with non-adherence and estimate the 
costs associated with non-adherence. Patterns of service use will be established to determine 
the impact of non-adherence on resource use and costs. Factors that may impact on the 
patient's experience include the type of medication prescribed, the type of residential 
accommodation, general health status, type of family unit, or demographic factors such as 
age, sex and ethnicity. 
 
 
1.2 Schizophrenia – prevalence and quality of life 
 
In 1896, Emil Kraepelin established a classification of mental disorders, one of which was 
dementia  praecox  (Pull 2002). This illness was given the name schizophrenia by Eugen Bleuler 
who emphasized the presence of a dissociation of mental functions as the essential characteristic 
of the illness. The aetiology of schizophrenia is complex with biological, psychological and social 
factors all thought to play a role in the onset of illness. Genetics are thought to be the most 
significant factor in the development of the illness, accounting for approximately 80% of risk of 
onset (Gelder, Harrison et al. 2006). Environmental factors, some of which are experienced 
prenatally and interact with genetic factors, are also important. Examples of social and 
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psychosocial factors that may contribute to the onset of schizophrenia are migration, social 
isolation and stressful life events (Gelder, Harrison et al. 2006). 
 
The relationship between the genes present in people diagnosed with schizophrenia and their 
development of the illness is not fully understood. It is understood that the illness cannot be 
attributed to a single gene, although it is not clear if schizophrenia arises from the cumulative 
effect of several genes or if there are a range of disorders of different genetic makeup that fit 
within the diagnostic category of schizophrenia (Gelder, Harrison et al. 2006).  
 
Schizophrenia is a severe disorder. Behaviour may be seriously disturbed during some phases 
of the disorder, leading to adverse social consequences. In the acute phase of the illness, 
characteristic symptoms include delusions (strong belief in ideas that are false and without 
any basis in reality), hallucinations, fundamental distortions in thinking and perception, and 
inappropriate emotions (WHO 2001). These are referred to as positive symptoms. Some 
patients recover from acute illness, while others will progress to chronic schizophrenia. 
During the chronic phase of the illness, negative symptoms appear. The most common 
negative symptoms are social withdrawal, underactivity, lack of conversation, few leisure 
interests and slowness (Creer and Wing 1975). Once chronic schizophrenia is established, full 
recovery is extremely unlikely. Other characteristics are disorders of thought and speech, 
disorders of behaviour, disturbance of emotions and affect, and cognitive deficits (Pull 2002).  
 
In a 14-country study on disability associated with physical and mental conditions, active 
psychosis was ranked the third most disabling condition, higher than paraplegia and blindness 
(Üstün and Sartorius 1995). Studies that have followed patients over a long period of time 
suggest that a minority of patients achieve full recovery, whereas 10-17% required sheltered 
care and approximately 40% had poor outcome in terms of social adjustment (Gelder, 
Harrison et al. 2006). Notably, an estimated 30% of patients diagnosed with schizophrenia 
attempt suicide at least once during their lifetime (Radomsky, Haas et al. 1999). 
 
Because it is a chronic illness, the prevalence of schizophrenia greatly exceeds the incidence. 
Based on relatively broad diagnostic criterion, the annual incidence of schizophrenia is 
between 0.16 and 0.54 per 1000 population, while the prevalence is estimated to be between 
1.4 and 4.6 per 1,000 population (Jablensky 2003). This prevalence range is observed across 
countries (Gelder, Harrison et al. 2006). Schizophrenia typically begins in late adolescence or 
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early adulthood. In a study of the age, beginning and course of the illness, the first psychotic 
episode began before the age of 30 in 63% of cases (Hafner, Maurer et al. 1993). 
 
There are important gender differences in the incidence, age of onset and severity of 
schizophrenia as well as differences in the effects of treatment. The incidence of 
schizophrenia is higher in men than it is in women and women have a later mean age of onset 
than men (Aleman, Kahn et al. 2003). Fewer women present with the illness between the ages 
of 15 and 29 as compared to men and a substantial number of women present with 
schizophrenia in their fifties. There is also evidence to suggest that men experience more 
severe illness (Aleman, Kahn et al. 2003), and that antipsychotic medications pose more risks 
for woman than men (Wieck and Haddad 2003).    
 
 
1.3 The cost of schizophrenia 
 
The total identified cost of schizophrenia in England was estimated at £6.7 billion in 2004/5 
(Mangalore and Knapp 2007). This is significantly greater than a 1997 estimate of annual UK 
costs of £2.6 billion (Knapp 1997). Mangalore and Knapp (2007) estimate that in 2004/5, the 
cost of schizophrenia in England separated into direct costs of £2 billion and indirect costs of 
£4.7 billion. The World Health Organisation (2004) estimated that in 2002 the sum of years of 
life lost due to premature death and the years lost due to disability attributable to 
schizophrenia in the UK was 85,000 years. 
 
The average annual health and social care (including medications) cost of treating and 
supporting a schizophrenia patient in the UK has been estimated for 2004/5 at approximately 
£39,000 and the average annual societal cost at £54,600 (Mangalore and Knapp 2007).  A 
census-based study in four metropolitan areas in Australia, conducted in 1997-1998, 
estimated the average, per patient, annual societal cost of schizophrenia to be AUS$51,600 
(Carr, Neil et al. 2003). The estimated average annual societal cost of schizo-affective 
disorder was AUS$ 47,900. Based on data collected between 1997 and 2003 in the US, Zhu et 
al (2008) estimate the average annual medical costs for a patient with schizophrenia to be 
US$16,100.  
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Typically, in the UK as elsewhere, in-patient hospital services and community-based 
(specialist) residential care account for over 70% of direct costs. Curtis (2008) estimated that 
for a patient with mental illness the UK daily cost of an inpatient stay in an acute NHS 
psychiatric ward is £219 and in a long-stay NHS hospital ward is £201. The shift towards care 
in the community has also led to increases in demand for treatment, care and support services 
that previously would have been provided in long-stay psychiatric hospitals (Pederson and 
Leese 1997). 
 
The shift towards community-based care has many facets. Crisis Resolution services, for 
example, provide individuals with serious mental illness who are at risk of requiring 
psychiatric hospitalisation with flexible, home-based care. Crisis Resolution Teams have been 
shown to reduce admissions and costs (Johnson, Nolan et al. 2005; Glover, Arts et al. 2006; 
McCrone, Johnson et al. 2009). Assertive Outreach teams work to keep people in contact with 
services and support people to continue with their treatment. Early Intervention teams support 
people intensively in the early phases of their illness. Generic Community Mental Health 
Teams, another service model providing community mental health care, are composed of 
professionals from a wide range of disciplines, who provide effective local mental health 
services primarily for people who use services whose illness is chronic and severe.   
 
Another important cost in treating patients with schizophrenia is the cost of medications. 
Gilmer et al (2004) estimated the average annual cost of prescribing among 15,962 Medicaid 
beneficiaries to be US$5,200 in 2004, up 27% from US$ 4,100 in 1999.  
 
Schizophrenia patients often require support in daily activities due to the poor personal and 
social functioning associated with the illness. Patients are likely to have difficulty in finding 
and holding onto jobs. Marwaha et al (2007), in a study of people with schizophrenia across 
the UK, France and Germany, observed unemployment rates of 87%, 89% and 70% 
respectively. The authors compared these rates to the rates of unemployment in the general 
population at the same point in time: 29% in the UK, 38% in France and 35% in Germany. 
Factors contributing to low rates of employment include low educational attainment, 
employers’ negative attitudes about people with mental health problems and self-stigmatising 
behaviour. The high rate of unemployment among patients with schizophrenia also has 
implications for their families and society at large, as they will be called upon to provide 
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informal care to patients. Lost productivity and costs incurred within the criminal justice 
system are other significant costs associated with the condition.  
 
In relation to their treatment, patients with schizophrenia will experience side effects and are 
likely at some point to not adhere with their recommended treatment. Antipsychotic 
medications have a very high incidence of unwanted side effects associated with poor quality 
of life, high rates of non-adherence or discontinuation of therapy, and several important 
comorbidities. Additionally, the lack of insight and cognitive impairment that are symptoms 
of the illness may lead to poor medication adherence by patients. Substantial health care 
resources are used in both managing side effects and managing the consequences of non-
adherence or discontinuation of antipsychotic medications.  
 
 
1.4 Adherence 
 
1.4.1 Definition and context 
 
The term ‘compliance’ has been defined as ‘the extent to which a person’s behaviour 
coincides with medical or health advice’ (Haynes 1979) or ‘the degree of conformity between 
treatment behaviour and treatment standards’ (Gaebel 1997). The first of these definitions 
suggests a degree of paternalism on the part of the clinician, whereas the latter, more recent 
definition, acknowledges the role of the patient in treatment decisions (Myers and Midence 
1998). The greater use of the term ‘adherence’, instead of ‘compliance’ also reflects current 
thinking of less paternalism in treatment decisions. The term adherence is used in this thesis. 
 
Non-adherence can refer to medication, to a therapy or to services (Kuipers 1996). As it 
relates in medicines, non-adherence covers a range of rates of missing medication across 
individuals. Some patients may only miss a few dosages while others may consistently not 
take their medication as prescribed. Non-adherence can also be classified as relating to (a) 
failure to fill a prescription; (b) filling the prescription but failing to take the medication; (c) 
taking only a portion of the prescription; and (d) not following the frequency or dose 
instruction of the prescription (Buckalew and Sallis 1986).  
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Across illnesses, non-adherence to medication is estimated to account for 135,000 deaths in 
the US per year (Peterson, Takiya et al. 2003). 
 
Little is known about attitudes of schizophrenia patients towards their medications. The 
definitions of compliance and adherence given above appear to take a clinical perspective on 
patient’s behaviour towards their treatment. But what are the perceptions of patients? Kuipers 
(1996) suggests that patients may choose to not adhere to treatment because their perception 
or experience is that it is inappropriate or inaccessible. It would be desirable to obtain more 
information from patients as to the reasons why they do or do not adhere to their medications. 
Some discussion is warranted of how patients’ feel about their medications, their 
understanding of their treatment, and the extent to which they feel committed to their 
treatment. This perception is particularly important in schizophrenia as, because of the 
chronic nature of the illness, patients are often on medication on a long-term basis 
(Fleischhacker 2002). In this thesis, the assumption is made that non-adherence takes place 
only after patients initially agree to the prescribing of medication to alleviate their symptoms 
associated with the illness. 
 
1.4.2 Theoretical models 
 
In a chapter of the book ‘Patient Treatment Adherence’ edited by Bosworth, Oddone and 
Weinberger, Bowsorth and Voils (2008) present several theoretical models that have been 
identified to try to understand treatment adherence. These include Locus of Control Theories, 
Theory of Reasoned Action, Protection Motivation Theory, the Health Belief Model and the 
Transtheoretical Model. Discussion of these models has sought to describe their application to 
a variety of health behaviours. These may be relating to preventative behaviours such as 
breast self-examination, smoking cessation or exercise adherence, to behaviours during 
treatment, such as medication adherence and behavioural changes sought through 
interventions to improve adherence. Discussion of theoretical models also covers the various 
stages of treatment: from seeking and accepting treatment, to starting and maintaining 
treatment. For the most part, the application of theoretical models in this area has focussed on 
the understanding of preventive behaviours and the initiation of treatment. There exists less 
understanding of the maintenance phase of treatment. 
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Rotter’s and Wallston’s The Locus of Control Theories 
 
Rotter sets out that there are internal and external dimensions to locus of control. Internal 
locus of control is the degree to which an individual perceives that reinforcement is 
contingent on one’s behaviour. External locus of control is based on believing that 
reinforcement is contingent on outside forces such as luck or fate. Wallstron expanded on 
these concepts by distinguishing external locus of control beliefs which stem from relying on 
powerful others, such as a physician, as opposed to unknown external forces. Locus of control 
theories suggest that individuals with good internal locus of control are more likely to adhere 
to their medical treatment. An individual who believes that by taking their medication as 
prescribed they will get better is more likely to adhere. 
 
 
Social Learning Theory and self-efficacy 
 
Bandura’s concept of Social Learning Theory is also based around expectations. This theory 
postulates that human behaviour is determined by expectancies and incentives (Bandura 1977; 
Bandura 1986). Three main categories of expectancies are described as expectancies about 
environmental cues, expectancies about the consequences of one’s own actions and 
expectancies about one’s ability to achieve a desired outcome. The last of these is termed self-
efficacy, and suggests that behaviour is based on both an individual’s belief in their ability to 
perform the behaviour and their opinion of the likely outcomes of the behaviour. The value 
which the individual places on the desired outcome determines the incentive. 
 
Self-efficacy relates well to medical adherence in that if a patient feels that what is asked of 
them in managing their health condition is not outside of their ability, they will follow that 
behaviour as directed. The role of expectation on remaining adherent to medication is, 
however, less applicable. It is likely that any patient will perceive there to be little difficulty in 
taking medications. Non-adherence to medication is likely to occur as a result of experiencing 
side-effects or the patient feeling like they no longer require the medication. In these cases, it 
is in improving adherence that these concepts can be applied, such as in explaining the 
consequences of missed dosages. 
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The Theory of Reasoned Action/Theory of Planned Behaviour 
 
The Theory of Reasoned Action suggests that attitude towards a behaviour and the perception 
of how others feel about the behaviour will predict whether or not an individual will follow 
the behaviour. The Theory of Planned Behaviour adds the notion that perception of control 
over performing a behaviour not only predicts behavioural intention, but will also predict 
whether or not they actually perform the behaviour. This relates to self-efficacy. The 
difficulties cited in applying this theory to medical behaviour relate to its inability to explain 
and account for changes in behaviour over time and the possible divergence between 
intentions and actual behaviour. It has been found that the type of behaviour and cognitive 
and personality variables affect the level of consistency between intentions and actual 
behaviour. By introducing implementation intentions, in effect cues to help determine when, 
where and how a behaviour is to be performed, can assist in improving adherence. For 
example, a patient could be told to take their medication each day with their evening meal to 
help create a pattern for completing the behaviour of medication taking. 
 
 
Protection Motivation Theory 
 
The Protection Motivation Theory relates to decision making in the face of health threats. The 
theory suggests that an individual will follow a prescribed behaviour if they are susceptible to 
a threat, the threat is severe and the individual is fearful of the threat. This theory is 
particularly relevant in encouraging preventative behaviours, such as condom use, and in 
medication adherence where physicians can highlight the deleterious consequences of non-
adherence.  
 
 
The Health Belief Model 
 
The Health Belief Model suggests that personal beliefs and perceived susceptibility, severity, 
benefits and barriers all combine to determine health behaviours (Rosenstock 1966). 
Susceptibility refers to the subjective perception of personal vulnerability to a particular 
health problem. Severity is the subjective perception of severity or dangerousness of a health 
problem and its effects. Benefits are the perceived effectiveness of a range of interventions to 
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treat the health problem and barriers are the perceived negative aspects of a particular action 
taken to reduce or eliminate the health problem. These beliefs are thought to be determined by 
demographic factors and psychological characteristics. The model is most relevant to the 
context of adopting preventing behaviours and stopping harmful behaviours. 
 
Bosworth and Voil’s (2008) review found no evidence that the health belief model has 
predictive validity in relation to medication adherence. There are studies, however, which do 
suggest a correlation between dimensions of the health belief model and adherence in 
schizophrenia. Budd et al (1996) found an association between beliefs around susceptibility 
and adherence status. That is, those who did adhere to medication perceived themselves to be 
more susceptible to relapse than non-adherers. Adams and Scott (2000) reported that 
perceived severity of illness and perceived benefits of treatment explained 43% of the 
variation in adherence behaviour. 
 
 
The Self-Regulatory Model of Illness 
 
This model is similar in concepts to those of the self-efficacy model. In a health behaviour 
context, the model defines there to be three stages of self-regulation: representation of the 
illness, development and implementation of a plan to cope with the illness and evaluation of 
the coping mechanism. Individuals are thought to move from one stage to another, in no 
particular direction. For example, an individual may have a coping mechanism, evaluate it to 
be ineffective and therefore move back to the stage of development and implementation of a 
new plan to cope with their illness. This model relates well to acute illnesses, where a 
cognitive response to a threat to adherence is likely, but does not well explain sustained 
behaviour in chronic diseases where immediate threats of impact on health are not 
immediately experienced (for example, hypertension).  
 
 
The Transtheoretical Model and the Precaution Adoption Model 
 
The Transtheoretical and Precaution Adoption models define stages of behavioural changes. 
The maintenance stage is only one stage of these. The advantage of these stages is in 
understanding that the different stages of behavioural change differ significantly. For example 
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the factors that encourage a patient to begin to follow a prescribed behaviour may be very 
different from those that encourage maintaining the behaviour in the long term. These models 
assert that intervention to promote a behaviour should be specific to the stage the individual is 
in. 
 
 
The Self-Medication Hypothesis 
 
The Self-Medication Hypothesis states that patients decide to start, adjust or stop prescribed 
medication according to perceived health needs and that such decisions are conducted 
intentionally and rationally, given the information available to the patients and their 
understanding of their condition (Mitchell 2007). Mitchell (2007) asserts that there is 
evidence that patients with a mental illness do interrupt or stop medication both intentionally 
and unintentionally, based largely on how they are feeling, which partly supports the self-
medication hypothesis. 
 
It is difficult to assess these theories in empirical analysis. One noted deficit of research of 
adherence in patients with schizophrenia is that the developmental process of decision relating 
to medication taking is not taken into account (Marland and Cash 2005). Alternative 
approaches to understating medication taking have been suggested. Demyttenaere (1997) 
discusses the relevance of considering a medical psychology approach to understand why 
each individual patient, with his or her specific symptoms, relational context and therapeutic 
alliance is or is not adherent. Within this approach, the theory of constraints asks the question 
‘what constrains this patient from more effectively managing his or her condition?’ 
 
Weiden (2007) suggests a similar approach in defining a more flexible approach to adherence 
theory that is more applicable to clinical practice. He suggests five theories regarding 
medication adherence in patients with schizophrenia. These are: 
(1) Adherence is not a clinical outcome and only matters as it interferes with outcome 
(2) Adherence problems are often entangled with efficacy limitations of antipsychotic 
medications 
(3) Adherence can be viewed as a behaviour (taking/not taking) or as an attitude (prefers 
taking/prefers stopping medication) 
(4) When considering adherence attitudes, patient beliefs are always reality 
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(5) Adherence behaviour changes and fluctuates over time and should be considered part 
of the illness. 
 
The ambiguity arising from the application of these theories can be illustrated by considering 
responses to the third of these theorems. If adherence is viewed as a behaviour, approaches to 
improve adherence should address whatever logistic problems prevent patients from taking 
their medications as prescribed. On the other hand, if adherence is viewed as an attitude, their 
physician must seek ways to educate and convince the patient of the benefits of their 
medication. As described by Weiden, non-adherence to medication in schizophrenia typically 
is not both behavioural and attitudinal. 
 
The theoretical models discussed set out to understand the factors that explain adherence-
related behaviours. These cover a range of adherent behaviours from preventative behaviours 
to adherence during the maintenance phase of treatment in chronic illnesses and responses to 
improve adherence. These models have led to successful strategies, primarily in the area of 
eliciting healthy behaviours. But these changes in behaviours are often not maintained. 
Models which further focus on the understanding the behavioural responses to being in the 
maintenance phase of prescribed medications in chronic diseases are needed. Such models 
will encourage the development of strategies of intervening to prevent maintenance phase 
non-adherence before it occurs.  
 
1.4.3 Prevalence of non-adherence in schizophrenia 
 
Higher rates of non-adherence are likely in chronic diseases, such as schizophrenia, where 
medication may be required to be taken indefinitely. Comparing non-adherence rates across 
studies is difficult due to the range of methods used. For example, Cramer and Rosenheck 
(1998) reviewed 24 studies in which the methods used to assess non-adherence included 
patient interview, clinical assessment, urine or blood markers and pill counts, and found non-
adherence to range from 10 to 76%. The mean rate of non-adherence across these studies was 
42%. Fenton et al (1997) reviewed 15 studies published between 1983 and 1996 which ranged 
in the period over which they assessed non-adherence from one month to two years. They 
found non-adherence to range from 24 to 88% with a median of 55%. A review by Lacro 
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(2002) found rates of non-adherence ranging from 4% to 72% with a mean of 41%. This 
review is described in greater detail later in this chapter in an overview of factors associated 
with non-adherence. 
 
The use of depot injections of antipsychotics to reduce rates of non-adherence does not 
eliminate the problem of non-adherence. A study by Kane (1996) found that one in five 
patients relapsed when receiving long-acting depot injections. A meta-review of depot 
antipsychotic drugs, based on studies observing in-patients and patients in the community, 
found no statistically significant difference in relapse, attrition and adverse effects between 
depot antipsychotics and oral antipsychotics (Adams, Fenton et al. 2001). This, however, may 
be due to the fact that those patients participating in trials were required to be reasonably 
compliant with oral medications, and thus the benefits of depot medications may be 
underestimated as compared to studies that included patients likely to be non-adherent to oral 
antipsychotics.  
 
The rates of non-adherence in other chronic diseases are comparable to those observed in 
schizophrenia. A mid 1990s study found that drugs for hypertension are discontinued within 
six months by approximately 55% of patients in the UK (Jones, Gorkin et al. 1995). Non-
adherence rates for medication for rheumatoid arthritis have been estimated as being 64%, 
with 24% of these being consistently non-adherent (Viller, Guillemin et al. 1999). Briesacher 
et al (2008) recently reviewed US health care claims data to compare the rates of adherence 
across seven conditions. They found that, based on the sum of each day’s supply of 
medications, the rate at which patients missed 20% or more of their medication was 30% for 
patients with hypertension, 50% for those with osteoporosis and 40% for those with type 2 
diabetes. Non-adherence rates of between 0-60% have been found in a review of studies of 
adherence in patients with rheumatoid arthritis (Harrold and Andrade 2008). For patients 
taking antibiotics, a 50% non-adherence rate has been reported (Ley and Llewellyn 1994). 
Rates of non-adherence vary widely in depression, likely in part because the illness can be 
present over a short or long term. Recent evidence estimates the six month non-adherence rate 
of patients taking SSRIs to be approximately 40-60% (Nemeroff 2003; Sheehan, Eaddy et al. 
2005; Cantrell, Eaddy et al. 2006). 
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1.5 Factors associated with non-adherence  
 
Several factors are thought to contribute to non-adherence in patients with schizophrenia. For 
example, the type of medication is thought to be important due to differences in the nature of 
side effects associated with each. The older generation of antipsychotic medications, the so-
called ’typicals’, elicit the following side effects: Parkinsonian side effects (including tremor, 
hypersalivation), akinesia (slowing of movements), acute dystonic reactions (characterised by 
dramatic muscle spasms), akatgusua (characterised by an inner subjective restlessness), 
tardive dyskinesia (a movement disorder), anticholinergic side effects (including dry mouth 
and constipation), diminished sexual function and weight gain (Bentall, Day et al. 1996). The 
newer antipsychotic medications reduce neurological problems commonly experienced with 
typicals, but many of the other side effects, such as weight gain and sedation are common to 
both classes of antipsychotics (Fleischhacker 2002). 
 
Fenton et al (1997) categorise the range of factors affecting adherence into patient-related, 
medication-related, environmental factors, and psychodynamic considerations. They identify 
patient-related factors as: demographic characteristics such as gender and ethnicity, illness 
characteristics such as age at onset and duration of illness, illness severity and subtype (e.g. 
paranoid schizophrenia), cognition or memory, insight, other health beliefs (i.e. attitudes 
towards medication), subjective well-being, and alcohol and drug use. The medication-related 
factors reviewed were side effects, dosage, agent, route, and complexity of regimen. 
Environment factors considered were: family and social support, practical barriers (e.g. 
financial burden prevented patient from filling prescription), physician-patient relationship, 
attitude of staff, interventions, reinforcement, education, and memory enhancement. 
Psychodynamic considerations include: psychological meaning (e.g. feelings about the role of 
authority and control in the prescribing of medications), psychological homeostasis (e.g. 
relationship between delusions and self-image), and transference/countertransference (i.e. 
attitudes towards the prescriber as an authoritarian figure).  
 
There is uncertainty as to the impact that cognitive impairment, a symptom of psychotic 
illness, may play in non-adherence in patients with schizophrenia (Buchanan 1996). 
Pinikahana (2005) points out that non-adherence rates with medicines for general medical 
conditions such as diabetes and arthritis, and antibiotics, which do not impair cognitive 
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function, have similar rates of non-adherence as those observed in patients with 
schizophrenia. 
 
To identify previous empirical studies assessing factors associated with adherence, structured 
searches in MEDLINE and PsychInfo were run using the search terms ‘(antipsychotic or 
psychosis or psychotic) and (adherence or compliance)’ to identify relevant empirical studies. 
The initial search was restricted to studies published in 2000 or later. Other studies were 
identified by reviewing the references from an initial selection of studies. The literature search 
identified five reviews. Empirical studies identified by the search and included in one of the 
reviews were not considered on their own so as to avoid double counting. The search 
identified 43 empirical studies in addition to the four reviews. From each of the identified 
studies, information was extracted on the date, location, sample size, sample characteristics 
(whether patients were inpatients, outpatients or both; and whether they had experienced 
psychosis or diagnosed as schizophrenic), method of assessing non-adherence, factors found 
to be significantly associated with non-adherence, and factors found not to be associated with 
non-adherence. The factors included in the empirical analyses are based on these variables 
previously considered in this literature. These studies are listed in appendix 1. 
 
1.5.1 Heterogeneity of methods 
 
The samples under observation across the studies differed along several dimensions. In 
particular, treatment settings, diagnoses, method of non-adherence assessment, and the length 
of time over which non-adherence was assessed differed across studies. A majority of the 
studies sampled patients with schizophrenia and schizophrenia-related illnesses. The 
remainder, along with the reviews, defined their samples more broadly, by looking at patients 
with psychosis.  
 
The length of time over which adherence status was assessed in the previous studies ranged 
from one month to five years. Assessment of non-adherence was by a range of methods: self-
report, medical records, and clinical assessment. As in the Psychiatric Morbidity Surveys 
(PMS), which I use later in this thesis to support new empirical analyses, in 11 of the 43 
empirical studies, the assessment of adherence relied exclusively on self-reported information. 
In a further fourteen, self-reported information was combined with the opinions of a family 
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member, a treating physician or a case-manager. Additional information may be helpful, but 
may also be problematic. Kampman et al (2001) found only a 0.50 correlation in adherence 
assessments between patients and doctors. Also, the investment in finding a successful 
treatment may bias the opinion of physicians (Diaz, Levine et al. 2001).  
 
It would appear that few studies corroborate self-reported adherence with pill counts or 
physiological data (Zygmunt, Olfson et al. 2002). These methods were used in only five of the 
40 empirical studies reviewed. All measures of adherence have their drawbacks (Thompson, 
Kulkarni et al. 2000; Coldham, Addington et al. 2002; Osterberg and Blaschke 2005), but 
only self-report will be feasible in a large scale survey. The methods used in empirical 
analysis of the factors associated with non-adherence in patients taking antipsychotics are 
discussed in more detail in the following chapter. 
 
The heterogeneity of results from previous studies may also be due to changes in treatment 
regimes across time and location. The newer atypical antipsychotics have been shown to be 
associated with different profiles of side-effects (Geddes, Freemantle et al. 2000), and this 
may influence the association between side effects and non-adherence. A trend towards lower 
non-adherence in patients receiving atypical medications has been observed elsewhere 
(Olfson, Mechanic et al. 2000; Sartorius, Fleischhacker et al. 2002). Chapter 3 of this thesis 
examines trends in prescribing in schizophrenia in greater detail.  
 
1.5.2 Summary of findings 
 
The literature search yielded five reviews of studies empirically assessing factors potentially 
associated with non-adherence (see Table 1.1; (Fenton, Blyler et al. 1997; Kampman and 
Lehtinen 1999; Lacro, Dunn et al. 2002; Nose, Barbui C et al. 2003; Voruganti, Baker et al. 
2008). The studies were published between 1997 and 2008. The method by which the authors 
of the reviews attributed significance to factors based on the results across the studies differed 
markedly. For example, Lacro et al (2002) determined the key factors to be those identified as 
being statistically significant in 50% or more of the studies included in the review. Voruganti 
et al (2008) on the other hand, did not explicitly state their criteria for assessing the balance of 
evidence on the influence of factors on non-adherence but appear to base this on significance 
observed in the vast majority of the studies included in their review.  
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Despite the limitations in comparing assessments across the reviews, the findings do reveal 
some consistencies (Table 1.1). Drug and/or alcohol abuse and lack of insight were identified 
as key factors in four of the five reviews. In the one review where lack of insight was not 
mentioned, patient attitudes and beliefs, which may be comparable to lack of insight, was 
deemed to be significantly associated with non-adherence. In three of the five  
reviews symptom severity was identified as a key factor in association with non-adherence to 
medication. 
 
Unlike the evidence reviewed by Voruganti et al (2008) there is some evidence of a greater 
risk of non-adherence with typicals relative to atypicals. The evidence, however, is not 
unanimous. This may be due to the fact that the range of experience of side effects within 
medication type may also differ. Olfson et al (2000) report improved adherence within three 
months of discharge for those patients prescribed an atypical antipsychotic, though other 
evidence that looked at adherence over the previous year did not show this relationship. A US 
study by Dolder et al (2002) compared non-adherence rates in haloperidal and perphenazine 
(typicals) with risperidone, olanzapine and quetiapine (atypicals) over a 12 month period and 
found no significant associations between non-adherence and type of antipsychotic or 
between adherence and age, gender, ethnicity or diagnosis. A study conducted in Spain 
comparing olanzapine (an atypical) with risperidone (an atypical) and haloperidol (a typical) 
found that non-adherence, as measured subjectively by the treating psychiatrist, was 
significantly lower in patients taking olanzapine relative to risperidone and haloperidal 
(Garcia-Cabeza, Gomez et al. 2001). 
 
A large US study of Medicaid recipients in Florida found that the class of antipsychotic, age, 
sex, ethnicity and substance misuse were all associated with adherence rates over a 2-year 
period (Becker, Young et al. 2007). Those prescribed atypical antipsychotics were found to 
have higher adherence rates as compared to those patients prescribed typical antipsychotics. 
Higher rates of adherence were observed amongst patients in the higher age groups, and 
among men, those of White ethnicity and those without co-occurring substance misuse.  
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Table 1.1: Factors associated with non-adherence – Reviews identified in literature search. ‘+’ denotes positive 
relationship; ‘-‘ denotes negative relationship; and ‘ns’ denotes not deemed significant as defined by study 
authors 
 
 
 
 
Factors 
Fenton 
 et al., 1997 
Kampman et 
al., 1999 
Lacro et al., 
2002 
Nose et al., 
2003 
Voruganti et 
al., 2008 
Not stated 15 studies 10 studies 103 studies 7 studies 
Age Ns  ns -  
Sex: Male Ns  ns +  
Drug and/or 
Alcohol abuse 
 
+ 
 
+ 
 
+ 
 
+ 
 
Unemployed    +  
Income Ns     
Education Ns  ns -  
Ethnicity Ns  ns   
Lack of insight  
+ 
 
+ 
 
+ 
 
+ 
 
Married or 
family support 
 
 
+ ns +  
Side effects + +    
Typical vs 
atypical meds 
    ns 
Low social 
functioning 
   +  
Cognitive 
impairment 
 ns    
Poor therapeutic 
alliance 
  + +  
Attitudes/beliefs     + 
Cost     + 
Life events     + 
Symptom 
severity 
 
+ 
 
+ 
  
+ 
 
Medication 
dosage 
 
+ 
 
 
 
+ 
  
Duration of 
illness 
   
- 
  
Inadequate 
discharge 
planning 
   
+ 
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A recent study in Brazil, utilising structured and semi-structured survey questions, asked 
patients to identify the motivations for their medication-taking behaviour (Rosa, Marcolin et 
al. 2005). The authors used the Rating of Medication Influences scale to assess the 
backgrounds of patients and their attitudes towards their medications. The main reason for 
maintaining adherence to medication was ‘perceived day-to-day benefit’. This was identified 
by 88% of patients. Forty percent of patients felt there was no reason for non-adherence, 
while ‘inconvenience of side-effects’ was identified by 36% of patients. 
 
A novel study by Marland and Cash (2005) used qualitative methods to get at the reasons why 
patients with schizophrenia did not adhere to medication. They found that medication taking 
decision-making in schizophrenia is not unique, though there may be particular difficulties 
associated with the illness that make it difficult for patients to progress through 
developmental patterns to a perceived optimum position which balances the benefits and 
disadvantages of medicine taking. These stages may include the ‘experimental-reflective’ 
stage which involves patients experimenting to optimize the balance between quality of life 
and the consequences of medication taking; and the ‘direct-reactive decision making’ stage 
which is reflected by difficulty linking discontinuation of medication with its consequences. 
Patients may also be ‘deferential-compliant decision makers’. These patients defer decisions 
about medication taking to their physician and will do whatever their physician tells them is 
best. Results suggest that adherence is more strongly established for those patients who go 
through the ‘experimental-reflective stage’ as compared to those whose decision making is 
‘deferential-compliant’. Further, the authors found that schizophrenia patients who experience 
a ‘direct-reactive’ stage will do so for a longer period of time as compared to patients with 
asthma or epilepsy. This may be due to the delay in the onset of adverse consequences of non-
adherence and/or impaired cognitive insight which is characteristic of schizophrenia. 
  
Rummel-Kluge et al (2008), while not conducting empirical analysis considering how factors 
associated with non-adherence interacted with each other, did conduct a large survey of 
psychiatrists in Germany to determine the factors they thought most related to non-adherence. 
A total of 669 psychiatrists participated. Each was asked to evaluate the compliance in ten 
consecutive patients over a ten day period. Due to some of the psychiatrists not completing 
the survey for a full ten patients, a total of 5,729 patients were assessed in the survey. The 
psychiatrists judged a lack of insight into the need for prophylactic medication, a lack of 
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insight/denial of illness and embarrassment at taking medication every day to be the factors 
most strongly contributing to non-adherence. 
 
 
1.6 The economic impact of non-adherence 
 
In addition to the clinical and quality of life effects attributable to non-adherence, there are 
substantial resource implications in the form of higher service use levels and costs that result 
from non-adherence. To assess the evidence relating to costs attributable to non-adherence in 
patients with schizophrenia, a search of PubMed was conducted using the medical subject 
headings ‘patient compliance’, ‘schizophrenia’ and ‘cost or cost analysis’. The search 
identified 26 studies. A search of PsychINFO within the Bath Information and Data Services 
using the search terms ‘(‘cost’ OR ‘cost analysis’) AND (‘adherence’ OR ‘compliance’) AND 
(‘schizophrenia’ or ‘antipsychotic’)’ identified a further 26 studies. The criteria for inclusion 
of studies in this review were that a study (i) either attempted to approximate the cost of 
services or resource use, or reviewed studies that did; and (ii) undertook an evaluation of the 
impact of non-adherence on the cost of services or use of services. These criteria identified 
eight relevant studies. 
 
Weiden and Olfsen (1995) estimated that non-adherence accounts for approximately 40% of 
rehospitalisation costs for patients with schizophrenia in the two years after discharge from in-
patient treatment. Meta-analyses of data from a number of countries concluded that a 50% 
improvement in adherence would decrease one-year rehospitalisation rates by 12%. The 
authors based their analysis on data from the US National Institute of Mental Health 1986 
Client/Patient Sample Survey and published estimates of the rate of non-adherence reported in 
published prospective studies. Their analysis included an estimate of the hospital cost burden 
resulting from non-adherence. This cost was estimated at US$705 million in the first two 
years following discharge from hospital for an acute schizophrenia admission.  
 
Loosbrock et al (2003) used an US employer claims database to compare the costs of patients 
with continuous antipsychotic treatment to those who had gaps in medication over the course 
of a year. Patients with gaps in medication of less than two weeks over the course of the year 
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had significantly lower costs than those with less than 250-days exposure to antipsychotic 
medication during the year. 
 
A study by Svarstad et al (2001) based non-adherence assessment on whether or not patients 
picked up their prescribed medication at a pharmacy. They observed that those patients 
deemed to be have irregular medication use had approximately US$1,700 higher mean annual 
hospital costs than the regular medication users. This difference was statistically significant.  
 
A significance association between non-adherence and direct medical costs was also observed 
by Glazer and Ereshefsky (1996). They used published estimates and clinical experiences 
judgements of non-adherence rates to compare various antipsychotic medications in the 
outcome of costs associated with relapse. 
  
Theida et al (2003) performed a review that sought to identify studies that looked at 
compliance, relapse, and economic costs. Their review identified five studies that ‘either 
estimated the direct cost-benefit from improved levels of drug compliance in schizophrenia or 
attempted to bring explicit measures of compliance levels into an overall economic 
consideration of antipsychotic drug therapy’. Two of the five studies they identified were not 
picked up by the search performed for this thesis. However, neither of these studies explicitly 
considered the effect of non-adherence on costs. A US based study by Palmer et al (1998) 
considered discontinuation of medicine due to adverse effects or a lack of response, while 
Davies et al (1998) considered dropout rates as a proxy for non-adherence. 
 
A large US-based study by Weiden et al (2004) observed that measures of partial adherence 
suggested that there is a direct link between the proportion of medication missed and the 
probability of rehospitalisation in a sample of patients with schizophrenia. They found that 
even gaps in medication taking of 1 to 10 days over a one year period were associated with 
twice the odds of hospitalisation. Their analysis indicated that the greater the level of non-
adherence along a continuum, the greater the risk of rehospitalisation. These results were 
consistent across methods of assessment of partial adherence. 
 
Another large US study of Medicaid recipients that examined the impact of the degree of 
adherence on health, social care and criminal justice costs through a series of one-way 
analyses of variance found that, in separate analyses looking at patients prescribed typical or 
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atypical antipsychotics, higher total costs were significantly associated with lower rates of 
adherence (Becker, Young et al. 2007). 
 
Eaddy et al (2005) studied the resource use implications of non-adherence for a group of 
patients with schizophrenia or bipolar disorder. Patients were judged to be partially adherent, 
where the degree of adherence was estimated as the ratio of the total days for which 
reimbursement of prescribed therapy was claimed to 365 days (the length of the period under 
study), if they had claims for less than 80% of days during the year. Partially adherent patients 
were significantly more likely to have had an inpatient hospitalisation during the study period. 
 
 
1.7 Policy relevance of the analysis 
 
The results and conclusions drawn from my analyses have potential relevance for a range of 
policies and so, potential implications for patients, their health professionals and the health 
care system. 
 
The analysis of factors associated with non-adherence and a discussion of whether or not the 
results of this analysis are consistent with theoretical models explaining non-adherence will 
be beneficial to identify those initiatives, be they clinical or behavioural, that are likely to 
assist patients in being more adherent to their antipsychotic medication. It will also identify 
those areas for further research which will further illuminate the factors behind non-adherent 
behaviour. 
 
Current policy responses to non-adherence include patient-centred compliance therapy and 
behavioural training, family behavioural therapy, and community-based interventions that 
provide strong and supportive social networks, close monitoring of clinical status and 
provision of stable housing (Kuipers 1996; Zygmunt, Olfson et al. 2002). Therapies which 
develop relationships between patients and therapeutic staff are also effective in improving 
compliance (Kuipers 1996). Interventions that are successful in reducing non-adherence rates, 
including new medications, will have considerable benefits for patients, their families, and the 
health and social care systems. 
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For NICE, the body within the UK health care system entrusted with evaluating the cost-
effectiveness of antipsychotic medication and making recommendations about their use, this 
thesis provides data on another aspect of costs that could potentially be included in 
evaluations. The thesis estimates the potential savings that may arise from reductions in health 
and social care service use costs attributable to improvements in adherence. Hughes et al 
(2001) highlight the need for more information on the consequences of non-adherence to 
allow economic evaluation to reflect their potential impact and my thesis identifies some of 
the issues involved in attempting to do this with antipsychotic medication. 
 
These issues will also have relevance for health professionals who treat individuals with 
schizophrenia in providing them with information that they can use, in addition to clinical 
information and their clinical judgement, in making prescribing choices. 
 
 
1.8 Hypotheses and research questions 
 
The theoretical models that have been put forward to describe the process of adhering to 
recommended health behaviours cover the prevention of illness and initiation of treatment as 
well as, to a lesser extent, the management of illness. Here my interest in non-adherence to 
medication is on this latter phase. Based on these theoretical models and the reviewed 
literature, my research hypotheses are as follows: 
 
1. Where adherence to medication is driven by attitudinal factors, the degree to which an 
individual feels threatened by the consequences of non-adherence, reflected by the 
severity of their illness and their level of insight into their illness, is a key factor in 
encouraging adherence. 
2. For some individuals, medication-taking behaviour is primarily the result of external 
factors that either encourage or discourage adherence. Here I include social support 
and the support of health care professionals as encouraging factors and the presence of 
drug or alcohol abuse and the experience of side effects as discouraging factors. 
3. In individuals taking antipsychotic medication, non-adherence to medication is likely 
to be associated with higher health and social care service use costs due to the 
worsening of symptoms associated with discontinuation of medication.  
 35 
The thesis aims to test these hypotheses by establishing which factors contribute to non-
adherence, examining the pattern of health care service use associated with non-adherence 
and estimating the costs associated with non-adherence in schizophrenia.  
 
In attempting to explore the relationships between non-adherence, resource use and costs, and 
other factors, it is likely to be the case that these relationships are specific to the type of 
medication that has been prescribed. In order to better understand these relationships in 
individuals taking antipsychotics, it is necessary to determine how these relationships differ in 
this patient population as compared to non-adherence to other medications. To facilitate this 
comparison, analyses will be conducted to determine the nature of the relationships between 
non-adherence to antidepressant medication, resource use and costs, and other factors. The 
results of these analyses will allow me to draw conclusions as to the impact of non-adherence 
to medication that is specific to those individuals prescribed antipsychotics. 
 
Questions to be addressed 
 
At what rate is treatment with antipsychotic medications discontinued and how is this linked to 
the experience of side effects? 
Once discontinuation of antipsychotic medication occurs, what are the implications for how 
health care resources are used and at what cost? 
What factors impact on the relationships between non-adherence to antipsychotic medications 
and resource use and costs and are these factors specific to this patient population? 
 
 
1.9 Thesis structure 
 
A brief outline of the structure of the remainder of the thesis is as follows: 
  
Chapter 2 will present and justify the methods used in the research. The methodological foci 
are (i) data sources; (ii) defining patients (iii) measuring non-adherence; (iv) costing methods; 
and (v) statistical analyses. 
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Chapters 3 and 4 will address the research question of the nature of the associations between 
non-adherence, service use, and costs. Chapter 3 will present results from analysis of the 
1993/4 Psychiatric Morbidity Surveys (PMS). Chapters 4 will build upon the previous 
findings by assessing the associations over time. This involves analysis of data from the 
Quality of Life following Adherence Therapy for People Disabled by Schizophrenia and their 
Carers (QUATRO) study, a multi-national randomised controlled trial which evaluated an 
adherence therapy intervention for people with schizophrenia. 
 
Chapter 5 will compare the significance of non-adherence in schizophrenia and depression. 
Analysis of the 2000 PMS analysis will provide the context for assessing the potential for 
containing costs given the nature of the association between non-adherence and costs. It will 
determine if the costs attributable to non-adherence, and therefore the potential savings, differ 
across the two illnesses.  
 
Chapter 6 will summarise the findings and present the policy implications of the findings in 
the context of current UK mental health policy. Conclusions will also be presented. 
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Chapter 2 
Methods and data 
 
 
In this chapter I aim to set out the methods used to address the research questions in the 
empirical analyses contained in this thesis. A range of methodological issues are discussed. 
These include the method used to define a sample, the potential options for measuring non-
adherence and costing methods. I then briefly describe the datasets that were used in the 
analyses, indicating key features of each. In discussing the methodological issues of the 
analyses, reference is made to the literature search described in the introductory chapter. The 
last part of the chapter is a description of common statistical analytical methods that arise in 
each of the empirical analyses. 
 
In looking at the relationship between non-adherence and service use costs, the aim was to 
conduct empirical research based on nationally representative UK data which used a fully 
robust measure of adherence and collected a broad range of data on health and social care 
service use and other potential costs such as informal care, time off work and criminal justice 
costs. By using nationally representative data, the results of the analyses would be relevant 
within a public health context (Boslaugh 2007). To date, much of the research describing the 
impact of non-adherence in schizophrenia is based on local data (Thieda, Beard et al. 2003). It 
would also be advantageous to use longitudinal data as these would provide clearer evidence 
as to the nature of associations between the variables of interest. The resources required to 
undertake primary data collection in this way would be quite substantial and thus the obvious 
choice was to use previously collected data that contain as much of the relevant information 
as possible.   
 
 
2.1 Defining a sample 
 
This thesis sought to identify samples of patients who were diagnosed as having 
schizophrenia and were taking antipsychotics. In identifying patients, those with 
schizoaffective disorder were also included. Henceforth, the single diagnosis label of 
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schizophrenia will be used to refer to patients with either schizophrenia or schizoaffective 
disorder.  
 
A majority of the studies identified in the literature review sampled patients with 
schizophrenia and schizophrenia-related illnesses. The remainder, along with the reviews, 
defined their samples more broadly, by looking at patients with psychosis. In reviewing data, 
it is apparent that in some cases diagnostic information is not available, incomplete or 
identified the primary diagnosis only. It is therefore difficult, in some cases, to confirm what 
proportion of patients had a diagnosis of schizophrenia. Therefore, identifying and including 
those patients who were prescribed antipsychotic medication at the time they were recruited 
into the study seemed to be the most appropriate method for defining a relevant sample in my 
analysis, rather than relying on diagnostic data. The majority of these patients will have 
schizophrenia or have experienced a psychotic episode. Others will have a primary diagnosis 
for another mental illness, such as bipolar disorder, for which antipsychotic medications are 
now prescribed. 
 
The physician practice of prescribing a drug or medical device for a purpose different from 
one of the indications for which the product is licensed is referred to as off-label prescribing. 
Off-label prescribing has taken place with antipsychotics for many years, although it is 
difficult to determine when it commenced. Antipsychotics are also now licensed for use in 
treating bipolar disorder (NICE 2006). Using data from 1994 to 2001 from the UK, Hodgon 
and Belgamar (2006) looked at the rate of off-label prescribing of atypical antipsychotics 
within patients in secondary care. They found that, averaged over the study period, just under 
60% of their sample had a diagnosis of schizophrenia or schizophrenia affective disorder. 
Based on ICD-10 diagnosis codes, 18.4% of patients prescribed atypical antipsychotics had a 
diagnosis of a mood disorder (bipolar disorder is one of the mood disorders), 12.4% an 
organic mental disorder diagnosis and 4.0% were diagnosed as having a personality disorder. 
Analysis of data from a population-based study in the Canadian province of Manitoba found 
that the proportion of patients who were prescribed an antipsychotic and had a diagnosis of 
schizophrenia declined from 65% in 1996 to 42% in 2006 in the 19 to 35 year age group and 
from 63% to 58% between 1996 and 2006 in the 36 to 65 year age group (Alessi-Severini, 
Biscontri et al. 2008). Medical and hospitalisation files were used to identify diagnoses in this 
study. A US study of non-institutionalised antipsychotics users observed that in 1996-1997, 
8% reported having a mood disorder without comorbid schizophrenia, and this rate rose to 
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22% by 2004-2005 (Domino and Swartz 2008). Throughout the study period, approximately 
18% of antipsychotic users reported having anxiety spectrum disorders without schizophrenia 
or mood disorders. Generally, estimates of off-label prescribing are difficult to obtain as it is 
often not recorded in a patient’s notes and is associated with increased liability for physicians 
(Hodgson and Belgamwar 2006). The dataset used in my analysis - which does not 
specifically identify individuals based on a diagnosis of schizophrenia - was from interviews 
that took place in the early 1990s and the data above suggests that at that time the majority of 
individuals prescribed antipsychotics would have a diagnosis of schizophrenia. 
 
In the UK it is now the case that the majority of patients with schizophrenia receive care in 
the community (Mangalore and Knapp 2007). Several previous studies which assessed non-
adherence to medication in patients with schizophrenia restricted their samples to inpatients 
only. Of the studies identified in the literature review reported on in chapter one, eight of 48, 
or 17% of studies, included inpatients only. The datasets analysed in this thesis either 
included both inpatients and outpatients or focused on outpatients only. Secondary analyses 
included homeless individuals.  
 
 
2.2 Measuring non-adherence 
 
Different options exist for assessing adherence. These include objective measures such as pill 
counts, prescription renewals, blood tests, or medication markers. Alternatively, assessments 
of adherence may be asked of patient or their clinicians. No method is without its limitations, 
however (Cramer and Rosenheck 1998; Thompson, Kulkarni et al. 2000; Diaz, Levine et al. 
2001; Kampman, Lehtinen et al. 2001; Coldham, Addington et al. 2002). Pill counts may not 
detect alternating under- and over-use of medication or discarding of pills and will not capture 
variations in the timing and duration of missed dosages (Hughes, Bagust et al. 2001). 
 
Relying on prescription renewal information will be effective only if patients use a single 
source for filling their prescriptions, and if there is a system in place to record all changes in 
medication and dosage. Blood tests may be misleading as plasma levels can vary widely 
among patients taking the same dose, and taking doses a few days before a test raises drug 
levels reasonably close to target. Medical markers, such as riboflavin, are not quantitative. 
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Assessments by patients may be subject to memory deficits, or distorted due to the level of 
psychosis, use of illegal substances or denial of illness. Because some patients are unaware of 
mistakes they are making in their medication regime the prevalence of non-adherence in 
studies where self-reporting is used will tend to be underestimated (Byerly, Thompson et al. 
2007; Velligan, Wang et al. 2007). 
 
Clinical assessments of adherence may be subject to potential bias caused by the clinician’s 
investment in finding a successful treatment (Diaz, Levine et al. 2001). The literature is 
conflicting with regards to the consistency between patient self-assessment of adherence and 
adherence as estimated by their physicians. Such an approach is supported in some studies 
(Kampman, Lehtinen et al. 2001; O'Donnell, Donohue et al. 2003), although a study by 
Kampman et al (2001) found only a 0.50 correlation in adherence assessments between 
patients and doctors. Another difficulty observed in the literature is in judging adherence in a 
clinical trial setting. It has been observed that patients who agree to participate in a clinical 
study of antipsychotic medications are more likely to adhere to medication and general 
treatment plans, suggesting a link between consent to research and compliance with treatment 
(Barnes 2002). 
 
Of interest is how non-adherence has been assessed in previous studies in this area. A 
structured literature search was described in the previous chapter identifying 43 empirical 
studies and five reviews. The samples under observation in the previous literature differed 
along several dimensions. With respect to non-adherence, assessment was by a range of 
methods: self-report, medical records, and clinical assessment. In ten of the 43 empirical 
studies (23%), the assessment of adherence relied exclusively on self-reported information. In 
a further 18 (42%), self-reported information was combined with the opinions of a family 
member, a physician or a case-manager to arrive at an assessment of adherence. Additional 
information of this kind may be helpful, but may also be problematic because of the 
inconsistencies described above. A study of primary care patients prescribed antidepressant 
medications for 12 weeks or more (defined as maintenance phase) found a 72% agreement 
between dichotomous classification based on self-reported adherence and adherence assessed 
from pharmacy refill data (Aikens, Nease et al. 2005). It would appear that few studies 
corroborate self-reported adherence with pill counts or physiological data (Zygmunt, Olfson 
et al. 2002). This method was used in only three of the 43, or 7%, of empirical studies 
reviewed. 
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It has been pointed out that self-report methods are generally the most cost-effective and time-
efficient (Thompson, Kulkarni et al. 2000). Also this may be the only feasible method for 
collecting adherence information in a large scale or population-based survey. Lecomte et al 
(2008) argue that the method used to elicit self-reported information on adherence can 
improve reliability. One suggestion given is that using interviewers unknown to the patient 
will prevent any incentive they may have in lying to an authority figure that has a stake in 
their treatment. Another suggestion is that by asking detailed questions about their medication 
taking, as opposed to a simple yes-no question, more accurate information is obtained. The 
data used in this thesis assessing adherence were based on self-reported information. The 
methods used will be described in more detail below in the description of the datasets. 
 
Across methods of assessing adherence, most studies use binary indices of non-adherence. In 
reality, however, it is much more likely that there is a continuum of the degree to which 
patients do not adhere to their medications (Aikens, Nease et al. 2005). Non-adherence can 
occur at different points in time after a drug is prescribed and varies as to the duration of 
missed dosages. For example, Urquhart (1997) identified six categories of non-adherers: (i) 
those that miss a dose but then take the missed dosage soon after they were supposed to take 
it; (ii) those who miss very few doses; (iii) those who miss a few doses, but never more than 
one at a time; (iv) those who a few times a year miss more than one dosage at a time (‘drug 
holidays’); (v) those who regularly take drug holidays; and (vi) those who take few or no 
doses. Weiden et al (2004) identified various degrees of partial compliance based on the 
maximum number of days in any gap in medication taking over a one year period and 
observed statistically significant increases in the rate of rehospitalisation as the maximum gap 
in medication increased. Donohue et al (2001) similarly used more than two categories to 
classify adherence, while Grunebaum et al (2001) used the continuous measure: number of 
days in the month prior to interview on which no medication was taken.  
 
In the studies reviewed, the definition of what constituted non-adherence varied substantially. 
Some studies defined non-adherence as discontinuation of medication for one week or longer 
(Robinson, Woerner et al. 2002), while others classified ever missing medication as 
constituting non-adherence (Weiden, Kozma et al. 2004). 
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The reviewed literature highlighted other important inconsistencies in the methods used in 
assessing factors associated with non-adherence in patients taking antipsychotics. In 
particular, the length of time over which non-adherence was assessed differed across studies. 
The length of time over which adherence status was assessed in previous studies ranged from 
one month to five years. This is important as the length of time under study is likely to impact 
on the prevalence of non-adherence observed. Shorter studies may not follow patients long 
enough to observe the long-run medication taking behaviour of patients. Of the 43 empirical 
studies reviewed, only 17 (40%) assessed medication taking over a time period of one year or 
more. 
 
In summary, there are a wide range of methods that can be used to assess adherence, and the 
choice of assessment method should be determined by the goals of the study and the relative 
advantages and disadvantages of the methods (Andrade, Kahler et al. 2006). 
 
 
2.3 Costing methods 
 
There are several sources of costs that result from the incidence of schizophrenia. The key 
cost drivers are: inpatient services, specialist community accommodation, medication, lost 
employment, premature mortality, family burden and public safety and concern (Knapp, 
Simon et al. 2002). The first three of these are examples of direct costs. That is, they are costs 
that are incurred for provision of health services to patients (Knapp 1996). Indirect costs are 
the necessary, or at least desirable (in some respect), complements to direct expenditure from 
local authorities and other agencies. An example of an indirect cost in the support of a patient 
with schizophrenia is a carer support service. Costs that are not immediately identifiable, but 
are measureable, such as family support, are considered hidden costs. Premature mortality, 
family anxiety, and public safety are examples of immeasurable costs (Knapp 1996). 
 
While many of these costs drivers can be identified, there may be difficulties in attaching a 
unit cost to them. This is because they may not best equate to the money cost or price of the 
resources because of market distortions of prices. The appropriate measure of the cost of a 
service is the benefit forgone or opportunity cost of not using the resource in is best 
alternative use. 
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Another important consideration in analyses of costs is the perspective taken. Typically this 
will either be the perspective of the health and social care system, the 
public/sector/government or of the society as a whole. Health and social care costs focus on 
the direct costs of services. A public sector/government perspective would include health and 
social care costs and those indirect costs, such as the cost of benefits, paid out of the public 
purse. Taking a societal perspective necessitates the inclusion of all costs borne by society, 
including such indirect costs as informal care and lost productivity. In this thesis the health 
and social care system is taken in each empirical analysis. The data necessary to conduct such 
analyses were available in each of the datasets. Where additional data were collected allowing 
for estimation of public sector/government costs, the cost of lost employment or societal 
costs, these were estimated and analysed.  
 
 
2.4 Measuring and costing psychiatric services 
  
Beecham and Knapp (2001) identified four ‘rules’ for costing mental health services. These 
are: 
 
1. Costs should be comprehensively measured ranging over as many service components 
of care packages as is relevant 
2. Variations between clients and variations between facilities or areas of the country 
should not be overlooked 
3. Assessments of the comparative performance of services should be made on a like-
with-like basis 
4. Cost information is more useful if it is used in conjunction with outcome data 
 
With regards to comprehensively measuring costs, this is most effectively done at the 
individual level. Thus collecting service receipt or utilisation data for individual patients or 
clients over a specific period of time will achieve comprehensiveness. 
 
The first step to comprehensively costing services is to describe the elements of the service 
(Beecham 1995). This involves collecting detailed information of the service and its 
 44 
components. Following this, a unit of measurement for each service is chosen which reflects 
the typical unit of contact patients or clients have with the service. For example, a social 
worker may typically see clients in hourly appointments so the number of contact hours 
would be most easily estimated. The third step is then to identify and collect data on the cost 
implications of all service components. For example, staff time potentially includes salary, 
national insurance contributions and travel costs and decisions must be made as to the most 
appropriate ways to assign these to each unit of service provision. The final step in costing 
services is to estimate the unit cost of the service. 
 
Unit cost measures should be based on long-run marginal opportunity costs (Beecham 1995). 
This method takes a long-term perspective on resource implications, taking into account 
developments in care that could be achieved by using present services more intensively. It 
also includes only those effects on resources that can be attributed to the service user (Knapp 
1996), and reflects the additional cost attributable to providing the service to an additional 
patient or client. Opportunity costs take the perspective that costs incurred are forgone 
opportunities to spend financial resources alternatively. 
 
The unit costs used in this thesis are estimates of long-run marginal opportunity costs at a 
national level, taken from an annual compendium of health and social care costs. Initially, an 
attempt was made to use unit costs consistent with the year in which the data from each 
source was collected. A later decision was taken to use the same year in two of the empirical 
analyses in which very similar sampling methods and questionnaires were used in order to 
facilitate comparisons across the results. The Unit Costs of Health and Social Care, compiled 
by Netten el al (2002), reported estimates of unit costs for over 70 health and social care 
services based on routine data, literature and ongoing research. The estimates include capital, 
revenue and other relevant direct or indirect costs of mental health and social care services. 
Revenue costs include salary, supplies, overhead costs as well as catering and domestic costs 
in the case of services provided in residential care settings. Because a long-term perspective is 
taken, the cost of creating services was also included. That is, the cost of buildings, land and 
equipment which constitute capital costs. Building and land costs are annuitized over 60 years 
(to reflect the assumed lifetime of a building) and discounted to arrive at an annual, present 
value cost. The compendium includes data to allow for unit costs to be specific to the area of 
the country in which patients reside but this information was not used here due to the 
complexity of applying this data for individual patients. With respect to the fourth rule of 
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costing psychiatric services, the focus here is on resource use, and as discussed in the 
introduction, there is an assumption in assessing the impact of non-adherence, that prescribed 
medications are clinically effective.  
 
 
2.5 Potential confounding variables 
 
The literature review of previously published empirical studies and reviews was used to 
identify factors to include in the modeling as potentially associated with non-adherence and as 
covariates in the analysis of costs. Table 1.1 in chapter 1 lists the factors assessed in 
previously published literature reviews for their association with non-adherence. As I am 
conducting secondary data analyses, the factors that could be considered were restricted to 
those relevant factors included in each of the datasets. Using the classification suggested by 
Fenton et al (1997), discussed in Chapter 1, the majority of the available and relevant data are 
patient-related. Little data were available on medication- or environment-related factors (e.g. 
intensity of treatment or therapeutic alliance) or those that related to psychodynamic 
considerations (e.g. degree of insight into illness). The control variables in each dataset are 
listed and described in the empirical chapters (3, 4 and 5) which describe the variables in 
more detail.  
 
 
2.6 Data sources 
 
The choice of datasets to use in the analyses was based on the extent to which relevant 
information was included in the dataset. The features deemed most important were that the 
sample was nationally representative, the data were collected relatively recently, had an 
adequate measure of non-adherence, included comprehensive information on health and social 
care service use and indices of as many as possible of the potential covariates relevant to non-
adherence and service use. Additionally, longitudinal data were sought as these have the 
advantage of allowing for greater confidence in determining the direction of associations 
between variables. As secondary data were used, it was inevitable that not all of these features 
could be identified in a single dataset. For example, there were data that would have improved 
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the analyses that were not included in the datasets chosen. Also, particular variables were not 
categorised in a way that would be most relevant in the analysis. These and other limitations 
are discussed in detail in the chapters presenting the empirical analysis. Here, a brief overview 
of the datasets is given.  
 
The relevant information in describing secondary data, as set out by Boslaugh (2007), are as 
follows: 
 
What was the original purpose for which the data was collected? 
What kind of data is it, and when and how were the data collected? 
What cleaning and/or recording procedures have been applied to the data? 
 
Given the methodological issues identified, and the desire to conduct an analysis on validated 
and representative data, the following sources were identified. 
 
2.6.1 The Psychiatric Morbidity Surveys, 1993-4 
 
The UK Psychiatric Morbidity Surveys (PMS) were cross-sectional, epidemiological surveys 
conducted in a range of settings. Interviews were conducted by the Social Survey Division 
field force of the British Office of Population Census and Surveys (now called the Office for 
National Statistics) between April 1993 and August 1994 (Meltzer, Gill et al. 1995; Gill, 
Meltzer et al. 1996; Meltzer, Gill et al. 1996). The PMS data were provided by the UK Data 
Archive. 
 
The nature of schizophrenia determines that there will always be significant subgroups of 
people with the illness who will be in difficult-to-reach areas of society. For example, rates of 
schizophrenia are high in prison and homeless populations (Lamb and Lamb 1990; Singleton, 
Meltzer et al. 1998). These patients are rarely considered in analytical studies (Gill, Meltzer et 
al. 1996). A significant advantage of the PMS 1993-4 data is that a sample of homeless people 
was included in the data. 
 
 
 
 47 
The aims of the 1993-4 PMS surveys are listed as: 
 
(a) to estimate the prevalence of psychiatric morbidity according to diagnostic 
category among adults aged 16 to 64 years in Great Britain 
(b) to identify the nature and extent of social disabilities associated with mental 
illness 
(c) to examine the varying use of services and the receipt of care in relation to the 
mental illness and the associated social disabilities 
(d) to investigate recent precipitating factors which are associated with mental 
illness 
(e) to investigate the relationship between mental illness and smoking, drinking 
and drugs use 
 
The assessment of non-adherence in the 1993/4 PMS was based on self-assessment by survey 
respondents. The assessment relates to current medications only and is based on survey 
responses to the questions ‘Do you sometimes not take your medications even though you 
should?’ and ‘Do you sometimes take more medication/pills than the stated dose?’ 
 
Data on the frequency of use of inpatient care, outpatient care, external services (including 
community psychiatric nurse, occupational therapist, social worker, community psychiatrist, 
home help, volunteer worker), day care and sheltered employment were available from the 
survey.  
 
The 1993/4 PMS includes several variables that relate to the analysis of the factors associated 
with non-adherence and the analysis of factors associated with costs. These are: age, sex, 
education, general level of health, illness severity, inpatient contact for mental health reasons 
in the past year, self-reported drug abuse, self-reported alcohol abuse, level of support from 
family or friends and familiarity with medication. The dataset also has a variable indicating if 
a patient is from an ethnic minority. 
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2.6.2 The QUATRO Study 
 
The QUATRO study was a multi-national randomized controlled trial carried out at four 
centres across four European countries (Germany, Italy, the Netherlands and the UK), funded 
by the European Commission and coordinated from the UK. It has the advantage of following 
patients over time. Its main aim was to compare the effectiveness of adherence therapy with a 
health education control intervention (which allows for therapist time and relationship), in 
improving health-related quality of life for people with schizophrenia receiving treatment 
from general adult mental health services (Gray, Leese et al. 2006). The sample was drawn 
from adults receiving care from psychiatric services in each of four European cities: 
Amsterdam (The Netherlands), Leipzig (Germany), London (United Kingdom) and Verona 
(Italy). Data collection took place between June 2002 and October 2003 (Gray, Leese et al. 
2006). Each sample was recruited from the patient records of senior treating clinicians at a 
range of local in-patient and community settings that were typical of general treatment centres 
in the catchment areas of each site. The inclusion criteria were that the patient must have had 
a clinical diagnosis of schizophrenia, must require on-going antipsychotic medication for at 
least one year following the baseline assessment, and must have exhibited evidence of clinical 
instability in the year prior to baseline (Gray, Leese et al. 2006). Clinical stability is defined as 
meeting one or more of the following criteria: a hospital admission on mental health grounds, 
a change in the type or dose of antipsychotic medication, planned or actual increased 
frequency of contact with mental health services, and indications of clinical instability 
reported by relatives, carers or the clinical team. Written, informed consent was obtained from 
all participants. 
 
The study was a two-arm randomised controlled trial. Patients were randomly assigned to 
either receive the experimental intervention, an individual cognitive-behavioural approach 
which is collaborative and patient-centred, or a standard health education control intervention. 
The six elements that form the core of the cognitive-behavioural approach are assessment, 
medication problem-solving, a medication timeline, exploring ambivalence, discussing beliefs 
and concerns about medication, and using medication in the future (Gray, Leese et al. 2006). 
 
Measurements were taken at baseline and after 12 months for both the intervention and 
control groups. Adherence to medication was based on patient responses on the Medication 
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Adherence Questionaire (MAQ). Positive responses on the MAQ are summed to obtain a 
Morisky score (Morisky, Green et al. 1986), a 5-point scale based on 4 questions relating to 
medication-taking behaviour. It asks patients if they ever forget to take medication, if they are 
careless about taking medication, if they ever stop taking medication once they feel better and 
if they ever stop taking medication because it made them feel worse. The Morisky score is 
widely used to assess adherence (Shalansky 2004; Day, Bentall et al. 2005). For the purpose 
of this analysis, values of 3 and 4 on the 5-point scale (0-4) were deemed as reflecting a high 
liklihood of non-adherence as per classifications found in the literature (Shalansky 2004). 
 
In the QUATRO study, service use information is collected on the Client Service Receipt 
Inventory (CSRI) (Beecham and Knapp 1992). The CSRI collects individual patient data on 
demographic characteristics, accommodation and living situation, employment history and 
earnings, including receipt of benefits, health and social care service receipt, and the role of 
informal carers. This questionnaire was originally designed to be used by an interviewer with 
the principle carer of a person with mental health problems. The QUATRO study team choose 
to have the CSRI administered by non-economist researchers in a face-to-face interview with 
participants (Patel 2006). Due to uncertainty over the reliability of service use reports by 
people with mental health problems, interviewers were advised that, where full data could not 
be obtained from participants, they should obtain supplementary information from key 
workers, service providers and/or carers to ensure that the information was as complete and 
reliable as possible. 
 
For use in the non-English speaking QUATRO study sites, local language versions of the 
CSSRI-EU were available from the EPSILON study (Chisholm, Knapp et al. 2000), which 
carried out a process of translation into local languages, focus groups and pilot activities to 
ensure face validity and semantic equivalence. 
 
The CSRI can be used for the chosen retrospective period as it breaks down service receipt 
into typical units of contact. In the QUATRO study the retrospective period to which the 
service use data refers was three months.  
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2.6.3 The Psychiatric Morbidity Survey, 2000 
 
The Psychiatric Morbidity Survey, 2000 collected information both in its own context and 
relating to the 1993-4 PMS studies. The positive aspects of this dataset are that it provides 
more recent service use data and by having a methodology largely consistent with the 
previous PMS data, offers a good comparison across the two studies. The difficulty is that the 
study sample includes individuals residing in private households only and is thus not ideal for 
comparison of schizophrenia patient samples. The 2000 PMS data was provided by the UK 
Data Archive. 
 
The main aim of the survey was to collect data on the prevalence of mental health problems 
among adults aged 16 to 74 years living in private households in Great Britain (Singleton, 
Bumpstead et al. 2001). The topics of the 2000 PMS Household survey were similar to those 
in the 1993-4 surveys. The questions relating to non-adherence to medication were worded 
identically to those in the 1993-4 surveys. Service use data were collected for each of the 
following category of services: GP consultations, inpatient visits, outpatient visits, day 
activity services, and community care services (including community psychiatrist, community 
psychologist, community psychiatric nurse, social worker, home help, outreach worker).  
 
The sample in the PMS 2000 was independent of the sample from the 1993-4 surveys. Given 
the likely similarity between the household samples in each, however, the PMS 2000 data 
would be ideal for comparing rates of non-adherence and the nature of the association 
between non-adherence, relevant covariates and service use. Unfortunately, in the 2000 PMS 
only 54 patients reported being prescribed antipsychotics at the time of the interview. This 
survey was used instead to assess service use and costs in another mental illness sample, 
patients taking antidepressants, to contrast the significance of non-adherence in relation to 
service use relative to the patients taking antipsychotics in the 1993-4 PMS. The service use 
data collected in the PMS surveys were quite similar which greatly enhances this comparison.  
 
The six to seven year gap between the surveys is acknowledged, however. The two PMS 
samples were not combined because of changes in the health care system in the intervening 
period. For example, the number of standard dosage units of antidepressants prescribed per 
1000 population increased by approximately 75% between 1993 and 2000 (Rose 2007). There 
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were also changes to the provision of services, including alterations to the organisation and 
configuration of community mental health teams, continued rebalancing of care between 
hospital and community settings, and growth of secure provision. 
 
 
2.7 Statistical analysis 
 
The statistical methods used in the thesis were chosen based on the features of the data. All 
statistical analyses were conducted using the STATA data analysis software (StataCorp 2007; 
STATA 10.1 2009).  
 
2.7.1 Logistic regression 
 
For the research question assessing factors potentially associated with non-adherence, a 
dichotomous index of non-adherence was used in each of the datasets. For the analyses, where 
the outcome involved whether a patient was adherent, a logistic regression model was fit to 
the data. The logistic regression model can be represented algebraically as: 
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where  pi represents the probability of a positive outcome in patient i, and Xi represents a 
column vector of observed values, for patient i, for the set of factors thought to be associated 
with non-adherence. 
 
This equation can be rearranged to be expressed as: 
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The logit transformation of pi is: 
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The function, g(x), has many of the properties of a linear regression model. That is, it is linear 
in its parameters, may be continuous, and may take on values from -∞ to +∞. 
 
The value then of a dichotomous outcome variable given a set of parameters, X, can be 
expressed as: 
 
yi = pi + ε 
 
where ε has a binomial distribution with mean zero and variance equal to pi [1-pi]. 
 
For a dichotomous variables (say Y), either equation above for p gives the conditional 
probability of a positive event (Y=1) given values X. The conditional probability that Y=0 is 
thus given by 1-p . 
 
The likelihood function is the product of the contribution to the likelihood function for the a 
pair of values (x,y): 
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The natural log (ln) of this equation is: 
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To find the values of the vector of coefficients, β, that maximizes this equation, it is 
differentiated with respect to β0 and β1 and the resulting expressions, given below, are set 
equal to zero.  
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This solution of coefficients is termed the maximum likelihood estimate. 
 
If an independent variable in a logistic regression model is itself dichotomous, the most 
commonly used measure of association is the odds-ratio. If the levels of the dichotomous 
independent variable are 0 and 1, and the outcome variable, also dichotomous is 1 for a 
positive outcome and 0 otherwise, the odds-ratio represents the probability of a positive 
outcome among individuals with independent variable value of 1 relative to those with 
independent variable at value 0. For example, in the analyses to follow, if a ‘positive’ 
outcome is defined as having been non-adherent to medication and alcohol abuse is 
represented by 1 if the respondent has previously abused alcohol and 0 if they have not, an 
odds-ratio of 2 would be interpreted as those with a history of alcohol abuse being twice as 
likely to report non-adherence relative to those without a history of alcohol abuse.  
 
The odds-ratio can be written as: 
 
OR = 
)]0(1/[)0(
)]1(1/[)1(
pp
pp
−
− , 
 
that is, the ratio of the odds of a positive outcome for those with a value of 1 on the 
independent variable relative to the odds of a positive outcome for those a value of 0 on the 
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independent variable (Hosmer and Lemeshow 2000). Given the algebraic representation of pi 
above, the formula for the odds-ratio can be reduced to: 
 
OR = ieβ . 
 
The odds-ratio has possible values ranging from 0 to +∞, with a value of 1 reflecting equal 
odds for each level of a dichotomous independent variable. Thus the distribution of the odds-
ratio is skewed right. The sampling distribution of the maximum likelihood coefficient 
estimate, β1, has a normal distribution. The endpoints of the 100(1-α)% confidence interval 
estimate for the odds ratio is then given by: 
 
exp[β1±z1-α/2 x [standard error( βˆ 1)]. 
 
If an independent variable is categorical but has more than two levels, a reference category is 
chosen from one of the levels of the variable and odds-ratios are calculated for the remaining 
levels which reflect the odds of a positive outcome for that outcome level relative to the 
reference level. Again as an example, consider non-adherence as the ‘positive’ outcome and 
level of education as an independent variable with 3 levels – without a secondary school 
education, completed secondary school or completed post secondary school qualification. If 
‘without secondary school education’ were the reference category, an odds-ratio of 2 for 
respondents with completed secondary school would represent a doubling of the odds of 
being non-adherent for those who had completed secondary school relative to those without a 
secondary school education. An odds-ratio of 3 for those who had completed a post-secondary 
school qualification would represent these individuals being three times as likely to be non-
adherent as those without a secondary school education. 
 
In the most basic case, the logit is assumed to be linear in relationship to a continuous 
covariate. In this case, the slope coefficient, β, is the change in the log odds for an increase of 
one unit on the continuous variable. For example, an odds ratio of 1.05 for the variable age 
means that a one year increase in age is associated with a 1.05 times the odds of a positive 
outcome. A more meaningful description of the association of a dichotomous outcome with a 
continuous independent variable may be to report the impact of a relevant or meaningful 
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change of units on the independent variable. It would possible then to say, for example, that ‘a 
10 year difference in age is associated with x times the odds of a positive outcome’. 
 
 
 
Say the choice of a relevant or meaningful change is ‘c’ units. The odds ratio for a change of 
‘c’ units is: 
 
OR(c) = exp(cβ) 
 
This can be estimated by replacing β with its maximum likelihood estimate βˆ . The endpoints 
of the 100(1- α)% confidence interval of OR(c) are: 
 
exp[cβ1±z1-α/2 x c x [standard error( βˆ 1)]. 
 
 
The link test is used to test the appropriateness of the specification of the logistic regression 
models (Tukey 1949). The link test regresses the outcome variable in the logistic regression 
on the values predicted by the model and the predicted values squared. If the squared 
predicted values have statistically significant explanatory power, the model is misspecified. In 
the case of logistic regression this would necessitate altering the specification of the 
independent variables as the specification of the dependent variable is set as the log likelihood 
function.  
 
Several options exist for testing the goodness-of-fit of the logistic regression model. Those 
used in the analyses are the Pearson’s chi-squared test, the Hosmer-Lemeshow test, the 
likelihood ratio test and the percentage of observations correctly predicted by the model 
(Hosmer and Lemeshow 2000). In logistic regression the fitted values are calculated for each 
covariate pattern and depend on the estimated probability for that covariate pattern. The 
Pearson’s chi-squared statistic is based on the residual probability of the observed and 
expected values for a particular covariate pattern. This statistic is approximated by the chi-
shared distribution with J – (p+1) degrees of freedom, where J is the number of observations 
and p is the number of independent variables included in the model. 
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The Hosmer-Lemeshow test involves regrouping the data by ordering on the predicted 
probabilities and then forming a number of equally sized groups (Hosmer and Lemeshow 
2000). The Hosmer-Lemeshow goodness-of-fit statistic is the Pearson chi-squared statistic for 
the table of observed and estimated expected frequencies for each group summed over all of 
the groups (Hosmer and Lemeshow 2000). This test statistic is also approximated by the chi-
squared distribution with degrees of freedom equal to the number of groups minus two. 
 
The likelihood ratio statistic is twice the difference in the log-likelihoods of two models. The 
significance of a particular independent variable can be tested by calculating the difference in 
log-likelihood of a model with the variable included and a model without the variable and 
multiplying this by two. The likelihood ratio test has an approximate chi-squared distribution 
with degrees of freedom equal to the number of independent variables in the model.  
 
The logistic regression model fit was further assessed by looking at the percentage of 
observations correctly predicted by the model. That is, what percentage of patients who were 
non-adherent were predicted by the model to be so. There is no specific percentage that can be 
taken to validate the choice of model, but this statistic is useful to judge the relative 
performance of logistic regression models. 
 
2.7.2 Two-part models and generalised linear models 
 
In analysing the association between non-adherence and service use costs, specific 
characteristics of the distribution of costs suggest that ordinary least square methods are not 
appropriate. A distribution of service use typically included a significant number of zero 
cases, that is, patients who did not use any services during the period under study. Also, cost 
outcomes across a large number of patients are usually skewed to the right. That is, there are a 
relatively small number of patients who require very high service use and as a result have 
unusually high costs. 
 
A common approach to dealing with the first of these features is to use a two-part model 
(Mullahy 1998). In the context of analysis of service use and costs, the first part of the model 
estimates whether or not a patient has any service use at all, and the second part of the model 
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estimates the amount of costs incurred among those patients who did use services. The first 
part of the model can by estimated with binary probability models - logistic or probit 
regression. In the analyses conducted for this thesis, when the data for a cost outcome 
contained a significant number of zero values, logistic regression modelling was used for the 
first part of a two-part model analysis.  
 
The second part of the two-part model is a model of the costs for those patients who used 
services. These costs can be modelled with a linear regression model, provided that the 
necessary assumptions or conditions are met. That is, that the relationship between the 
dependent and independent variables is linear; that the residuals of the model are not 
correlated and have constant variance and the residuals are normally distributed (Cohen, 
Cohen et al. 2003). Typically, high skewed data, a common feature of cost data, will violate 
the condition of constant variance across the residuals (Dunn, Mirandola et al. 2003). 
Heteroscedasticity is the term given to non-constant variance in the residuals. 
Heteroscedasticity, along with the residuals not having a normal distribution, will lead to 
underestimates of the standard error of the parameter estimates and thus overestimation of 
significance levels. One approach to dealing with the skewed distribution of a regression 
outcome variable is to perform a transformation on the cost values – usually using the natural 
log: ln(y). These values are then analysed with ordinary least squares regression. This method 
has its deficiencies, however, as the results may be biased if not appropriately retransformed 
(Manning and Mullahy 2001). Here part two of the model was modelled with a generalised 
linear model (GLM) where an extension of Park’s test is applied to the raw-scale residuals 
from the GLM model to determine which specific GLM to use (Mullahy 1998). 
Algebraically, this can be represented by: 
 
Part 1:  Pr(yi>0| xi) = ii XBBe −−+ 11
1
 
 
Part 2:   E[ln(yi)| yi>0,xi] = Xiβi 
 
where yi is the observed cost of patient i, and Xi represents observed values, for patient i, for 
the set of factors thought to be associated with non-adherence. 
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The overall model has expected value: 
 
 
E[y| X] = Pr(y>0|X) x E[y|y>0,X] 
 
The logit model has been described above. The generalised linear model is an extension of a 
linear model with three components (Blough, Madden et al. 1999). The first of these is the 
linear component: 
 
ηi = Xi β 
 
where X is a column vector of observed values for the model covariates and β is a column 
vector of coefficients. 
 
The second component of the GLM model is a link function, g, which describes how the 
expected value of a response, yi, is related to the linear predictor: 
 
g(μi) = Xi β 
 
where μi = E(yi). The log link function was used in the analysis of service use costs on account 
of the values being skewed to the right. 
 
The third component is the variance function. The variance function value determines the 
relationship of the variance of the outcome variable across patients and their mean where each 
observed outcome has a probability distribution from an exponential family. This can be 
written as: 
 
Var(yi) = σi2 = ΦV(μi) 
 
where Φ is a constant called the dispersion parameter. The exponential family of probability 
distributions includes the normal (Gaussian), binomial, Poisson, gamma and the inverse 
Gaussian distributions.                                          
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The choice of distributional function was made based on the modified Park Test described by 
Manning and Mullahy (2001). The Park Test statistic is estimated using a ordinary least 
square with a log link where the dependent variable is: 
 
ln (yi - iyˆ )
2 
 
and the explanatory variable is ln( iyˆ ), the natural log of the fitted value from one of the GLM 
specifications. Thus the model is: 
 
ln (yi - iyˆ )
2 = λ0+ λ1 ln( iyˆ ) + vi 
 
The coefficient λ1 is used to determine which distributional family to use. If λ1=0 the 
Gaussian distribution can be used. The Poisson distribution is suggested by λ1=1 and the 
gamma model is suggested if λ1=2. And if λ1=3 the inverse Gaussian model is suggested 
(Manning and Mullahy 2001). 
 
As mentioned above, the overall estimate of an individual patient’s expected service use costs 
was estimated by multiplying the probability of use of services from the logistic regression 
model by the expected costs from the GLM. The method to estimate the standard error of 
overall costs involves using a bootstrap algorithm. Because the distribution of the overall 
estimate of service use costs cannot be easily defined (as the product of a logistic regression 
estimate and a GLM estimate), bootstrapping simulates the distribution to arrive at an 
estimate of the standard error. Based on random samples drawn from the original sample, the 
overall estimate of service use costs is estimated. This process was repeated 1,000 times with 
varying random samples to create a distribution of estimates. The dispersion of these values 
estimates the dispersion around the estimate of costs incurred. In each analysis where two-part 
models were used, the bootstrap algorithm was used to derive standard errors.  
 
2.7.3 Case types 
 
To graphically illustrate the effect of the factors in the model, predicted costs were calculated 
from the models for a series of case types. An initial case was selected for each outcome 
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which combined the factors included in the model at arbitrarily assigned values. The overall 
estimate of service use costs was estimated for this case and is represented by a bar in the 
graph. The 95% confidence interval for this case, derived from a bootstrap algorithm when 
two-part models were used, were calculated and are represented by a line extending from the 
lower limit of the confidence interval to the upper limit of the confidence interval. Further 
case types, in turn, varied the value of a single factor to see the impact on predicted costs of a 
shift in the value for that factor. For example, an initial case type may show the predicted total 
service use costs for a man aged 45 on medication for over 2 year. To illustrate the effect of 
age, an additional prediction on the graph could show the predicted total costs for a man, aged 
64 on medication for over 2 years.  
 
2.7.4 Multiple imputation 
 
A common problem when modelling data from a large sample is that a number of sample 
members will have missing data for some of the explanatory variables to be included in the 
model. If the individuals with missing data on one or more of the variables of interests are 
excluded from the modelling, the model will have less power, and the findings will be less 
representative of the population sampled from. There are several techniques for dealing with 
missing variables.  
 
An important first step in dealing with missing values is to determine if they are a random 
occurrence. In many instances, missing data is not random and is related to the values of the 
variable under study. For example, missing data on a survey question about an individual’s 
income is potentially related to the respondent not wanting to divulge their income if very 
high or very low. Where missing data are unrelated to the values of the variable or any other 
variable observed in the dataset it is termed ‘missing completely at random (MCAR)’. Testing 
whether or not any of the variables with complete data is associated with an observation 
having missing data may be used to test the assumption of MCAR but is inconclusive as it is 
not possible to test that the missing values are completely random without knowing what the 
missing values are. For example, if it is assumed that in response to being asked their income, 
those with particularly high or low incomes are less likely to be willing to reveal their 
incomes, then the missing values on this question would relate to the values that would have 
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been observed had the question been answered. It is a strong assumption to assume 
missingness completely at random. 
 
A less strong assumption is that missing data may be conditional on another of the 
explanatory variables, but not on their values or the dependent variable. This is termed 
‘missing at random (MAR)’ (Schafer 1997). Following the previous example, missing values 
on an income variable would be considered MAR if those with a particular level of another 
explanatory variable in the model, say education, are more or less likely than others to report 
their income, but among those with the same level of education, the probability of reporting 
income is unrelated to an individual’s actual income (Byrne 2001). Data is not missing at 
random (NMAR) if missingness is dependent on the value of the missing variable, as in the 
example of those with higher incomes being less willing to reveal their income.  
 
The options for dealing with missing data depend on the assessment of its randomness. Where 
data is MCAR, the entire observation may be deleted (listwise deletion) or the estimation can 
ignore missing values but include the observation (pairwise deletion) (Scheffer 2002). 
Options for estimating missing values when data is MAR are to replace missing values with 
the mean of observed cases or use the non-missing data to predict the values of missing data 
using a regression model. Both these methods are mainly criticised for underestimating 
standard errors of estimates based on the imputed data as they do not incorporate uncertainty 
around the imputed values. Other methods such as weighting adjustments, where each 
observation is weighted according to the inverse probability of observing that observation’s 
pattern of missing data, can produce estimates with excessive variability (Rubin 1996). 
 
The approach taken here is to use multiple imputation. The procedure uses the observed data 
to estimate the missing data a multiple of times, creating equally plausible versions of the 
complete data set. Each of the data sets is then analysed, and the results combined using 
Rubin’s (1987) rules for scalar estimands to produce one set of estimates and standard errors. 
The advantage of this method is that it preserves the variance structure of the data and 
incorporates uncertainty around the imputed values.  
 
The imputation of multiple datasets was performed using the STATA program Imputation by 
Chained Equations (ICE) (Royston 2004; Royston 2005; Royston 2005b). The number of 
imputations necessary was discussed by Rubin (1996). He demonstrated that the relative  
 62 
efficiency of an estimate based on the number of imputations is approximated by the 
equation: 
 
2/1
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where γ  is the rate of missing information for the quantity being estimated, m is the number 
of imputations and efficiency is measured in units of standard deviations. Based on this 
formula, Table 2.1 below indicates efficiencies for various values of γ  and m. 
 
 
Table 2.1: Relative efficiencies for multiple imputation estimates based on the rate of 
missingness, γ , and number of imputations, m. 
 
 
 
M 
γ  
0.1 0.3 0.5 0.7 0.9 
3 98 95 93 90 88 
5 99 97 95 94 92 
10 100 99 98 97 96 
20 100 99 99 98 98 
 
 
 
 
 
 
Analysis of each multiply imputed dataset uses the same method that would be used in the 
absence of nonresponse. Let lθˆ , Wl, l=1,…,M be M complete-data estimates and their 
associated variances for an estimated θ , calculated from M repeated imputations under one 
model (Little and Rubin 1987). The combined estimate is: 
 
Mθ = ∑
=
M
l
l
M1
θˆ  
 
 
There are two components to the variability associated with this estimate. The first is the 
average within–imputation variance, given by: 
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The second variance component is the between-imputation component, given by: 
 
MB = 
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1
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Ml θθ  
 
The total variability is estimated as: 
 
MT = MW + MBM
M 1+  
 
where (M+1)/M is an adjustment for finite M. 
 
 
Based on a Satterwaite approximation, the t distribution is the reference distribution for 
confidence interval and significance level estimates (Rubin and Schenker 1986; Rubin 1987). 
That is, 
 
( ) 2/1−− MM Tθθ ~ vt  
 
With degrees of freedom, v, estimated as: 
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2.7.5 Endogeneity  
 
 64 
Endogenous means ‘defined within’ and in economic modelling refers to reverse causality or 
simultaneity in cross-sectional models. Simultaneity arises when one or more of the 
expanatory variables in a model are jointly determined with the dependent variable. That is, 
an explanatory variable is determined at the same time as the dependent variable and it is not 
possible to determine the direction of causality. The jointly determined explanatory variable is 
endogenous and a model that does not account for the simultaneity will produce a biased 
estimate of its effect. 
 
The problem of an endogenous independent variable is typically addressed by the 
instrumental variable method (Maddala 2001). Consider the standard ordinary-least-squares 
regression model, 
 
uXY iii ++= ββ0   
 
where Yi is the dependent variable, 0β is the intercept, iβ is the slope parameter for the 
independent variable Xi and u is the error term. 
 
If Xi is simultaneously determined by Yi , it can be modelled as: 
 
vYX iii ++= γγ 0  
 
But while u is random in its effect on Yi , it will not be random in its effect on Xi meaning 
that  Xi and u will be correlated and X is endogenous in the model predicting Yi (Wooldridge 
2006). Inclusion of an endogenous variable in a model will result in iβ being biased and 
inconsistent. 
 
Instruments are variables that are correlated with the endogenous variable but uncorrelated 
with the error term. Thus it is necessary to identify a variable, observed in the dataset, say z , 
that is correlated with the endogenous variable Xi and uncorrelated with the error term u . The 
condition that z is correlated with Xi can be tested by regressing Xi against z . That is 
modelling 
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vzX ++= 10 ππ . 
 
Then z is correlated with Xi (i.e. Cov( z , Xi) ≠ 0) if and only if we can reject the null 
hypothesis that 1π = 0. In non-linear models such as logistic regression, a two-stage residual 
inclusion method is necessary for addressing endogeneity (Terza, Basu et al. 2008). 
 
Endogeneity may also result from omitted variables and measurement error (referred to as 
errors-in-variables). Omitted variable bias occurs if a variable which affects the dependent 
variable and is correlated with one or more of the expanatory variable is not included in the 
regression model (Wooldridge 2006). The variation associated with the omitted variable 
becomes part of the error term in the standard OLS regression model. The result of omitting a 
key variable is that the variable(s) in the model with which it is correlated are then 
endogenous. Typically, omitted variable bias comes about (particularly in secondary data 
analysis) because omitted variables are not observed in the dataset being analysed. 
 
Errors-in-variables arises if the true value of an explanatory variable in a regression model is 
unobserved but is estimated in the model by a variable that has associated with it some 
measurement error. Consider the model  
 
uxxy +++= 22
*
110 βββ  
 
where y  and 2x are observed but 
*
1x is not. Let 1x be an oberserved measurement of 
*
1x  such 
that 
1
*
11 exx +=  
 
where 1e is the measurement error. If 1x is used in place of 
*
1x in the modelling of y and 1x and 
1e are correlated, this model will be biased and inconsistent. 
 
Both omitted variable bias and error-in-variables bias can be addressed with the method of 
instrumental variables. An alternative method for dealing with potentially omitted variables is 
to identify a suitable proxy variable for the unobserved variable.  
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In addressing potential omitted variable bias, one must also be alert to the impact of 
multicollinearity. Multicollinearity occurs when some or all of the explanatory variables are 
highly correlated. Thus in adding variables to avoid omitted variable bias, one may encounter 
multicollinearity if the additional variables are highly correlated with explanatory variables 
already included in the model. Multicollinearity may affect the estimated coefficients and 
their standard errors, but the model will be unbiased (Wooldridge 2006). 
In the model of factors associated with service use, it may be the case that, if in accessing 
services an individual is reminded to be consistent in their medication taking, then non-
adherence and use of services are simultaneously determined. One can also accept, for 
example, the possibility that the therapeutic alliance between the patient and their physician is 
correlated with non-adherence and if not included in the modelling, would contribute to 
omitted variable bias. The therapeutic alliance between the patient and their physician is 
unobserved in the datasets used in the analyses. Because this effect is unobserved, it will 
contribute to the error term in the model and the error term may then be correlated to the 
effect of non-adherence, thus making non-adherence endogenous. 
 
One approach to dealing with the potential endogeneity of non-adherence in the modelling of 
service use would be to identify an instrumental variable for non-adherence. The difficulty 
posed is that due to the limited scope of the datasets analysed, it may be difficult to identify a 
variable that can satisfactorily be used as an instrument; that is, a variable that is correlated 
with non-adherence but not correlated with service use. If the basis for the endogeneity is the 
absence in the modelling of an omitted variable, the alternative approach would be to identify 
a suitable proxy measure for the ommited variable which is observed in the dataset.  
 
 
2.8 Summary 
 
To examine the nature of the association between non-adherence to medication in patients 
taking antipsychotics, data from the 1993/4 PMS and the QUATRO study, a randomised 
control trial of adherence therapy were used. As a comparison for these associations, similar 
analyses were conducted on a sample of patients in the PMS 2000 taking antidepressants. 
Within each dataset, non-adherence was assessed based on self-reported information provided 
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in interviews of patients. In each data source, patients were asked for detailed and thorough 
information on their use of health and social care services. These data were used in 
conjunction with estimates of the long-run marginal cost of specific services to estimate the 
total cost of service use from a health and social care perspective. Logistic regression models 
were estimated to determine the significance of factors identified in previous literature, and 
available in the datasets, in their association with whether a patient was adherent or not. 
Modelling the effect of non-adherence on service use costs involved first determining the 
prevalence of observations with no service use and therefore, zero costs. Where a significant 
number of such cases existed, two-part models were estimated. This involved modelling the 
presence or absence of service use in the first part of the model and using generalised linear 
models in determining which factors were associated with the cost of services used among 
those patients that did use services. In the analysis of the QUATRO data, additional terms 
were included to utilise the longitudinal nature of the data. Also, in each dataset, where a 
significant number of variables had substantial missing data, multiple imputation was used to 
estimate the missing values.  
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Chapter 3 
Patterns of non-adherence with antipsychotic medication and the impact of non-
adherence on costs – analyses of the 1993/4 Psychiatric Morbidity Surveys 
 
 
3.1 Background  
 
Much of the analysis of the factors associated with non-adherence and the impact of non-
adherence on service use costs has been based on small surveys and medical trials data. My 
review of the literature, described in chapter 1, found few studies based on large, population-
based data. Valenstien et al (2002) used US Veterans data to look at factors associated with 
non-adherence. In similar large-scale population-based studies, Cooper et al (2007) conducted 
a population-based study in the province of Quebec in Canada using the provincial health 
insurance database, and Karow et al (2007) used data from the European Schizophrenia 
Outpatient Health Outcomes (SOHO) study to again look at a factors associated with non-
adherence. Also, Janssen et al (2006) studied inpatients with schizophrenia and other 
psychoses in Germany, identifying patients through hospital admissions in seven psychiatric 
hospitals across Germany. Becker et al (2007) identified patients based on Medicaid lists in 
the US state of Florida. Only the study by Becker et al looked at the role of non-adherence on 
service use costs. 
 
This analysis, a secondary analysis of the 1993/4 Psychiatric Morbidity Survey data, sought to 
provide results based on a large, nationally representative, British sample. The Psychiatric 
Morbidity Surveys are cross-sectional, epidemiological surveys conducted in a range of 
settings throughout Great Britain. Interviews were conducted by the Social Survey Division 
field force of the British Office of Population Census and Surveys (OPCS; now called the 
Office for National Statistics) between April 1993 and August 1994 (Meltzer, Gill et al. 1995; 
Gill, Meltzer et al. 1996; Meltzer, Gill et al. 1996). The first part of the analysis aims to 
examine rates of non-adherence to antipsychotic medication, and to identify the key factors 
that appear to be associated with patterns of non-adherence. The second part seeks to estimate 
the impact of non-adherence on resource use and their associated costs. 
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3.2 Methods 
 
3.2.1 The sample 
 
The 1993-4 Psychiatric Morbidity Surveys collected data from residents of private 
households, persons living in institutions, and homeless persons. Each group were sampled 
separately. The OPCS postcode address file was the source of the sampling frame from which 
sectors and addresses were selected for the household sample (Meltzer, Gill et al. 1995). The 
sampling aimed to identify a relatively small number of people in a large number of areas. 
Postal sectors were the primary sampling unit, and were stratified by socio-economic group. 
In England and Wales postal sectors were sampled with probability proportional to the 
number of postal delivery points, and addresses were selected within each of these. In 
Scotland, the multiple occupancy count was used as the basis of probabilistic sampling within 
sampling sectors to identify addresses. In total, 200 postal sectors were selected. At each 
address, eligible individuals were given an initial questionnaire and those who reported a 
long-standing mental illness, use of antipsychotic medication or contact with services relating 
to a psychotic illness or screened positive on the CIS-R (a diagnostic instrument for neuroses) 
or the Psychosis Screening Questionnaire were followed up in greater detail relative to the 
remaining interviewees. Interviews took place between October and December 1993. 
 
The initial step in identifying intstitutions to sample from was to obtain the names and 
addresses of all institutions that provide some medical and/or residential care for adults with 
mental illness. Institutions included in the sample included the following: establishments 
which accommodate mentally ill adults were categorised into residential accommodation, 
National Health Service (NHS) accommodation, and private hospitals, homes and clinics and 
unregistered accommodation (Meltzer 1993). Within the three types of registered 
accommodation for people with mental illness, the survey aimed to sample one in thirty of all 
adults in the 16 to 64 years age range. These institutions were ordered by their number of beds 
and a sampling fraction applied to each. No centralised list of unregistered accommodation 
for mentally ill adults existed from which to sample, so the study team wrote to all general 
managers of district health authorities and all directors of social services of health authorities 
to construct a list to use as a sampling frame of unregistered accommodation. 
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A pilot survey was conducted in 1992 to test the organisation of the survey and the interview 
schedules and procedures. The interviews for the main institutional survey took place between 
April and July in 1994. 
 
The homeless sample included residents of hostels, residents of private sector leased and short 
life accommodation, adults staying in night shelters and people sleeping rough (Gill, Meltzer 
et al. 1996). The survey team categorised hostels specifically catering for people with mental 
illness as institutions to be included in the institutional sampling as opposed to the homeless 
sampling. Hostels were ordered by size within local authorities and a systematic equal 
probability sample of hostels was drawn. Those sleeping rough were sampled through their 
use of day centres. The survey did not attempt to sample those sleeping rough who did not use 
day centres. For each of the types of temporary accommodations used by the homeless, the 
sampling frame was stratified by size and a sample of units/addresses was systematically 
sampled from, after taking account of the probability of being sampled. The interviews of 
homeless persons took place between July and August 1994.  
 
All patients prescribed antipsychotic medication at the time of the survey were included in the 
analyses. This sample may include some patients who are being treated for a mental illness 
other than schizophrenia, but based on evidence of the trends in the off-label prescribing of 
antipsychotics, at the time of the PMS 1993-1994, only a small minority of  patients would be 
prescribed antipsychotics without having a diagnosis of schizophrenia (Hodgson and 
Belgamwar 2006). For consistency, interviews conducted with proxy respondents were 
excluded. Much of the information required in the analyses was based on reporting of 
personal information on medication taking and service use which, in order to be reliable and 
accurate, would be provided by the interviewee. 
 
3.2.2 Variable definitions 
 
The analyses rely on self-reported determination of non-adherence. In the dataset it was not 
possible to distinguish between medication not taken deliberately and occasions when patients 
forgot to take their medication. The assessment of non-adherence in the PMS relates to 
current medications only and is based on survey responses to the questions ‘Do you 
sometimes not take your medications even though you should?’ and ‘Do you sometimes take 
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more medication than the stated dose?’. Thus I sought to include not only patients who took 
less medication than they were prescribed, but also those who took more. In the analysis no 
differentiation is made between patients prescribed oral medication and those prescribed to 
receive depot injections. It was not possible to corroborate self-reported adherence with pill 
counts or physiological data in the survey. Indeed, few studies do so (Zygmunt, Olfson et al. 
2002). All measures of adherence have their drawbacks, but only self-report will be feasible 
in a large-scale survey such as this. Because I rely on self-reported information, it is likely 
that patients who are unaware of mistakes they are making in their medication regime are 
incorrectly classified as being adherent. Thus my analyses may underestimate the prevalence 
of non-adherence. Also, as the analyses include only those taking antipsychotics at the time of 
the survey, it excludes those patients who were not on medication when interviewed because 
they had refused medication.  
 
The review of previous empirical literature that analysed the relationship between non-
adherence and patient- , medication- and environmental-related factors identified the 
following variables within the data to include in the modelling: age, sex, ethnicity, education, 
general level of health, illness severity, previous experience of side effects, inpatient contact 
for mental health reasons in the past year, self-reported drug abuse, self-reported alcohol 
abuse, level of support from family or friends, and familiarity with medication. These factors 
were analysed for their association with non-adherence and as covariates in modelling service 
use costs. 
 
Data on ethnicity was collected in nine categories: White, Black–Caribbean, Black–African, 
Black–Other, Indian, Pakistani, Bangladeshi, Chinese and none of the above. Due to the small 
number of non-White respondents in each of the remaining ethnicity categories, these were 
combined to create a dichotomous ethnicity variable to use in the analysis. Education was 
classified into those with higher qualifications or A-levels, those who completed O-levels, and 
those with no O-level qualifications.  
 
Levels of general health were reported by patients on a five-point scale which was collapsed 
to three levels: very good/good; average; and poor/very poor. Severity of neurosis was based 
on results from the Revised Clinical Interview Schedule (CIS-R), a standardised instrument 
used to assess the prevalence and severity of symptoms in minor psychiatric disorders. 
Although administered by non-clinicians, the CIS-R has been shown to correlate closely with 
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standard clinical assessments (Lewis, Pelosi et al. 1992). Support from an adult with whom 
the patient feels close was based on the question ‘How many adults who live/are staying here 
with you do you feel close to?’. Medication familiarity was represented by being on 
medication for greater than two years. Additionally, a dummy variable was created which 
identified the patient’s place of accommodation, so that the statistical analyses could 
differentiate those patients living in hospitals from those in ‘other’ settings (residential care 
homes, supervised housing, group homes and hostels).  
 
The primary analysis uses the institutions sample only. This is because very few household 
respondents report that they are currently taking antipsychotics and of those that do, the rate 
of missing values amongst the other variables included in the analyses is high. The rate of 
missingness is also a problem in the homeless sample. The rates of missingness and 
identification of the variables most affected by missingness are given in the results section. 
 
3.2.3 Costing service use 
 
Data on the frequency of use of inpatient care, outpatient care, external services (including 
community psychiatric nurse, occupational therapist, social worker, community psychiatrist, 
home help, volunteer worker), day activity services (including sheltered employment) for the 
period of one year were available from the survey (see Table 3.1).  
 
Data on the frequency of use of inpatient care, outpatient care and day activity centres in the 
three months prior to interview were obtained in the survey. The number of visits was 
multiplied by four to estimate annual usage. The dataset categorises inpatient stays into six 
categories: secure or semi-secure unit, acute psychiatric ward, rehabilitation or long-stay 
ward, A&E department or emergency ward, general medical ward, or other. Outpatient visits 
were categorised into visits to A&E department of hospital casualty department, psychiatric 
outpatient department, other hospital outpatient department and other outpatient or daypatient 
service. The questionnaire differentiated day activity services as one of community mental 
health centre, day activity centre, sheltered workshop or other service.  
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Table 3.1: Health and social care services included in analyses, PMS 1993-4 
 
Professional services 
for those in hospital, 
clinic or nursing 
home 
Psychiatrist/Psychotherapist 
Other consultant/hospital doctor 
Psychiatric Nurse 
Social worker/Counsellor 
Occupational Therapist 
Psychologist 
Voluntary worker 
GP visits  
Hospital inpatient 
stays 
Secure/semi-secure or special hospital unit 
Acute psychiatric ward 
Rehabilitation or long-stay ward/facility 
A&E department or emergency ward 
General medical ward 
Hospital outpatient 
visits 
A&E department 
Psychiatric outpatient department 
Day activity services Community mental health centre 
Day activity centre 
Sheltered workshop 
External services Community Psychiatrist 
Community Psychologist 
Community Psychiatric Nurse 
Community learning difficulty nurse 
Other nursing services 
Social worker 
Self-help/support group 
Home help/home care worker 
Outreach worker/family support 
 
 
 
 
 
Data on whether or not respondents had visited their GP was available for the two-weeks prior 
to the interview or, as with other health service use, for the previous year. The advantage of 
the two-week estimate is that the number of visits was given; the disadvantage being that the 
prior two weeks do not necessarily reflect typical recent GP service use. The current analysis 
uses the data on GP visits in the prior year and assumes two visits for those who have visited 
their GP during this time period.  
 
The best available approximations to long-run marginal opportunity costs at a national level 
were taken from a well-known compendium for 2001 (Netten, Rees et al. 2001). This year 
was chosen to be consistent with the later analysis of the 2000 Psychiatric Morbidity Survey. 
Qualification costs were not included in the unit costs used in this analysis. The unit costs for 
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each type of inpatient stay were based on daily rates and include accommodation costs. For 
A&E outpatient visits and community care services a cost per visit was the basis of the unit 
cost. Here an average length of time of one hour was assumed per visit and the unit cost 
relating to hourly patient contact time was used. For community mental health centre and 
sheltered workshop visits, the average length time of visits was estimated and an hourly unit 
cost applied. For day activity centre visits a sessional unit cost was applied with a session 
being either a morning, afternoon or evening. 
 
The unit cost of each service used was multiplied by the total number of visits to that service 
to estimate the annual cost for that service. The data were then summed to estimate total costs. 
The analyses examined total costs, and its three main components: inpatient service costs, 
external service costs and the costs associated with day activity service use. 
 
3.2.4 Statistical analyses 
 
As described in chapter 2 on methods, multiple imputation was employed when missing data 
was judged to be missing at random. The primary analysis was conducted on the imputed 
dataset. For subsamples where missingness at random could not be assumed, two secondary 
analyses were performed. The variables found to be significant in their association with non-
adherence in the primary analysis were compared univariately with non-adherence. These 
univariate comparisons were made using the Pearson’s chi-squared test for categorical 
variables (Plackett 1983) and the Wilcoxon Rank Sum test for continuous variables 
(Wilcoxon 1945). Secondly, total service use costs were compared across adherence status 
groups using the non-parametric Wilcoxon Rank Sum test.  
 
In the primary analysis, where there is overlap with covariates used to explain non-adherence, 
I hoped to determine if these factors significantly affect costs over and above their influence 
on non-adherence. Given that this analysis looks at cross-sectional data, it can not be ruled out 
that the correlation between a covariate and the indicator of non-adherence will affect the 
significance of the main effect of that covariate in the analysis of costs. That is, that 
multicollinearity may exist. Whether or not a patient had an inpatient stays in the previous 
year was not included as a covariate in the analyses of costs as these visits were included in 
the services costed. 
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As described in the methods section, logistic regression models were used to determine the 
factors associated with non-adherence. These models were assessed by the link test, the 
Pearson’s chi-squared test, the Hosmer-Lemeshow test, the likelihood ratio test and the 
percentage of observations correctly predicted by the model. Generalised linear models were 
used to test factors for their association with costs. With respect to inpatient, external and day 
activity service costs a significant proportion of the study sample did not utilise these services 
and so a two-part model was used. Part one modelled the probability that costs are incurred, 
while the second part modelled the intensity of costs among those who did use the service 
(Mullahy 1998). The probability that costs were incurred was estimated with a logistic 
regression model, while estimations of the intensity of costs were modelled using GLM 
models. Within a GLM model a link function can be specified to allow for the estimates of the 
parameters to be directly derived in the linear scale, and the algorithm outlined by Manning 
and Mullahy (2001) was used to select the distributional form of the GLM based on an 
extension of the Park test.  
 
In the modelling of the probability of service use (where included) and service use costs, the 
effect of institution type was included as a covariate. This effect accounted for the fact that the 
use of certain services was likely to be associated with institution type. For example, use of 
inpatient services may have been more likely for individuals who at the time of the survey 
were not already in long-stay hospitals. 
 
Endogeneity is a potential problem in these models. Simultineity may arise if regular contact 
with services has the effect of improving adherence through health service providers 
reminding and encouraging patients to adhere to their medication. I considered using the 
experience of side-effects as an instrument for non-adherence, but the obvious difficulty is 
that this variable itself may by associated with use of services. The limited scope of the PMS 
dataset with respect to factors associated with non-adherence made no other observed variable 
a good choice as an instrument for non-adherence. The potential for omitted variable bias 
exists in that factors associated with non-adherence and service use, supported by the 
theoretical literature, were not found in the dataset and could therefore contribute to 
correlation between non-adherence and the error term in the modelling. In particular, factors 
relating to attitudes to and preferences for support such as the therapeutic alliance between the 
 76 
patient and their physician were not assessed in the PMS surveys. I included medication 
familiarity in the modelling of service use costs as a proxy for this effect. 
 
Factors achieving significance at the 0.05 level were deemed statistically significant. The 
analysis was performed using the STATA data analysis software (STATA 2008). 
 
Based on the modelling results, predicted costs were derived for a hypothetical case which 
arbitrarily set values for the predictive variables included in the modelling. Predicted values 
were then estimated for variations of the hypothetical case with one value of one of the 
explanatory variables changed. In order to estimate the confidence intervals around these 
predictions, a bootstrapping algorithm, incorporating 1000 repetitions, was used. This allowed 
me to obtain estimates of the standard error around each of the predictions. This data was then 
plotted in histograms illustrating the relative impact of changes to key variables. These plots 
were produced using the EXCEL software (Microsoft Corporation 2003). 
 
 
3.3 Results 
 
The rate of cooperation among institutions selected for the survey was poor with just over 
50% participating. Thirty-one percent of the non-participating institutions were deemed 
ineligible as they were either acute units and did not have permanent residents, catered for 
people aged 65 and over or catered for those who were mentally handicapped as opposed to 
mentally ill. The remainder refused to take part. Refusals were most common among private 
institutions, smaller hospitals and residential care homes, supported lodging, unstaffed group 
homes and hostels. 
 
In the household sample, of the 12,730 individuals selected for interview, 10,108 (79%) co-
operated and had an initial interview which included questions on socio-demographic 
characteristics, general health, the Clinical Interview Schedule – Revised and the Psychosis 
Screening Questionnaire. Within the homeless sample the response rate varied substantially 
according to the source of selecting individuals to be interviewed. Of individuals identified 
from hostels, 74% were interviewed; within private sector leased and short-life 
accommodation, interviews were completed in 44% of households selected; within 
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nightshelters, 79% of individuals approached did in fact provide an interview; and 68% of 
selected visitors to day centres for homeless people were interviewed. 
 
The Psychiatric Morbidity Survey institutions sample consists of data on 1,191 patients. Of 
these, the data on 313 residents of institutions were provided by a proxy, and excluded 
information relevant to the analyses. Of the remaining 818 subjects, 658 persons were 
prescribed antipsychotic medication at the time they were surveyed. The household sample 
has data on 10,108 patients of which 271 were interviews of proxies. Of the remaining 9,837 
there were 54 respondents who were prescribed antipsychotics at the time of the interview. 
The homeless sample includes 1,166 individuals (530 in hostels, 268 in private sector leased 
(PSL) or short life accommodation, 187 in nightshelters and 181 from day centres). Within 
the hostel and PSL samples, data for 50 patients were provided by proxies. Only 27 
individuals in the homeless sample reported that they were currently taking antipsychotics in 
their interview. 
 
Table 3.2 summarises demographic data for each sample. The institutions sample is broken 
down into those in hospitals and those in ‘other’ institutions to explore the comparability of 
these two groups. The samples were comparable in age and ethnicity. The household sample 
was balanced between the sexes whereas the other samples had more males than females. The 
household and homeless sample members were more educated than the patients in 
institutions. All of the homeless respondents report good general health while less than 30% 
of the household sample report this level of general health. This divergence may reflect the 
subjective nature of responses to questions on a patient’s general health. The homeless 
patients were found (after screening) to have higher levels of neurosis and were more likely to 
report side effects with their medication and drug and alcohol abuse as compared to the other 
samples. The homeless sample also had been taking antipsychotics for a shorter period than 
the remaining patients. Patients in residential care homes, supervised housing, group homes or 
hostels were most likely to have been on medication for greater than 2 years. Over 50% of the 
homeless report non-adherence to medication as compared to approximately 30% in the 
household sample, 20% of those in residential care homes, supervised housing, group homes 
or hostels and 10% of those in hospital. 
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Table 3.2: Demographic characteristics of sample members currently taking antipsychotics, 
PMS 1993-4 
 
 Resident in 
Household 
(n=54) 
Resident in 
 Hospital 
(n=304) 
Resident in 
other 
institutions 1 
(n=354) 
Homeless 
(n=27) 
Age: mean (SD) 46.1 (11.7) 43.0 (12.6) 44.8 (10.6) 38.4 (13.5) 
Sex: % male 46.3 % 71.1 % 68.4 % 77.8% 
Ethnicity: % White 94.4 % 89.5 % 95.5 % 92.6 % 
Education: 
  % Higher qual. or A-levels 
  % O-levels2 
  % No O-levels 
 
15.1 % 
22.6 % 
62.3% 
 
11.2 % 
12.5 % 
76.3 % 
 
12.4 % 
16.2 % 
71.4 % 
 
16.0 % 
20.0 % 
64.0 % 
General health: 
  % Good 
  % Fair 
  % Bad 
 
29.6 % 
48.2 % 
22.2 % 
 
50.3 % 
33.6 % 
16.1 % 
 
47.7 % 
41.2 % 
11.1 % 
 
100 % 
0 % 
0 % 
Illness severity: mean (SD) 
CIS-R score 3 
 
12.4 (11.9) 
 
12.9 (10.9) 
 
10.5 (9.7) 
 
20.1 (13.3) 
Ever experienced side effects: 
  % yes  
 
9.3 % 
 
6.6 % 
 
7.9 % 
 
14.8 % 
Mental health hospital stays: 
  % yes 
 
16.7 % 
 
12.8 % 
 
17.8 % 
 
14.8 % 
Drug abuse: % yes 9.3 % 7.2 % 9.3 % 29.6 % 
Alcohol abuse: % yes 0 % 6.1 % 6.7 % 22.2 % 
Lives with adult with whom 
feels close: % yes 
 
85.7 % 
 
55.7 % 
 
66.2 % 
 
100 % 
Greater than 2 years on 
medications: % yes 
 
64.7 % 
 
52.8 % 
 
78.6 % 
 
34.8 % 
Self-reported non-adherence 18 
(33.3%) 
34 
(11.2%) 
75 
(21.2%) 
14 
(51.9%) 
 
 
 
 
Overall 220 individuals (29.8% of the sample) had data missing on one or more of the 
variables included in the analyses. The prevalence of missing values was particularly a  
problem in the homeless sample. None of these respondents had complete data on the 
variables of interest. Within the homeless sample (n=27), 11 (40.7%) were missing one 
variable, 7 (25.9%) were missing two variables and 9 (33.3%) were missing three or more. 
Age, health status, CIS-R score and living or staying with an adult with whom they feel close 
                                                 
1 Residential care home, ordinary housing with a degree of protection, supervised ordinary housing, group home 
or hostel. 
2 O-level were a British exam taken by students at age 16. This exam was replaced by the GCSE exam. In the 
PMS, achievement of O-Level equivalent qualifications constituted O-level passes of Grades A-C, GCSE passes 
of Grades A-C or National Vocational Qualifications level 2. 
3 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor psychiatric disorder. Higher scores 
indicate greater prevalence/severity of neurosis. 
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were the variables least frequently answered by homeless respondents. Only 8 (29.6%) of the 
homeless sample reported their age and only 13 (48.1%) reported their general health status. 
Of note, all homeless respondents who responded to the question on their general health status 
reported very good or good health. This suggests a potential bias towards not responding to 
this question if the answer did not put the respondent in a favourable light. Similarly, the 19 
(70.4%) of the homeless sample who responded to the question regarding whether or not they 
live or stay with an adult with whom they feel close all reported having such social support.  
 
Within the household sample 33 of 54 respondents (61.1%) had compete data on the variables 
to be included in the analyses, 19 (35.2%) were missing one variable only, while 2 (3.7%) 
were missing two variables. The variable that asked whether or not the patient lived or was 
staying with an adult with whom they felt close was missing for 35% of the sample. Of those 
that did respond to the question on social support, 85.7% report living with an adult with 
whom they feel close.  
 
Within the sample of respondents resident in institutions, 486 of 658 (73.9%) had complete 
data. One hundred and eighteen (17.9%) were missing one variable only, 35 (5.3%) were 
missing two variables, 16 (2.4%) had 3 missing values, 3 (0.5%) had 4 missing values. The 
variables with the highest number of missing values were length of time on medication 
(12.8% missing), whether or not they lived or stayed with an adult with whom they felt close 
(12.6% missing) and alcohol use (5.3% missing). The following variables had no missing 
values: non-adherence, experience of side effects, ethnicity, sex, age, inpatient mental health 
contact and type of residence. Within the homeless sample, 11 of the 27 (40.7%) patients had 
missing values for one variable to be included in the analysis. Seven patients (25.9%) had 
missing values for two variables and 9 (33.3%) had missing values for three or more 
variables. Data on general health was missing for two-thirds of the homeless sample and age 
was not reported by 19 (70.4%) of the sample.  
 
Due to the apparent association between the missingness on questions relating to health status 
and social support and the observed values on these items, missingness at random, required 
for multiple imputation, cannot be assumed within the homeless sample. It is unclear as to 
whether or not a similar problem exists with the question on social support when asked within 
the household population. Given the small number of observations contributed by the 
household sample and the concern about the missing at random assumption, the decision was 
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taken to restrict the primary analysis to the institutions sample only. Within the institutions 
sample missing values are observed on the social support and length of time on medication 
questions, but the distribution of observed values does not suggest a bias towards non-
response being associated with a particular response option. 
 
The overall rate of self-reported non-adherence amongst the institutions sample was 16.7%. 
This rate differed between patients resident in hospitals (11.2%) and those living in residential 
care homes, group homes or hostels (21.2%). This range is somewhat lower than reports in 
the literature (Battaglia 2001; Conley and Kelly 2001), probably a consequence of focussing 
on an institutions sample where patients may receive support, encouragement and/or 
incentives to adhere to medication.  
 
The logistic regression analysis identified significant associations between non-adherence and 
the following factors: residence in a residential care home, supervised housing, group home or 
hostel, having higher qualifications or A-levels, having had a mental health hospital stay in 
the previous year, having previously experienced side effects, and reporting alcohol abuse 
(see Table 3.3). Also, the probability of non-adherence increased as CIS-R scores increased 
(reflecting greater prevalence and/or severity of symptoms of neurosis) and decreased as the 
age of patients increased. 
 
Significantly, those people resident in non-hospital institutions were over twice as likely to be 
non-adherent as people resident in hospital. Having higher qualifications or A-levels 
approximately doubles the predicted probability of non-adherence, as does having had a 
mental hospital stay in the previous year. The odds of not adhering with current medication 
were 3.2 times greater for those who have previously experienced side effects with 
antipsychotic medication compared to those who had not. Those who report alcohol abuse 
were three times as likely to be non-adherent as those who did not report it. 
 
The model diagnostics reported are the average values across the five imputed datasets. The 
link test p-value (0.203) of the square of the predicted value suggests that the model is not 
misspecified. The Pearson’s and Hosmer and Lemeshow chi-squared p-values (0.0659 and 
0.2168 respectively) were not significant, indicating acceptable goodness of fit, as did the 
significance of the likelihood ratio chi-squared test. The percentage of observations correctly 
predicted by the model was 70.9%. 
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 Table 3.3: Results of logistic regression model on factors associated with non-adherence, PMS 1993-
4 Institutions sample 
 
Variables N=658 
Odds Ratio 95% CI 
Resident in ‘other’ institution 1(n=354)… 
…relative to resident in hospital (n=304) 
2.43*** 
 
1.46, 12.34 
 
Age (5 year increase in age) 0.85*** 0.76, 0.96 
Male (n=458)… 
…relative to Female (n=200) 
0.84 
 
0.50, 1.41 
Higher qualifications or A-levels (n=76)… 
O-level  2 (n=102)… 
…relative to below O-level qualifications (n=480) 
2.42*** 
0.94 
1.29, 4.55 
0.48, 1.83 
Average general health (n=250)… 
Poor general health (n=87)… 
…relative to good general health (n=321) 
1.17 
0.81 
0.71, 1.93 
0.37, 1.77 
Non-White (n=48)… 
…relative to White (n=610) 
1.39 0.61, 3.19 
Prevalence/severity of neurosis: CIS-R score 3 (five unit increase) 1.18*** 1.05, 1.33 
Had a hospital stay for a mental, nervous or emotional problem 
(n=102)… 
…relative to not having had hospital stay for a mental, nervous or 
emotional problem (n=556) 
 
1.89** 
 
1.08, 3.31 
Two or more years on medication (n=439)… 
…relative to less than 2 years on medication (n=219) 
1.29 0.73, 2.28 
Experienced side effects or worries about side effects (n=48)… 
…relative to having not experienced or worried about side effects 
(n=610) 
3.19*** 1.60, 6.40 
Lives with adult with whom feels close (n=403)… 
 …relative to does not live with adult with whom feels close 
(n=255) 
0.93 0.56, 1.54 
Reports moderate or high alcohol dependency (n=42)… 
…relative to no alcohol dependency (n=616) 
3.08*** 1.39, 6.85 
Reports illegal drug use (n=55)… 
…relative to non drug users (n=603) 
1.29 0.62, 2.71 
Link test p-value 0.203 
Pearson’s chi-sqpared test p-value 0.0659 
Hosmer-Lemeshow chi-squared test p-value 0.2168 
Likelihood ratio chi-squared p-value <0.0001 
Percent correctly classified 70.85% 
 
* p≤0.10;  ** p≤0.05;  *** p≤0.01 
 
 
 
1 residential care homes/supervised housing/group homes/hostels 
2 O-level were a British exam taken by students at age 16. This exam was replaced by the 
GCSE exam. In the PMS, achievement of O-Level equivalent qualifications constituted O-
level passes of Grades A-C, GCSE passes of Grades A-C or National Vocational 
Qualifications level 2. 
3 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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In the analysis of resource use and resource use costs, initially individual services were 
considered. Those services that were most often used and those that incurred the greatest costs 
were analysed individually. These services were inpatient, external and day activity services 
(see Table 3.4). 
 
Table 3.4: Distribution of costs by service type, PMS 1993-4 Institutions sample 
 
 N Mean Median Standard 
deviation 
Interquartile range 
Inpatient costs 151 32,627 26,146 15,083 23,860 – 33,923 
Outpatient costs 159 1,339 512 1,838 256 – 1,536 
GP costs 85 483 442 147 442 - 442 
External service costs 251 2,705 1,617 3,282 356 – 3,109 
Day activity service 
costs 
232 4,645 5,616 3,159 432 – 5,616 
(Sheltered) work costs 41 7,983 5,284 3,254 5,284 – 11,512 
Total costs 657 34,003 34,413  21,224 14,130 – 48,180 
 
 
 
3.3.1 Inpatient services 
 
A total of 151 patients (23.0% of sample) reported having an inpatient stay in the past year. 
Of those who had an inpatient stay, mean inpatient costs were £32,630. A logistic regression 
model of whether or not inpatient services were used found statistically significant 
associations between use of inpatient services and living in a residential care home, 
supervised housing, group home or hostel, being from an ethnic minority and having been 
prescribed an antipsychotic medication for less than two years (see Table 3.5). Ethnic 
minority patients were two and a half times as likely to have used inpatient services. Those 
who live in a residential care home, supervised housing, group home or hostel were over one 
and a half times as likely to report use of inpatient services as compared to hospital residents, 
as were those that were on medication for less than two years as compared to those on 
medication for two or more years. The association between use of inpatient services and non-
adherence to medication approached statistical significance (p=0.059), with those non-
adherent being over one and a half times as likely to have used inpatient services. Similarly,  
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Table 3.5: Results of logistic regression model on factors associated with having had an 
inpatient stay, PMS 1993-4 Institutions sample  
 
Independent variables N=658 
Odds Ratio 
(of using services) 
95% CI 
Resident in ‘other’ 2 institution (n=354)… 
…relative to resident in hospital (n=304) 
1.64** 
 
1.09, 2.49 
Age (5 year increase in age) 0.93 0.84, 1.02 
Male (n=458)… 
…relative to Female (n=200) 
0.70 
 
0.46, 1.07 
Higher qualifications or A-levels (n=76)… 
O-levels (n=102)… 
…relative to below O-level qualifications (n=480) 
1.44 
1.02 
 
0.79, 2.60 
0.59, 1.79 
Non-White (n=48)… 
…relative to White (n=610) 
2.46** 1.24, 4.85 
Average general health (n=250)… 
Poor general health (n=87)… 
…relative to good general health (n=321) 
0.91 
0.71 
0.60, 1.38 
0.37, 1.38 
Prevalence/severity of neurosis: CIS-R score 3 (five 
unit increase) 
 
1.02 
 
0.93, 1.14 
Non-adherent (n=109)… 
…relative to adherent (n=549) 
1.61* 0.98, 2.63 
Lives with adult with whom feels close (n=403)… 
 …relative to does not live with adult with whom 
feels close (n=255) 
 
1.55* 
 
0.97, 2.45 
Reports illegal drug use (n=55)… 
…relative to non drug users (n=603) 
1.35 0.70, 2.59 
Reports moderate or high alcohol dependence 
(n=42)… 
…relative to no alcohol dependence (n=616) 
 
1.88* 
 
0.90, 3.93 
Two or more years on medication (n=439)… 
…relative to less than 2 years on medication (n=219) 
0.56** 0.35, 0.90 
Link test p-value 0.714 
Pearson’s chi-sqpared test p-value 0.3304 
Hosmer-Lemeshow chi-squared test p-value 0.6646 
Likelihood ration chi-squared p-value <0.0001 
Percent correctly classified 65.59% 
 
* p≤0.10;  ** p≤0.05;  *** p≤0.01 
 
 
 
1 residential care homes/supervised housing/group homes/hostels 
2 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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the effect of living with an adult with whom the respondent feels close approached statistical 
significance with social support positively associated with having had an inpatient visit. 
 
The goodness-of-fit tests for this model were as follows: the link test p-value (0.714) of the 
square of the predicted value suggests that the model is not misspecified. The Pearson’s and 
Hosmer and Lemeshow chi-squared p-values (0.3304 and 0.6646 respectively) were not 
significant, indicating acceptable goodness of fit. The significance of the likelihood ratio chi-
squared test also suggested the model fits the data well. The percentage of observations 
correctly predicted by the model was 65.6%.  
 
A GLM model with a log link function and a gamma distribution was fitted to inpatient costs. 
Among those using inpatient services, the only factor found to approach a statistically 
significant association with inpatient costs was ethnicity (see Table 3.6). Non-White patients 
reported greater costs than White patients. This observed association, however, was based on 
a small sample of Non-White patients (n=18). Estimates of inpatient costs for a range of case 
types appear in Figure 3.1. The base case was of a man, age 45, White, with no O-levels, good 
general health, resident in hospital, who adheres to his antipsychotic medication, has a CIS-R 
score of 11, does not report drug or alcohol abuse, who lives with an adult with whom he feels 
close and has been on medication for over 2 years. Changing the characteristics of this case 
illustrates the relative impact of significant factors.  
 
Ethnicity clearly had a major effect on in-patient costs: non-Whites were predicted to cost 
approximately £6,600 more per annum than the base case type. Patients reporting non-
adherence were predicted to have excess inpatient costs of approximately £2,500 per year 
above the base case type. 
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Table 3.6:  Generalised linear model on factors associated with inpatient costs, PMS 1993-4 
Institutions sample  
 
Independent variables N=151 
Coefficient 
 
95% CI 
Resident in ‘other’ 1 institution (n=91)… 
…relative to resident in hospital (n=60) 
-0.095 -0.24, 0.051 
Age 0.0020 -0.0048, 0.0089 
Male (n=99)… 
…relative to Female (n=52) 
0.019 
 
-0.13, 0.17 
Higher qualifications or A-levels (n=24)… 
O-levels (n=28)… 
…relative to below O-level qualifications (n=99) 
-0.019 
0.14 
-0.22, 0.18 
-0.076, 0.35 
Non-White (n=18)… 
…relative to White (n=133) 
0.23* -0.028, 0.50 
Average general health (n=58)… 
Poor general health (n=17)… 
…relative to good general health (n=76) 
0.044 
0.071 
-0.10, 0.19 
-0.20, 0.34 
CIS-R score 2 -0.0044 -0.010, 0.0015 
Non-adherent (n=39)… 
…relative to adherent (n=112) 
0.079 -0.097, 0.26 
Lives with adult with whom feels close (n=101)... 
 …relative to does not live with adult with whom feels 
close (n=50) 
0.082 -0.069, 0.23 
Reports illegal drug use (n=20)… 
…relative to non drug users (n=131) 
-0.060 -0.27, 0.15 
Reports moderate or high alcohol dependence (n=15)... 
…relative to no alcohol dependence (n=136) 
 
0.074 
 
-0.22, 0.37 
Two or more years on medication (n=87)… 
…relative to less than two years on medication (n=64) 
-0.064 
 
-0.22, 0.096 
Constant 10.29*** 9.90, 10.67 
Link function Log 
Distributional family Gamma 
 
* p≤0.10;  ** p≤0.05;  *** p≤0.01 
 
 
 
1 residential care homes/supervised housing/group homes/hostels 
2 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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3.3.2 External services 
 
External services include visits by a community psychiatric nurse, occupational therapist, 
social worker, community psychiatrist, home help or volunteer worker. The mean annual cost 
of external services among those who used this service was estimated at £2,705 per annum 
and 251 patients used these services. There was no reported use of external services by 
hospital residents so the dummy variable representing the effect of being in a residential care 
home, supervised housing, group home or hostel was excluded from the model. 
 
Use of external services was significantly associated with non-adherence to medication, 
ethnicity, the CIS-R score and length of time on medication (see table 3.7). Patients who were 
non-adherent or were on medication for two or more years were over two and a half times 
more likely to use external services as compared to adherent patients and those on medication 
for less than two years, respectively. Non-Whites patients were significantly less likely to use 
external services as compared to White patients. Increases in the severity of neurosis were 
associated with a lower likelihood of external service use.  
 
The square of the predicted value estimated in the link test had a p-value of 0.787 which 
suggests that the model was not misspecified. The Pearson’s and Hosmer and Lemeshow chi-
squared p-values (0.3833 and 0.6381 respectively) were not significant indicating acceptable 
goodness of fit, as did the significance of the likelihood ratio chi-squared test (p<0.0001). The 
percentage of observations correctly predicted by the model was 62.9%.  
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Table 3.7:  Factors associated with use of external services 1, PMS 1993-4 Institutions sample  
 
 
Independent variables N = 658 
Odds Ratio 
(of using services) 
95% CI 
Age (5 year increase in age) 0.94 0.86, 1.02 
Male (n=458)… 
…relative to Female (n=200) 
1.002 
 
0.69, 1.46 
Higher qualifications or A-levels (n=76)… 
O-levels (n=102)… 
…relative to below O-level qualifications (n=480) 
1.39 
1.35 
0.81, 2.38 
0.82, 2.23 
Non-White (n=48)… 
…relative to White (n=610) 
0.48** 0.23, 1.01 
Average general health (n=250)… 
Poor general health (n=87)… 
…relative to good general health (n=321) 
1.37* 
1.32 
0.94, 2.00 
0.74, 2.34 
Prevalence/severity of neurosis: CIS-R score 2 (five 
unit increase) 
0.90** 0.81, 0.99 
Non-adherent (n=109)… 
…relative to adherent (n=549) 
2.66*** 1.67, 4.23 
Lives with adult with whom feels close (n=403)… 
 …relative to does not live with adult with whom 
feels close (n=255) 
 
1.17 
 
0.79, 1.72 
Reports illegal drug use (n=55)… 
…relative to non drug users (n=603) 
1.40 0.74, 2.65 
Reports moderate or high alcohol dependence 
(n=42)… 
…relative to no alcohol dependence (n=616) 
 
1.50 
 
0.73, 3.07 
Two or more years on medication (n=439)… 
…relative to less than 2 years on medication 
(n=219) 
2.86*** 1.89, 4.31 
Link test p-value 0.787 
Pearson’s chi-sqpared test p-value 0.3833 
Hosmer-Lemeshow chi-squared test p-value 0.6381 
Likelihood ration chi-squared p-value <0.0001 
Percent correctly classified 62.86% 
 
* p≤0.10;  ** p≤0.05;  *** p≤0.01 
 
 
 
1 External services include visits by a community psychiatric nurse, occupational therapist, 
social worker, community psychiatrist, home help or volunteer worker. 
2 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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Analysis of the factors associated with the cost of external services was based on the 251 
patients who had used these services in the past 12 months. A GLM model using a log link 
function and gamma distribution was fitted to the data (see Table 3.8). Patients who reported 
drug use incurred significantly lower costs if they accessed external services as compared to 
those who did not report drug use. There is also a trend for having been on medication for two 
or more years having an association with increased external service use costs (p=0.096). Even 
though non-adherence increased the likelihood of use of external services, the volume of use 
was lower, other things being equal. Indeed the product of probability and intensity of use 
suggested that non-adherence increased external service use costs, while costs were 
substantially lower for patients on medication for less than two years (see Figure 3.2) relative 
to the base case. Being of average general health (as compared to good health) had the 
greatest impact on increasing the predicted costs of external services. 
 
3.3.3 Day activity services 
 
The estimated mean day care costs among users of this service were £4,645 per annum. A 
total of 232 patients (35.3% of sample) reported having used day activity services during the 
recall period. A logistic regression model of whether or not day activity services were used 
found statistically significant associations between use of these services and living in a 
residential care home, supervised housing, group home or hostel, age, self-reported health 
status and length of time on medication (see Table 3.9). Those who lived in a residential care 
home, supervised housing, group home or hostel were four times as likely to have used day 
care services as compared to hospital residents. Each five-year increase in age was associated 
with a 10% reduction in the odds of using day care services and those reporting poor health 
were 60% less likely to use these services as compared to those who report good health. 
Additionally, having been prescribed antipsychotics for two or more years was associated 
with 1.7 times the odds of using day care services as compared to those patients who had been 
prescribed antipsychotics for less than two years. The association between use of day activity 
services and non-adherence to medication was not statistically significant (p=0.333). 
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Table 3.8: Factors associated with costs of external services 1, PMS 1993-4 Institutions 
sample 
 
Independent variables N=251 
Coefficient 
 
95% CI 
Age -0.0026 -0.017, 0.11 
Male (n=176)… 
…relative to Female (n=75) 
0.21 
 
-0.09, 0.51 
Higher qualifications or A-levels (n=35)… 
O-levels (n=42)… 
…relative to below O-level qualifications (n=174) 
-0.16 
0.32 
-0.55, 0.23 
-0.078, 0.72 
Non-White (n=12)… 
…relative to White (n=239) 
0.11 -0.55, 0.77 
Average general health (n=107)… 
Poor general health (n=30)… 
…relative to good general health (n=114) 
0.16 
-0.25 
-0.15, 0.47 
-0.65, 0.16 
CIS-R score 2 0.0042 -0.012, 0.020 
Non-adherent (n=64)… 
…relative to adherent (n=187) 
-0.16 -0.49, 0.18 
Lives with adult with whom feels close (n=164)... 
 …relative to does not live with adult with whom feels 
close (n=87) 
0.12 -0.17, 0.41 
Reports illegal drug use (n=28)… 
…relative to non drug users (n=223) 
-0.44** -0.85, -0.026 
Reports moderate or high alcohol dependence (n=23)... 
…relative to no alcohol dependence (n=228) 
 
-0.15 
 
-0.60, 0.30 
Two or more years on medication (n=199)… 
…relative to less than two years on medication (n=52) 
0.32* 
 
-0.058, 0.71 
Constant 7.48*** 6.71, 8.25 
Link function Log 
Distributional family Gaussian 
 
* p≤0.10;  ** p≤0.05;  *** p≤0.01 
 
 
 
1 External services include visits by a community psychiatric nurse, occupational therapist, 
social worker, community psychiatrist, home help or volunteer worker. 
2 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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Table 3.9:  Factors associated with use of day activity services 1, PMS 1993-4 Institutions 
sample 
 
 
Independent variables N = 658 
Odds Ratio 
(of using services) 
95% CI 
Resident in ‘other’ 2 institution (n=354)… 
…relative to resident in hospital (n=304) 
4.05*** 2.76, 5.95 
Age (5 year increase in age) 0.91** 0.83, 0.99 
Male (n=458)… 
…relative to Female (n=200) 
1.19 
 
0.80, 1.76 
Higher qualifications or A-levels (n=76)… 
O-levels (n=102)… 
…relative to below O-level qualifications (n=480) 
1.15 
1.18 
0.67, 1.98 
0.70, 1.97 
Non-White (n=48)… 
…relative to White (n=610) 
0.82 0.39, 1.70 
Average general health (n=250)… 
Poor general health (n=87)… 
…relative to good general health (n=321) 
0.74 
0.40*** 
0.51, 1.08 
0.21, 0.78 
Prevalence/severity of neurosis: CIS-R score 3 (five 
unit increase) 
1.0056 0.91, 1.11 
Non-adherent (n=109)… 
…relative to adherent (n=549) 
0.79 0.48, 1.28 
Lives with adult with whom feels close (n=403)… 
 …relative to does not live with adult with whom 
feels close (n=255) 
 
1.08 
 
0.74, 1.58 
Reports illegal drug use (n=55)… 
…relative to non drug users (n=603) 
1.12 0.59, 2.12 
Reports moderate or high alcohol dependence 
(n=42)… 
…relative to no alcohol dependence (n=616) 
 
1.70 
 
0.83, 3.48 
Two or more years on medication (n=439)… 
…relative to less than 2 years on medication 
(n=219) 
1.70** 1.10, 2.62 
Link test p-value 0.152 
Pearson’s chi-squared test p-value 0.4436 
Hosmer-Lemeshow chi-squared test p-value 0.3924 
Likelihood ration chi-squared p-value <0.0001 
Percent correctly classified 65.02% 
 
* p≤0.10;  ** p≤0.05;  *** p≤0.01 
 
 
 
 
1 Day activity services include visits to a community mental health centre, day activity centre 
or sheltered workshop. 
2 residential care homes/supervised housing/group homes/hostels 
3 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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The link test p-value (0.152) suggested that the model was satisfactorily specified. The 
Pearson’s and Hosmer and Lemeshow chi-squared p-values (0.4436 and 0.3924 respectively) 
were not significant indicating acceptable goodness of fit. The significance of the likelihood 
ratio chi-squared test (p<0.0001) also suggested acceptable goodness of fit. The percentage of 
observations correctly predicted by the model was 65.0%.  
 
A GLM model with a log link function and a Gaussian distribution was fitted to day activity 
service use costs (see Table 3.10). Among those using day care services, none of the factors 
included in the model were found to be associated with day activity service use costs. Figure 
3.3 presents the predicted cost of day activity services combining the logistic regression and 
GLM results. Compared to the base case type, the effects of living in an institution other than 
a hospital and being younger in age had the greatest impact on increasing the cost of day 
activity services. 
 
3.3.4 Total health and social care costs 
 
The final model examined factors associated with the total costs of all health and social care 
services. The mean observed total cost was £33,795 per annum. A single GLM model was 
used, as opposed to a two-part model, because all but one patient had used at least one service 
and therefore incurred costs. A log link function and a Gaussian distribution were used in the 
GLM (see Table 3.11). Type of residence was found to be statistically significant. People 
living in residential care homes, supervised housing, group homes or hostels incurred 
significantly lower total costs compared to hospital residents. There was a trend for those 
patients who reported non-adherence to have greater total costs than those who adhered to 
their antipsychotic medication 
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Table 3.10: Factors associated with costs of day activity services 1, PMS 1993-4 Institutions 
sample 
 
 
Independent variables N=232 
Coefficient 
 
95% CI 
Resident in ‘other’ 2 institution (n=175)… 
…relative to resident in hospital (n=57) 
0.085 -0.17, 0.34 
Age -0.0069 -0.020, 0.0058 
Male (n=166)… 
…relative to Female (n=66) 
0.12 
 
-0.090, 0.34 
Higher qualifications or A-levels (n=29)… 
O-levels (n=38)… 
…relative to below O-level qualifications (n=165) 
0.14 
-0.071 
-0.11, 0.39 
-0.30, 0.16 
Non-White (n=12)… 
…relative to White (n=220) 
0.060 -0.27, 0.39 
Average general health (n=89)… 
Poor general health (n=18)… 
…relative to good general health (n=125) 
-0.0069 
-0.014 
-0.26, 0.25 
-0.44, 0.41 
CIS-R score 3 0.00038 -0.011, 0.012 
Non-adherent (n=42)… 
…relative to adherent (n=190) 
0.015 -0.24, 0.27 
Lives with adult with whom feels close (n=151)... 
 …relative to does not live with adult with whom feels 
close (n=81) 
0.078 -0.17, 0.33 
Reports illegal drug use (n=24)… 
…relative to non drug users (n=208) 
0.13 -0.17, 0.43 
Reports moderate or high alcohol dependence (n=19)... 
…relative to no alcohol dependence (n=213) 
 
0.16 
 
-0.21, 0.53 
Two or more years on medication (n=181)… 
…relative to less than two years on medication (n=51) 
0.18 
 
-0.058, 0.41 
Constant 8.35*** 7.73, 8.97 
Link function Log 
Distributional family Gaussian 
 
* p≤0.10;  ** p≤0.05;  *** p≤0.01 
 
 
 
1 Day activity services include visits to a community mental health centre, day activity centre 
or sheltered workshop. 
2 residential care homes/supervised housing/group homes/hostels 
3 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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 Table 3.11:  Factors associated with total cost of services, PMS 1993-4 Institutions sample 
 
 
Independent variables N=657 
Coefficient 
 
95% CI 
Resident in ‘other’ 1 institution  (n=269)… 
…relative to resident in hospital (n=217) 
-0.91*** -1.01, -0.82 
 
Age -0.0016 -0.0045, 0.0012 
Male (n=335)… 
…relative to Female (n=151) 
0.013 
 
-0.064, 0.090 
Higher qualifications or A-levels (n=55)… 
O-levels (n=76)… 
…relative to below O-level qualifications (n=355) 
0.059 
0.016 
-0.040, 0.16 
-0.095, 0.13 
Non-White (n=38)… 
…relative to White (n=448) 
0.0026 -0.16, 0.16 
Average general health (n=186)… 
Poor general health (n=66)… 
…relative to good general health (n=234) 
0.0078 
0.035 
-0.056, 0.072 
-0.081, 0.15 
CIS-R score 2      0.00004 -0.0033, 0.0033 
Non-adherent (n=91)… 
…relative to adherent (n=395) 
0.089* -0.010, 0.19  
Lives with adult with whom feels close (n=298)... 
 …relative to does not live with adult with whom 
feels close (n=188) 
0.071* -0.013, 0.15 
Reports illegal drug use (n=46)… 
…relative to non drug users (n=440) 
-0.069 -0.22, 0.078 
Reports moderate or high alcohol dependence 
(n=31)... 
…relative to no alcohol dependence (n=455) 
-0.035 -0.22, 0.15 
Two or more years on medication(n=328)… 
…relative to less than 2 years on medication 
(n=158) 
0.051 -0.032, 0.14 
Constant 10.79*** 10.61, 10.96 
Link function Log 
Distributional family Gaussian 
 
* p≤0.10;  ** p≤0.05;  *** p≤0.01 
 
 
 
1 Residential care homes/group homes/hostels 
2 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor psychiatric 
disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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(p=0.079). Predicted total costs for residents of care homes, group homes and hostels were 
less than half of the amount for comparable hospital residents (see Figure 3.4). Predicted 
excess total service use costs for patients reporting non-adherence was over £5,000 per year. 
 
3.3.5 Secondary analysis 
 
Of the variables found to be associated with non-adherence in the institutions sample, age and 
having had a recent mental health inpatient stay were also found to be associated with non-
adherence in the household sample (p=0.007 and p=0.020 respectively). As with patients in 
institutions, higher non-adherence was observed amongst younger respondents in the 
household sample. Likewise, having had a recent mental health inpatient stay was also 
univariately associated with non-adherence in the household sample. The homeless sample 
was half the size of the household sample and the univariate comparisons were only 
conducted where greater than 80% of the sample had non-missing data for the relevant 
variable. Of the variables associated with non-adherence within the institutions sample, this 
excluded analyses of the association of non-adherence and each of age and the CIS-R score. 
Both having had a recent mental health inpatient stay and experiencing side effects were 
associated with non-adherence in the homeless sample (p=0.037 in both cases). 
 
The Wilcoxon rank-sum test comparing total service use costs across adherence status groups 
did not find a significant difference in the distribution of costs in the household sample 
(p=0.2070). Similarly, there was no difference in total costs between homeless respondents 
who reported adherence to their antipsychotic medication and those that reported non-
adherence. However, both samples were extremely small (households: n=54; homeless: n=27) 
as it has been estimate that the number of persons with the illness in private households and 
homeless in England  in the 2003/4 were 72,600; and 22,800 respectively (Mangalore and 
Knapp 2007). 
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Predicted total health and social care costs, PMS 1993-4 Institutions sample
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
case type: male, age 45, White, no O-levels,
good general health, resident in hospital,
adheres to meds, CISR score=11, no drug or
alcohol abuse, with adult to whom feels close
and on meds for over 2 years
case type: resid in hostel or group home case type: on medication for less than 2 years case type: medication non adherence case type: CIS-R score=5
an
nu
al
 c
os
t i
n 
£ 
(2
00
1 
un
it 
co
st
s)
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
Figure 3.4
 
 99 
3.4 Discussion 
 
Analysis of the institutions sample of the PMS found significant associations between patient-
related factors such as education and alcohol abuse. The experience of side effects was also 
significantly associated with non-adherence. With respect to service use and related costs, 
non-adherence was significantly associated with the use of external services, while the effect 
on non-adherence approached statistical significance in the use of inpatient services and the 
total cost of services. 
 
3.4.1 Factors associated with non-adherence 
 
Previous studies that have examined the factors that influence non-adherence in patients with 
schizophrenia or taking antipsychotic medication have typically been based on relatively 
small, local samples. Thus while there are inconsistencies between the findings of these 
studies, the differences may relate to the nature of the populations sampled or to reduced 
power due to small sample sizes. The Psychiatric Morbidity Survey has the advantage of 
being a large, nationally representative survey. I focused on people living in institutions 
(hospital and community-based) because analyses found high rates of missing data for the 
other data sets (that is, people living in households and people who were homeless). 
 
The heterogeneity of results from previous studies may also be due to the setting in which the 
study took place. Results may differ due to changes in treatment regimes across time and 
location. At the time of the PMS survey interviews (1993-94), the majority of schizophrenia 
patients in the UK were prescribed older drugs. Atypical antipsychotics have been shown to 
be associated with different profiles of side effects (Geddes, Freemantle et al. 2000), and this 
may have influenced the association between side effects and non-adherence observed here. A 
trend towards lower non-adherence in patients receiving atypical medications has been 
observed elsewhere (Olfson, Mechanic et al. 2000; Sartorius, Fleischhacker et al. 2002).  
 
A further difficulty in assessing the magnitude of the impact of non-adherence in the 
treatment of patients with schizophrenia is variability in the methods used to detect its 
presence. Some studies have employed patient-reported non-adherence, as in the PMS, while 
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others have used assessments by health care professionals. As discussed in chapter 2, the 
consistency in the assessment of non-adherence has not been established. 
 
Factors that influence non-adherence are typically placed into one of three categories:  
patient-, medication- and environment-related (Oehl, Hummer et al. 2000). Among patient-
related factors, the results are not consistent. Reviews by Fenton et al. (1997) and Lacro et al. 
(2002) showed inconsistency in the influence of age, gender and ethnicity, illness severity and 
the number of prior hospitalisations. However, they did observe greater consistency in the 
non-significance of education and income on non-adherence. 
 
My results are at variance with this latter finding as I observed a significant association 
between education and non-adherence. Ruscher et al. (1997) found a similar association in a 
sample including a range of psychiatric patients and speculated that more educated patients 
may have a greater interest in, or feel more confident about, exercising control over their 
medication regimen. Better educated patients may also be more sensitive to and reflective 
about medication side effects. 
 
As elsewhere (Trauer and Sacks 1998) I did not observe a relationship between gender and 
non-adherence. A review by Oehl et al. (2000) did report such a relationship and attributed it 
to poorer health care of men in general and the greater likelihood of women to be care-givers 
and thus with an incentive to take their medication. A trend exists in the sample for women to 
be in better health, though this result does not achieve statistical significance (chi-squared test 
p-value=0.108).  
 
As noted earlier, the association between age and non-adherence is not universally observed, 
although my analysis does find such a link, with older people reporting better adherence 
(Coldham, Addington et al. 2002). My initial hypothesis was that this effect was related to 
patient insight and familiarity with medications over time. It has been shown that the longer 
the history of illness, the more likely patients are to adhere to their medications (Mojtabai, 
Lavelle et al. 2002). But testing the model without the effect of age did not make the index of 
medication familiarity significant in the model. 
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Illness severity was found to be associated with non-adherence. Patients with greater  
prevalence and severity of symptoms of neurosis and those who had an inpatient stay for a 
mental illness in the year prior to being interviewed were more likely to be non-adherent. The 
reviews by Fenton et al (1997), Kampman et al (1999)and Nose et al (2003) observed 
associations between non-adherence and the severity of psychotic symptoms. 
 
Substance abuse is likely to increase non-adherence (Fenton, Blyler et al. 1997; Kampman 
and Lehtinen 1999; Olfson, Mechanic et al. 2000; Lacro, Dunn et al. 2002; Nose, Barbui C et 
al. 2003). A significant association was found in my analysis between alcohol abuse and non-
adherence. Previous studies by Swartz et al. (2001) and Owen et al. (1996) have also observed 
this association, though Grunebaum et al. (2001) and Coldham et al. (2002) did not. However, 
the Grunebaum study was based on a relatively small sample, reducing the ability to observe 
significant effects, and focussed on patients in residential care settings where a low 
prevalence of substance abuse reflected the sobriety requirement that often exists in 
residential settings.  
 
With respect to medication-related factors, I observed a significant association between past 
experience of side effects and non-adherence. It has been estimated that between 25% and 
66% of patients on antipsychotics discontinue their medications because of side effects 
(Conley and Kelly 2001); akathisia being most highly associated with non-adherence (Fenton, 
Blyler et al. 1997) and weight gain also likely to be a key factor (Allison and Casey 2001). In 
a study examining the degree of moderate and severe distress of side effects the following 
ranking was reported: akinesia (40% of patients), weight gain (37.3%), anticholinergic 
(33.2%), sexual problems (30.8%) (Weiden and Miller 2001). The same study also found that 
side effects are under-reported by up to factor of four when relying on spontaneous report 
versus focused interview. Also, adherence has been found to be adversely affected by 
complex treatment regimens (Kampman and Lehtinen 1999). 
 
Results of previous studies are inconsistent in the association found with the route of 
administration of medication (Fenton, Blyler et al. 1997), but adherence is more easily 
monitored in patients receiving depot injection, thus allowing for earlier intervention if non-
adherence occurs (Oehl, Hummer et al. 2000) 
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3.4.2 The association between non-adherence and resource use and costs 
 
Patterns of resource use and costs are associated with a range of patient characteristics, but 
differ by service type. Only non-adherence to medication appears to exhibit a consistent 
association with greater resource use, and is a significant factor in the use of inpatient and 
external services.  
 
A significance association between non-adherence and service use and costs is observed by 
Glazer and Ereshefsky (1996) who concluded that measures taken to improve adherence are 
likely to decrease total direct treatment costs. Meta-analyses of data from a number of 
countries concluded that a 50% improvement in adherence would decrease one-year 
rehospitalisation rates by 12% (Weiden and Olfson 1995). Svarstad et al (2001) estimated the 
annual cost of hospital expenditures for schizophrenia patients on Medicaid in the US state of 
Wisconsin and found irregular medication users to cost, on average, an additional $1,620 per 
annum. This difference was statistically significant based on a linear regression analysis of 
log-transformed hospital costs that included age, sex, age of onset of illness, Global 
Assessment Scale score, alcohol or drug abuse, use of any oral neuroleptic and previous 
hospitalisations as covariates. The analysis of the PMS data found the effect of non-adherence 
to approach statistical significance in the use of inpatient services and when this result was 
combined with the effect on inpatient costs, the difference in costs for a hypothetical patient 
was over £2,500 per annum. 
 
Eaddy et al  (2005), using medical and pharmacy claims data from a large Southeastern 
Medicaid program in the US, found that inpatient hospitalisation charges were 54.5% greater 
for partially compliant patients as compared to compliant patients. This effect was statistically 
significant. Statistically significant differences were not found in this study when comparing 
total health care costs (including inpatient, outpatient and physician costs) for partially 
compliant patients with compliant patients. The effect of compliance was estimated using 
multivariate linear models of the log transformed charges with the total number of non-
antipsychotic prescriptions, the total number of distinct non-antipsychotic medication classes, 
switching and augmentation and prior hospitalisation included as covariates. 
 
Further evidence of a positive association between non-adherence and inpatient stays was 
observed by Weiden et al (2004) who used California Medicaid pharmacy refill and medical 
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claims data for 4,325 outpatients with schizophrenia. They found that the longer the gaps in 
use of medication (based on the medication possession ratio), the greater the odds of 
hospitalisation.  
 
3.4.3 Other factors associated with resource use and costs 
 
Symptom severity and patient satisfaction 
 
The finding that costs of external service use were associated with severity of neurosis was 
consistent with results from a study comparing service utilisation in five European locations 
(Knapp, Chisholm et al. 2002). Further results from this study (EPSILON) indicate, however, 
that satisfaction with services was only weakly associated with demographic and clinical 
characteristics (Ruggeri, Lasalvia et al. 2003). It would be expected that satisfaction with 
services would be partly reflective of use of services. 
 
 
Ethnicity 
 
There exists limited published evidence on the relationship between ethnicity and service use 
in the treatment of schizophrenia. A US study found that among adolescents, Caucasian 
students received more services in the early stages of treatment than did African American 
students, but this difference diminished over time (Cuffe, Waller et al. 2001). A survey of US 
Medicare recipients found that among persons under age 65, Caucasians were one and a half 
times as likely as African Americans to receive an ambulatory care service and 1.3 times as 
likely to have received individual therapy. In a study based on data from the Fourth National 
Survey of Ethnic Minorities, among respondents with similar scores on the CIS-R, Caribbean 
respondents were less likely to have used therapist or social work services (Nazroo 1999). 
 
My findings suggest that visible ethnic minorities are disproportionately more likely to access 
inpatient services and less likely to access external services. This suggests a substitution effect 
between these two types of services. It is possible that this pattern is the result of a differential 
response to symptoms by clinicians. For example, it may be the case that non-White patients 
are more likely than White patients to be admitted to inpatient care. Also, Nazroo (1997) 
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suggests that it is possible that if the instruments used underestimate rates of mental illness 
among certain ethnic minority groups, a larger proportion of those who were ill in these 
groups will not receive treatment. Another factor in this pattern of service use may be the 
effect of not having social support to encourage patients to access services. In the sample 
studied by Nazroo, 63% of White respondents reported that they lived with an adult with 
whom they feel close, while the corresponding rate for non-Whites was only 42%. A previous 
study suggested that the incidence of schizophrenia in non-White ethnic minorities increased 
significantly as the proportion of such minorities in the local population fell (Boydell, van Os 
et al. 2001), while another study showed that differences in the prevalence rate of psychosis 
between White British and African or African-Caribbean British samples were markedly 
reduced when social and economics factors were accounted for (Brugha, Jenkins et al. 2004). 
These results support the inference that social isolation is likely to influence the types of 
resources used for psychiatric services by individuals from ethnic minority backgrounds. 
 
 
Residential care 
 
A study of residents of psychiatric nursing homes found family contact to be associated with 
greater likelihood of service use (Anderson, Lyons et al. 2001). A secondary analysis of the 
PMS data that focussed on residents of residential care homes, group homes or hostels did not 
replicate this result. Those patients with one or more family members with whom they were 
close were no more likely to use inpatient services (odds ratio=0.83; 95% confidence interval 
= 0.32 - 1.34) or external services (odds ratio=1.43; 95% confidence interval = 0.60 - 2.25).  
 
An interesting finding was that rates of external service use decreased as severity of neurosis 
increased. This result was consistent with a US-based study of residents of an intermediate 
care facility that also observed an inverse relationship between severity of illness and service 
use (Anderson and Lewis 1999). This result may occur because patients with more serious 
symptoms are more likely to be in a psychiatric hospital. 
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Age 
 
Cuffel et al (1996) observed a non-linear relationship between age and service use. Total costs 
for schizophrenia were higher for the youngest (18-29) and the oldest cohorts (65-74 and 
74+). My results did not indicate an association of this kind. In the analysis of the PMS 
institutions sample, only use of day activity services differed by age. As in the PMS, Svarstad 
et al (2001) did not observe age to have a significant effect on inpatients’ hospital costs.  
 
 
Drug use 
 
Interestingly, patients who reported drug use incurred significantly lower costs when external 
services were accessed. This suggests that once accessed, relatively limited use of these 
services was made by these patients. This may reflect a lack of consistency on the part of drug 
users in accessing services.  
 
Svarstad et al (2001) observed an association between alcohol or drug abuse and inpatient 
costs. This association was not found in analysis of the PMS data. 
 
3.4.4 Limitations 
 
A potential source of bias in the analysis of the PMS institutional sample arises from the poor 
rate of cooperation of institutions selected to take part in the survey. The rate of cooperation 
was poorest among private and smaller institutions. It may be the case, for example, that these 
cater to individuals with different levels of severity of illness as compared to larger 
institutions. As such, it is not necessarily the case that the results observed can be generalised 
to all individuals across the full range of accommodation types. Indeed, in the present context, 
it is the smaller institutions that are now more common in providing permanent residence to 
individuals with schizophrenia.  
 
While the Psychiatric Morbidity Survey dataset offers advantages over some previously 
available data used to study non-adherence, there are measures not included that would have 
improved the analyses. As previously mentioned, establishing a strong therapeutic alliance 
between doctor and patient has previously been shown to be an important influence on 
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adherence (Olfson, Mechanic et al. 2000; Battaglia 2001; Grunebaum, Weiden et al. 2001), 
but is not measured in this dataset. 
  
The analyses would also have been improved with inclusion of a measure of patients’ 
attitudes towards their medication, their insight and cognitive functioning generally 
(Robertson, Woerner et al. 2002), and perceptions of their quality of life. A positive view of 
psychiatric medications and patient insight has been shown to improve adherence 
(Grunebaum, Weiden et al. 2001). These factors may be associated with the health belief 
model, which Oehl et al. (2000) suggests is a major determinant of adherence. The model 
establishes that adherence is related to a patient’s perception of severity of illness, efficacy of 
treatment and ability to influence illness course. The debilitating nature of the illness, 
therefore, is thought to relate to lower health belief by the patient, and thus, poorer adherence. 
 
The potentially important omitted variable bias created by some of the above factors not being 
available in the dataset was diminished by including the length of time on medication in the 
modelling, which is likely to be correlated with patients’ attitutes towards medication and 
insight into their illness. 
 
The models do not test for endogeneity due to the lack of suitable instruments in the dataset. It 
may be the case that service use may partly explain adherence, and therefore, in modelling the 
effect of non-adherence on service use I am missing the reverse causality that might be 
present. This simultaneity would lead to the estimate of the effect of non-adherence to be 
biased. Note, however, that if services do include reminders and encouragement regarding 
medication taking, the effect would be to improve adherence. Thus this effect would be 
counter to the effect that I am trying to observe – the effect of non-adherence. That is, the 
observed effect of non-adherence would be greater if simultaneity existed and was accounted 
for. 
  
The cross-sectional nature of the Psychiatric Morbidity Survey data does not allow for 
analysis of the direction of causation in the associations between service use, costs and 
potentially associated factors. The analysis of the QUATRO study in the following chapter 
presents results where observations over time are collected. The PMS data also do not include 
information on the nature of the physician–patient relationship or attitudes towards service 
provision which may impact on individual decisions regarding use of services by patients 
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with schizophrenia. Also, supply-side factors could not be considered, although they are 
likely to impact on the availability of and access to services and hence on costs. In particular, 
inpatient services are sometimes used in place of less costly outpatient mental health services 
if the latter are not available (Sullivan, Jackson et al. 1996; Salvador, Haro et al. 1999). 
 
The interpretation of significant vs. non-significant results is complicated by the potential co-
linearity of variables. Preliminary analysis of the PMS data found significant associations 
between non-adherence and age, education, illness severity, alcohol abuse and residential 
setting. Other models with different combinations of variables were tested but here those that 
best summarised the associations found are reported. 
 
Despite these limitations, the analyses are unusual in attempting to identify the factors 
associated with the use and cost of services by employing data from national, representative 
surveys. In particular, the link with non-adherence is examined closely. Robust statistical 
methods are used, increasing confidence in the associations reported. The 1993/4 PMS 
surveys were the only source of nationally representative data on psychiatric morbidity at the 
time this analysis was undertaken. I am aware that prescribing patterns have changed in the 
time since this data was collected. Most significantly, the newer class of antipsychotics, 
termed atypical antipsychotics, have become much more widely prescribed. I undertook 
research on the trends in antipsychotic prescribing and the factors associated with which type 
of antipsychotic was being prescribed in separate analyses which appear in appendix 2. 
 
This analysis showed that the prescribing of the newer atypical antipsychotics in primary care 
practices increased significantly between 1993 and 1999, rising from 1.8% of antipsychotics 
prescribed in 1993 to 20.8% in 1999. It also found that older individuals were significantly 
less likely to be prescribed atypical antipsychotics. Individuals who had had a inpatient stay in 
the previous year were one-and-a-half times as likely to be prescribed the newer 
antipsychotics as compared to those who had not had a recent inpatient stay. Those 
individuals with more frequent primary care consultations were also significantly more likely 
to be prescribed the newer antipsychotics as compared to less frequent users of primary care. 
These results suggest that the newer antipsychotics were prescribed to patients found in my 
analysis to be significantly more likely to not adhere to their medication. 
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3.5 Summary 
 
Patterns of resource use and costs are associated with a range of patient characteristics, but 
differ by service type. Only non-adherence to medication appears to exhibit a consistent 
association with greater resource use, and is a key factor in the use of inpatient and external 
services.  
 
Important factors appear to relate to the degree of needs of the patient and the ability of the 
system to address them. For example, after standardising for severity of neurosis, drug misuse 
and other factors, the use of inpatient services and the costs incurred as a result of use are 
associated with being from a visible ethnic minority. Patients on medication for a significant 
length of time tend to make greater use of external services while being less likely to require 
inpatient services. The total cost of all services used was strongly associated with residence in 
hospital. 
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Chapter 4 
The impact of non-adherence to medication in patients with Schizophrenia on 
health, social care and societal costs – analysis of the QUATRO study 
 
 
 
4.1 Background and aims 
 
Subsequent to completing the analyses of the PMS 1993/4 data reported in the previous 
chapter, another dataset was sought which would allow robust conclusions to be drawn 
regarding the associations between non-adherence and service use costs. As described in 
chapter 2 the features sought were that the data were nationally representative of the UK, 
sampled relatively recently, had an adequate measure of non-adherence, included 
comprehensive information on health and social care service use and indices of as many as 
possible of the potential covariates relevant to non-adherence and service use and collected 
these data at more than one time point to allow for analysis of changes over time. The Quality 
of Life following Adherence Therapy for People Disabled by Schizophrenia and their Carers 
(QUATRO) study was chosen for this analysis. While the study data was not nationally 
representative of the UK population, it met the other criteria.  
 
The aim of analysis of the QUATRO study was to supplement the analyses of the previous 
chapter in determining the impact of non-adherence to medication on service use costs 
attributable to schizophrenia. QUATRO was a multi-national randomised controlled trial that 
evaluated an adherence therapy intervention for people with schizophrenia. 
 
This analysis builds on the analyses of the Psychiatric Morbidity Surveys (PMS) described in 
the previous chapter in three important ways. Firstly the data are more up-to-date. Patients 
were recruited for the QUATRO study in 2002/3, whereas the Psychiatric Morbidity Survey 
interviews took place in 1993 and 1994 (Meltzer, Gill et al. 1996). A number of changes have 
taken place in the treatment of schizophrenia in the intervening period, most notably the 
introduction and sharply increased uptake of atypical antipsychotics (King and Knapp 2006). 
The newer medications have been argued to reduce side-effects (Sartorius, Fleischhacker et 
al. 2002; Sartorius, Fleischhacker et al. 2003), and therefore - other things being equal - are 
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likely to reduce rates of non-adherence. Also, as more patients now live in the community, 
rather than in hospital, they are less frequently in contact with care providers who, in 
residential or hospital settings, often provide reminders for medication taking. 
 
Secondly, data are collected at two time points and therefore allow for longitudinal analysis. 
Longitudinal analysis is superior to cross-sectional modelling. If samples of the same size 
were used in each method, the longitudinal study provides greater statistical power. This is 
due to the fact that the intra-subject variability is significantly lower than the variability across 
subjects (Hedeker and Gibbons 2006). Also, because longitudinal studies allow one to follow 
the same individuals over time, they have the advantage of allowing for the analysis of 
dynamic responses. This, in turn, makes these studies better suited to make judgements as to 
the direction of causality in significant associations (Arellano 2003). Another advantage of 
longitudinal studies is that they allow ageing effects (i.e. changes over time within 
individuals) to be differentiated from cohort effects (i.e. differences between subjects at 
baseline), which cross-sectional studies do not allow (Hedeker and Gibbons 2006). 
 
The third advantage of the QUATRO study relative to the PMS is that it included a wider 
range of service use contacts and considered non-health and social care costs which allowed 
me to take a wider perspective in assessing the impact of non-adherence to medication in 
schizophrenia on costs in society. With respect to costing services in schizophrenia, much of 
the costs to the patient, their family and the society as a whole are outside the health and 
social care system. For example, lost employment or employment in low-paid work are costs 
to both the individual and society that may result from a patient having schizophrenia.  
Criminal justice costs, the cost of informal care and the cost of lost employment are the non-
health and social care related costs included in the costing of services reported in the 
QUATRO dataset. Mangalore and Knapp (2007) estimated that, in 2004/5, health and social 
care costs represented approximately 30% of total societal costs. They further estimated that 
annual cost of informal care, criminal justice costs and cost of lost employment for people 
with schizophrenia were £604 million, £1.1 million and £4.8 million respectively.  
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4.2. Methods 
 
4.2.1 The QUATRO study 
 
The QUATRO study was a multi-national randomized controlled trial carried out at four 
centres across four European countries (Germany, Italy, the Netherlands and the UK), funded 
by the European Union and coordinated from the UK. The sample was drawn from adults 
receiving care from psychiatric services in each of four European cities: Amsterdam (The 
Netherlands), Leipzig (Germany), London (United Kingdom) and Verona (Italy). Data 
collection took place between June 2002 and October 2003 (Gray, Leese et al. 2006). Each 
sample was recruited from the patient records of senior treating clinicians at a range of local 
in-patient and community settings that were typical of general treatment centres in the 
catchment areas of each site. The inclusion criteria were that the patient must have had a 
clinical diagnosis of schizophrenia, must require on-going antipsychotic medication for at 
least one year following the baseline assessment, and must have exhibited evidence of clinical 
instability in the year prior to baseline (Gray, Leese et al. 2006). Clinical instability is defined 
as meeting one or more of the following criteria: a hospital admission on mental health 
grounds, a change in the type or dose of antipsychotic medication, planned or actual increased 
frequency of contact with mental health services and indications of clinical instability 
reported by relatives, carers or the clinical team. Written, informed consent was obtained from 
all participants. 
 
The study was a two-arm randomised controlled trial. Its main aim was to compare the 
effectiveness of adherence therapy with a health education control intervention (which 
allowed for therapist time and relationship) in improving health-related quality of life for 
people with schizophrenia receiving treatment from general adult mental health services in the 
four cities (Gray, Leese et al. 2006). Patients were randomly assigned to either receive the 
experimental intervention, an individual cognitive-behavioural approach which is 
collaborative and patient-centred, or a standard health education control intervention. The six 
elements that form the core of the cognitive-behavioural approach are assessment, medication 
problem-solving, a medication timeline, exploring ambivalence, discussing beliefs and 
concerns about medication, and using medication in the future. 
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Study participants were interviewed at baseline and after 12 months. Interviews were 
conducted by a researcher who was blinded as to the allocation of the participant to the 
intervention or control group, but the participants were not blinded as to which intervention 
they were receiving. Participants were not told, however, which of the two interventions was 
regarded by the study investigators as experimental. 
 
Adherence to medication was based on patient responses on the Medication Adherence 
Questionaire (MAQ). Positive responses on the MAQ are summed to obtain a Morisky score 
(Morisky, Green et al. 1986). The Morisky score is a 5-point scale based on four questions 
relating to medication-taking behaviour. It asks patients if they ever forget to take medication, 
if they are careless about taking medication, if they ever stop taking medication once they feel 
better and if they ever stop taking medication because it made them feel worse. The Morisky 
score is widely used to assess adherence (Shalansky 2004; Day, Bentall et al. 2005). The total 
score on the scale ranges from 0 (all items rated ‘yes’) to 4 (all items rated ‘no’). For the 
purpose of this analysis, values of 0 to 2 on the 5-point scale (0-4) were deemed as reflecting 
non-adherence as per the classification used by the QUATRO study team in their analyses 
(Gray, Leese et al. 2006). That is, individuals who responded in agreement with two or more 
of the medication-taking behaviour questions was classified as non-adherent.  
 
The other main clinical measures assessed in the study were the mental component summary 
score on the Medical Outcome Study (MOS) 36-Item Short Form Health Survey (SF-36) and 
the Brief Psychiatric Rating Scale – Expanded (BPRS-E). The SF-36 is a self-report measure 
of health-related quality of life and well-being (Ware and Sherbourn 1992). The BPRS-E 
measures psychiatric symptoms, negative symptoms, depression and anxiety and manic 
excitement or disorganisation (Lukoff, Liberman et al. 1986; Ventura, Green et al. 1993). 
 
The Client Service Receipt Inventory (CSRI) (Beecham and Knapp 1992) was used to collect 
service use data. The CSRI collects individual patient data on demographic characteristics, 
accommodation and living situation, employment history and earnings, including receipt of 
benefits, health and social care service receipt, and the role of informal carers. In the 
QUATRO study a three month retrospective period was used. Local language versions of the 
CSSRI-EU were available from the EPSILON study (Chisholm, Knapp et al. 2000), which 
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carried out a process of translation into local languages, focus groups and pilot activities to 
ensure face validity and semantic equivalence.  
 
The study team had non-economist researchers administer the CSRI in face-to-face interviews 
with participants.  Where there was a concern about the reliability of the reporting of service 
use, on account of a patient’s mental illness, supplementary information from key workers, 
service providers and/or carers was sought to ensure that the information was as complete and 
reliable as possible. 
 
The main finding of the QUATRO study investigators was that adherence to antipsychotic 
medication was not directly linked to quality of life in people with schizophrenia, but may be 
indirectly linked to quality of life through improvements in symptoms (Gray, Leese et al. 
2006; Puschner, Born et al. 2006). The study investigators tested for differences in medication 
adherence attributable to the intervention but did not find significant differences (this analysis 
controlled for baseline MAQ score and site). A further analysis which restricted the analysis 
to a subgroup of the less treatment-adherent participants also found no significant difference 
between the groups at follow-up. 
 
The primary outcomes of interest were the direct health and social care costs and societal 
costs. Health and social care costs included the cost of medication(s), special (non-hospital) 
accommodation, inpatient stays (including the cost of accommodation), outpatient visits, 
community-based day services and community-based professional contacts. The individual 
items from the questionnaire included in each of these health and social care cost categories, 
as well as those that were included as criminal justice and informal care costs, appear in Table 
4.1. 
 
Societal costs included health and social care costs, criminal justice, and informal costs as 
well as the cost of lost employment. All unit costs were estimated at 2003 price levels. This 
year was chosen as it corresponds to the period of time when the trial took place. Unit costs 
were estimated in each study site using either suitable national costs or local service activity 
and finance data (Patel 2006). Based on the human capital approach, the national average 
wage was used to estimate the cost of time off work. The national average wage was also used 
to estimate the cost of informal care based on the opportunity cost method. Because the study  
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Table 4.1: Health and social care services and benefits included in analyses, QUATRO study 
 
Health  and 
social care 
services 
Medication  
Special 
accommodation 
 
Hospital inpatient 
stays 
 
Hospital outpatient 
visits 
Psychiatric outpatient department 
Day hospital visits 
Community-based 
day services 
Community mental health centre 
Day activity centre 
Group therapy 
Sheltered workshop 
Specialist education 
Community-based 
professional contacts 
Community Psychiatrist 
Community Psychologist 
GP 
District Nurse 
Community Psychiatric Nurse 
Social worker 
Occupational therapist 
Home help/home care worker 
 
Criminal Justice  Police contacts 
Nights in police cell or prison 
Psychiatric assessments 
Criminal court appearances 
Civic court appearances 
 
Informal care  Childcare 
Personal care 
Help in/around home 
Help outside home 
Other care 
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centres were across four countries, it was necessary to convert unit costs to a common 
currency. The costs were adjusted to purchasing power parity (PPP)-adjusted Euros (Patel 
2006).  
 
4.2.2 Statistical methods 
 
To assess the effect of an intervention in a trial with measurements taken of the outcome of 
interest before and after the intervention, the most appropriate method is the difference- in-
difference model (Meyer 1995). The standard difference- in-difference equation is: 
 
iiiiii etimetreattimetreaty ++++= )*(*** 3210 ββββ  
 
where treatmenti = 1 if in the treatment group or treatmenti = 0 if in the control group and 
timei = 0 if outcome was assessed at baseline or timei = 1 if outcome was assessed at 
followup. This model accounts for changes that may be occurring over time that are not due to 
the treatment. An example often given for the application of the difference- in-difference 
model is that of the effect of a new policy within a particular region. A model that attempted 
to determine the impact of the policy change by simply comparing values on the outcome of 
interest before and after the intervention assumes that there are no other changes taking place 
at the same time as the intervention that may be impacting the outcome. The difference- in-
difference model identifies a control group similar to the group receiving the intervention. In 
the example, say another region that did not introduce the policy change. The diffence-in-
difference model estimates the change over time in this control group and compares it to the 
change over time in the group that received the intervention. In doing so, this model can more 
accurately identify the effect of the intervention as the difference on the outcome that 
occurred within the treatment group over and above the difference in the outcome that 
occurred in the control group. In the notation above, the coefficient of the interaction term, 
3β , is the difference- in-difference estimate of the treatment effect. That is, this is the effect of 
treatment after the intervention over and above the effect of any treatment effect at baseline. 
 
In the case of the model I wanted to estimate, I was primarily interested in the effect of 
adherence before and after treatment where individuals were randomised to receive treatment 
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or control. An indicator of adherence status was added to the model, as was its interaction 
with treatment. I have assumed that there was no interaction between time and adherence. 
That is, there was no reason to think that the effect of adherence status on the outcome of 
interest, costs, will be different at baseline as compared to at follow-up. I also added to the 
model covariates that were deemed relevant to the analysis of associations with health, social 
care and societal costs. The model becomes: 
 
iiiiiiiiii eXnonadhtreatnonadhtimetreattimetreaty +++++++= 6543210 )*()*( βββββββ
 
 
where nonadhi = 1 if the patient is judged to be non-adherent or nonadhi = 0 if the patient is 
judged to be adherent. A significant interaction between adherence status and treatment would 
imply that the effect of adherence on costs would be different according to whether or not the 
individual had received treatment or not. I would not expect this to be the case. This is 
different from saying that there is an association between receipt of treatment and adherence 
status which suggests that receipt of treatment affects adherence. 
  
The model I wanted to fit differs, however, from the standard difference- in-difference model 
in that individuals are randomised to the treatment and control group and as such, differences 
between the two groups at baseline are due to chance alone. As it can be assumed that there is 
no difference between the groups before the intervention, I assigned a value of 0 to treatment 
for all individuals at baseline to reflect the fact that at this point no actual treatment was 
received. That is, for those patients who were randomised to treatment, a value of 0 would be 
assigned at baseline as they had not yet received any treatment. Since it can be assumed that 
randomisation eliminated any differences between the two groups, measuring the effect of 
randomisation on costs would be redundant. Assigning a value to treatment which reflects the 
actual state of the individual with regards to receipt of treatment at each time point is the 
appropriate model structure for the design of this study and the model I wanted to fit.  
 
In this case the model reduces to: 
 
iiiiiiii eXnonadhtreatnonadhtimetreaty ++++++= 543210 )*( ββββββ  
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as the treatment variable and treatment by time interaction take on identical values for every 
observation. If the interaction between adherence and treatment is significant, the effect of 
non-adherence on costs is β4 for those who did not receive treatment and the linear 
combination of β4+β5 for those who did receive treatment. 
 
The notation X  represents a vector of patient-specific covariates. The model sought to 
control for the following variables identified in the dataset as potentially relevant to the cost 
outcomes: age, sex, whether or not the patient lived alone, their study site, education level, 
ethnicity and familiarity with medication. The significance of the treatment, time and study 
site variables are not commented on here as these were not the focus of my analyses. The 
results reported focus on non-adherence and individual patient characteristics. The effect of 
time on costs are not commented on although it is assumed that cost will reduce over time. 
The effect of study site on costs are interesting, but may in part be due to how services are 
organised within each site which is not the focus of this study. 
 
Age was included in the modelling as a continuous variable. Age was assessed at the time of 
the initial interview. Education was measured as a dichotomous variable distinguishing those 
who had completed further or tertiary education from those who had not. Ethnicity was also a 
dichotomous variable distinguishing White Europeans from all other ethnic backgrounds. It is 
likely that the effect of ethnicity may not be consistent across minority ethnic groups, but the 
limited sample size made it infeasible to test for differences between specific minority ethnic 
groups. The length of time on medication was used as an index of familiarity with medication 
and was modelled as a continuous variable. 
 
In cases where missing values result in only one of a pair of observations from a particular 
respondent entering in the model, the one observation was retained as it still provides 
information as to the relationship between the outcome and explanatory variables. 
 
The cost of treatment itself was not included in the measure of costs used as the outcome as 
this would be in effect replicating a difference in the treatment and control groups that is 
accounted for by having a treatment effect in the model. Therefore, in relation to the treatment 
effect, I wanted to know differences in cost over and above the cost of treatment. 
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Analysis of the PMS 1993/4 Surveys in chapter 3 had suggested that looking at the 
component services seperately may reveal some associations between non-adherence and the 
costs associated with specific services, even where there was not a significant association 
between non-adherence and total health and social care costs. Additional models were 
estimated using the QUATRO dataset to look at those component costs that were used by a 
large proportion of the sample and significantly contributed to total costs. The component 
costs analysed were inpatient, community-based day service and informal care costs. 
 
Due to the skewness in the distribution of the cost data, GLM models were estimated with the 
Park test employed to determine the appropriate distribution and link functions. It was 
expected that the Park test would suggest a Gamma function as this is the natural 
distributional family for skewed continuous values as were the measures of costs attributable 
to illness. A Poisson distribution is usually used for skewed count values (e.g. number of 
visits to GP). 
 
Robust standard errors were estimated. The robust option accounts for heterskadisticity – a 
non-random pattern in the error terms. This is separate from correcting for the within-
individual correlation in the error term. In the GLM procedure in STATA, the ‘cluster’ 
command will account for this correlation.  
 
In the analyses of some of the component costs, it was necessary to undertake two-part 
modelling. This was because a number of patients did not use a particular subset of services. 
In this case, they would have cost values of zero. If a substantial number of individuals have 
zero values a two-part model is recommended (Mullahy 1998). Firstly, a logistic regression 
model was run on the outcome of whether or not costs were incurred. The second part of this 
approach was then to run a GLM on the costs for the subsample of patients who did use the 
service being modelled. That is, the patients who did not use the service are excluded from the 
second stage GLM modelling.  
 
Analysis was undertaken using the STATA 10.1 software package (STATA 10.1 2009). 
Significance values below 0.05 were deemed statistically significant. 
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4.3. Results 
 
4.3.1 Demographics 
 
Four hundred and nine adults were recruited from across the four sites. The mean age of the 
sample was 42 years and 60% of the sample were male (see Table 4.2). Over 30% of the 
sample had educational qualifications above the secondary school level, and on average, the 
sample had been prescribed antipsychotic medication for over 13 years, reflecting the chronic 
nature of their illness. Approximately 30% of respondents had Morisky scale scores reflecting 
non-adherence to their medication. 
 
Of the initial 409 patients interviewed at baseline, 357 completed both interviews. There were 
no significant differences on the demographinc indices between the individuals who did not 
complete a follow-up interview and those who did (see Table 4.2).  
 
Table 4.3 presents the demographic variables by study site. The mean age and years on 
antipsychotic medication were similar across sites. The sample from Amsterdam included a 
greater proportion of men as compared to the other sites. The Amsterdam and London 
samples were ethnically diverse while the Leipzig and Verona samples were not. A greater 
porportion of London sample members reported completion of tertiary or further education. 
Verona sample members were also less likely to live alone relative to the other sites. The rate 
of non-adherence at baseline was low and differed widely across the four sites. In Leipzig, 
London and Verona the percentage of the sample with Morisky scores of 0 to 2, and therefore 
indicating non-adherence, were 32.3%, 48.9% and 30.8% respectively. In Amsterdam, 
however, 11.2% of the sample registered Morisky scores at that level. This value seems 
unusually low given that estimates are that between 20% and 80% of schizophrenia patients 
do not adhere to their medication (Battaglia 2001; Conley and Kelly 2001). The scores on the 
BPRS-E were significantly lower within the Dutch sample, which suggested less severe 
symptoms within this subsample. 
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Table 4.2: Characteristics of QUATRO study sample at baseline: overall, completers and non-
completers 
 
 
Characteristic 
 
Completers 
(n=357) 
Non-completers 
(n=52) 
Overall 
(n=409) 
Centre: N (%) 
  Amsterdam 
  Leipzig 
  London 
  Verona 
 
87 (24.4) 
81 (22.7) 
80 (22.4) 
109 (30.5) 
 
13 (25.0) 
16 (30.8) 
12 (23.1) 
11 (21.2) 
 
100 (24.5) 
97 (23.7) 
92 (22.5) 
120 (29.3) 
Age: mean (sd) 41.7 (11.5) 40.3 (11.4) 41.5 (11.5) 
Sex: % male 59.9% 59.6% 59.9% 
Ethnicity: % White European 75.1% 80.8% 75.8% 
Education: % with 
further/tertiary qualifications 
 
32.4% 
 
32.7% 
 
32.4% 
Years using antipsychotics: 
mean (sd) 
 
13.9 (9.9) 
 
11.6 (9.8) 
 
13.7 (9.9) 
Living situation: % living 
alone 
40.2% 42.3% 40.4% 
Morisky scale total score: 
mean(sd) 
3.0 (1.2) 2.9 (1.2) 2.9 (1.2) 
Percent non-adherent to 
medication at baseline * 
 
30.5% 
 
28.2% 
 
30.3% 
SF-36 mental component 
score: mean (sd) 
39.1 (11.9) 40.1 (10.7) 39.2 (11.7) 
BPRS-E total score: mean (sd) 45.0 (13.0) 46.1 (13.5) 45.2 (13.0) 
 
 
* based on Morisky total scores of 0, 1 or 2 indicating non-adherence
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Table 4.3: Characteristics of QUATRO study sample at baseline: overall and by study site 
 
 
Characteristic 
 
Amsterdam 
(n=100) 
Leipzig 
(n=97) 
London 
(n=92) 
Verona 
(n=120) 
Overall 
(n=409) 
Age: mean (sd) 40.0 (10.2) 38.7 
(10.7) 
42.5 (11.7) 44.3 (12.4) 41.5 (11.5) 
Sex: % male 73.0% 56.7% 54.4% 55.8% 59.9% 
Ethnicity: % White 
European 
44.0% 100% 53.3% 100% 75.8% 
Education: % with 
further/tertiary 
qualifications 
 
19.0% 
 
27.8% 
 
54.4% 
 
30.5% 
 
32.4% 
Years using 
antipsychotics: 
mean (sd) 
 
12.7 (9.2) 
 
11.6 (8.7) 
 
15.8 (11.4) 
 
14.3 (9.7) 
 
13.7 (9.9) 
Living situation: % 
living alone 
43.0% 55.2% 40.2% 26.7% 40.4% 
Morisky scale total 
score: mean (sd) 
3.6 (0.9) 2.8 (1.3) 2.5 (1.2) 3.0 (1.2) 3.0 (1.2) 
Percent non-adherent 
to medication at 
baseline * 
 
11.2% 
 
32.3 
 
48.9 
 
30.8 
 
30.3% 
SF-36 mental 
component score: 
mean (sd) 
41.7 (11.5) 34.7 
(11.3) 
40.2 (12.0) 40.2 (11.1) 39.3 (11.7) 
BPRS-E total score: 
mean (sd) 
37.5 (10.2) 48.3 
(15.7) 
46.1 (11.1) 48.3 (11.5) 45.2 (13.0) 
 
 
 
* based Morisky total scores of 0, 1 or 2 indicating non-adherence 
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Four patients were missing data on two of the factors identified as potentially being associated 
with costs. A further 51 were missing data on one variable only. Length of time on medication 
was the variable with the most missing data. These data were not provided by 43 individuals. 
Other variables with missing data were the Morisky self-assessed adherence score which was 
missing for 13 patients, level of education which was not reported by two patients and 
whether or not they lived alone which was missing for one patient. 
 
Excluding the variable on length of time on medication would thus reduce the number of 
observations in the dataset by 10%. In deciding whether or not to use multiple imputation, the 
key criteria is whether or not the missing values can be assumed to be missing at random. 
That is, the data being missing was not conditional on their values or the value of the 
dependent variable. In the case of length of time on medication, it not obvious as to why a 
patient would be more or less likely to report this information based on the length of time they 
were on medication. Similarly, there would be no reason to not report this information based 
on their service use. Thus this variable was assumed to be missing at random and multiple 
imputation was performed to replace the missing data. There are potential reasons, however, 
why a patient would not want to disclose that they had a low level of educational 
qualifications, lived alone or had not taken their medication. For this reason, and the fact that 
relatively very few observations would be lost by excluding observations where one of these 
three variables were missing, missing values on these variables were not imputed. 
 
4.3.2 Distribution of costs 
 
Table 4.4 presents the distribution of baseline costs across all patients in the sample. Among 
those who used health and social care services, the mean cost was approximately €26,000 and 
the median  €11,200. The mean value being greater than the median value reflected the fact 
that these costs were significantly skewed to the right. The mean societal cost was 
approximately €33,000 and these costs were similarly skewed. The median societal cost 
incurred was €19,500. The two services most influencial on health and social care costs at 
baseline were inpatient visits and non-hospital accomodation costs (median costs of €10,720 
and €29,230 respectively). The latter costs were incurred, however, by fewer than 35% of the 
sample. Inpatient costs were reported by approximately half of the sample. 
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Table 4.4: Distribution of costs at baseline, QUATRO study (in PPP Euros) 
 
 Number 
of users 
Mean Standard 
Deviation 
Median Interquartile 
range 
Min Max 
Medication 388 €4,022 €5,869 €2,348 €550-€4,400 €3 €41,371 
Inpatient 189 25,767 34,145 10,720 4,998-30,346 398 172,628 
Outpatient 140 1,366 3,369 557 551-1,101 55 36,236 
Community-based 
day services 
147 9,484 32,910 1,001 331-4,935 13 243,426 
Community-based 
professional 
contacts 
371 1,065 2,085 604 292-1,107 13 34,149 
Accommodation – 
non-hospital 
70 33,009 15,041 29,227 25,894-
40,065 
4,484 56,966 
Total health and 
social care 
401 25,959 35,134 11,202 3,750-38,013 211 270,495 
Informal care 201 10,163 16,087 3,599 1,611-10,798 474 112,713 
Criminal justice 31 4,859 14,282 336 336-1,527 82 59,001 
Absenteeism 37 15,143 16,804 5,449 2,071-27,531 463 50,134  
Societal costs 398 32,946 38,161 19,506 5,912-48,244 211 276,178 
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The costs associated with days off work were substantially higher than those of informal care, 
but few respondents reported incurring these costs. This was, in part, a result of less than 20% 
of the sample reporting being in paid employment at baseline.  
 
Table 4.5 lists the estimates of health and social care costs and societal costs, at baseline, 
across the four study sites. The vast majority of patients in each site incurred health and social 
care costs. These costs varied significantly across sites, with the median ranging from 
approximately €44,050 in Leipzig to approximately €8,270 in London. The median societal 
costs, at baseline, were highest in Amsterdam, followed by Leipzig, London and Verona.  
 
The median component costs are compared across the study sites in Table 4.6. Data on the 
percentage of individuals in each sample site who used each of the services is also included in 
the table. Some interesting patterns emerge from these data. For example, within the Dutch 
sample, where inpatient and community-based day services were used, the costs incurred are 
higher than in the other sites. Inpatient services were more frequently used in Leipzig as 
compared to the other sites, with non-hospital accomodation less frequently used in this site. 
Outpatient services were more commonly used and the cost of community-based professional 
contacts were higher in London as compared to the other sites. Also, informal care was more 
widely reported, and at a higher cost, in London. 
 
4.3.3 Health and Social Care costs 
 
The first model estimated the significance of non-adherence and other factors on health  and 
social care costs. In this model, 770 observations, across the two time points, contributed to 
the analyses. A single GLM model was estimated as all individuals with complete data across 
the independent variables incurred health and social care costs. The model determined that the 
effect of non-adherence was not statistically significantly associated with health care costs 
(see Table 4.7). Of the remaining factors considered, significantly higher costs were incurred 
amongst those that lived with others as compared to those who lived alone and females 
incurred significantly lower health and social care costs than did men. None of the other 
individual characteristics were significantly associated with these costs. 
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Table 4.5: Distribution of baseline (i) health and social care and (ii) societal costs in QUATRO study sites (in PPP Euros) 
 
 Health and social care costs Societal costs 
 Number 
of users 
Mean Median Interquartile 
range 
Number 
of users 
Mean Median Interquartile 
range 
Amsterdam 
(n=100) 
 
97 
 
42,802 
 
36,315 
    
5,480-71,188 
 
96 
 
46,207 
 
37,676 
    
6,640-72,710 
Leipzig (n=97) 95 28,382 44,067 7,651-31,722 95 37,035 26,514 12,515-44,351 
London (n=92) 90 16,195 17,623 3,755-30,258 90 25,631 18,372 8,474-34,246 
Verona (n=120)  119 17,679 4,994 1,923-20,360 117 4,374 9,669  3,848-39,954 
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Table 4.6: Distribution of health and social care and societal cost components at baseline in QUATRO study sites (in PPP Euros): Median cost 
(% of sample that used service) 
 
 Amsterdam 
(n=100) 
Leipzig 
(n=97) 
London 
(n=92) 
Verona 
(n=120) 
Medication €2,227 (92)  €4,058 (99) €1,736 (96) €1,774 (100) 
Inpatient 54,784 (45) 10,142 (78) 7,875 (37) 5,579 (28) 
Outpatient 397 (25) 1,236 (13) 551 (76) 675 (27) 
Community-based day 
services 
 
4,524 (32) 
 
719 (30) 
 
1,001 (42) 
 
902 (39) 
Community-based 
professional contacts 
 
430 (84) 
 
446 (84) 
 
946 (98) 
 
487 (97) 
Accommodation – non-
hospital 
 
36,989 (29) 
  
19,297 (4) 
 
29,227 (22) 
 
40,065 (14) 
Total health and social 
care 
 
36,315 (97) 
 
17,623 (98) 
 
8,271 (98) 
 
4,994 (99) 
Informal care 1,611 (41) 5,209 (51) 6,779 (63) 3,599 (44) 
Criminal justice 1,007 (7) 336 (18) 336 (4) 336 (3) 
Absenteeism 20,389 (10) 16,348 (7) 2,294 (5) 3,625 (13) 
Societal costs 37,676 (96) 26,514 (98) 18,372 (98) 9,669 (98) 
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Table 4.7: Generalised linear model of factors associated with health and social care costs – 
QUATRO study 
 
 
Potentially associated factors N=770 
 
Coefficient 95% Confidence 
Interval 
Treatment… 
…relative to no treatment 
-0.091 -0.40, 0.22 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
-0.29*** -0.49, -0.08 
Non-adherent… 
…relative to adherent 
-0.12 
 
-0.37, 0.14 
Intervention x Non-adherence interaction 0.51 -0.14, 1.16 
Age – 5 year increment 0.017 -0.044, 0.079 
Females… 
…relative to males 
-0.27** -0.52, -0.023 
Lives alone… 
…relative to lives with others 
-0.40*** -0.65, -0.15 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
0.80*** 
0.45** 
-0.10 
0.50, 1.10 
0.045, 0.86 
-0.46, 0.26 
Education – further or tertiary... 
...relative to primary, secondary or 
general 
0.084 -0.16, 0.33 
Not White European… 
…relative to White-European 
-0.23 -0.51, 0.046 
Number of years on medication 0.0027 -0.011, 0.016 
Constant 9.91*** 9.36, 10.46 
Link function Log  
Distributional family Gamma 
 
 
* p<0.10; ** p<0.05; *** p<0.01 
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Figure 4.1 illustrates the relative impact on health and social care costs of non-adherence and 
the factors found to be significantly associated with these costs. A hypothetical reference case 
of a woman, aged 45, of White European ethnicity, without tertiary or further (post-
secondary) education, resident in London, who adhered to medication, lived with others, 
received adherence education and had been on medication for one year was estimated by the 
model to have incured health and social costs of approximately €17,700 in the three months 
prior to the follow-up visit. Altering the combination of factors such that this case was that of 
a man (all other characteristics remaining the same), the model estimates additional costs of 
over €5,400. Living alone was associated with a €5,800 reduction in costs relative to the base 
case. Altering the ethnicity to that of somone not White European was associated in the model 
with a €3,800 reduction in costs relative to the base case. A €5,000 reduction in costs was 
associated with altering the base case to that of someone who does not adhere to their 
medication. Note, however, that across the full range of potential values for the remaining 
variables considered in the model, the effect of non-adherence was not found to be 
statistically significant. 
 
4.3.4 Societal costs 
 
Societal costs were estimated as the sum of health and social care, informal care, criminal 
justice and absenteeism costs. As with health and social care costs, a two-part model was 
unnecessary as these costs were incurred for all individuals with complete data on the 
independent variables. In the model assessing factors for their association with societal costs, 
those who reported non-adherence did not differ from those reporting adherence (see Table 
4.8; p=0.186). The interaction between treatment and non-adherence approaches statistical 
significance (p=0.090) suggesting that the effect of non-adherence on societal costs is 
different for those who received treatment compared to those who did not. A test of the linear 
combination determined that the effect of non-adherence for the latter group was also not 
significantly different from zero (p=0.212). 
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Predicted health and social care costs, QUATRO study
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
case type: female, age 45, White-
European, no tertiary or further education,
resident in London, adhers to meds, lives
with others, allocated to adherence educ,
followup, on medication for 1 year
case type: male case type: lives alone case type: not White-European case type: Non-adherent
an
nu
al
 c
os
t i
n 
€ 
(2
00
3 
un
it 
co
st
s)
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
Figure 4.1
  
130 
Table 4.8: Generalised linear model of factors associated with societal costs, QUATRO study 
 
 
Potentially associated factors N=770 
 
Coefficient 95% Confidence Interval 
Treatment… 
…relative to no treatment 
-0.065 -0.35, 0.22 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
-0.33*** -0.51, -0.16 
Non-adherent… 
…relative to adherent 
-0.16 -0.38, 0.063 
Intervention x Non-adherence interaction 0.48* -0.076, 1.04 
Age – in 5 year increments -0.025 -0.080, 0.030 
Females… 
…relative to males 
-0.037 -0.25, 0.18 
Lives alone… 
…relative to lives with others 
-0.39*** -0.61, -0.16 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
0.49*** 
0.15 
-0.22 
0.22, 0.76 
-0.19, 0.50 
-0.53, 0.087 
Education – further or tertiary... 
...relative to primary, secondary or general 
0.17 -0.040, 0.38 
Not White European… 
…relative to White European 
-0.40*** -0.64, -0.15 
Number of years on medication 0.0036 -0.0085, 0.016 
Constant 10.60*** 10.13, 11.07 
Link function Log 
Distributional family Gamma 
 
 
* p<0.10; ** p<0.05; *** p<0.01 
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As with the model of health and social care costs, those who lived with others had 
significantly higher societal costs as compared to those who lived alone. Additionally, White 
Europeans had significantly higher costs as compared to repondents of other ethnicities.  
 
The relative magnitude of these effects on predicted societal costs are illustrated in Figure 4.2. 
The base case was chosen as a man, aged 45, of White European ethnicity, without tertiary of 
further education, resident in London, who adhers to his medication, lives with others, 
received adherence education and was on medication for 1 year. The model predicted that for 
this hypothetical case, societal costs at follow-up would be €27,830. The effect of changing 
the base case to that of someone living alone reduced the predicted societal costs by €8,900 as 
compared to the base case. A similar reduction in costs would be expected if the case was 
changed to that it was of a non-White European. A change to the educational level of the base 
case to having tertiary or further education increases the predicted societal costs by €5,350 
relative to the base case. An individual with the same characteristics as in the base case but 
who was non-adherent was predicted by the model to incur €6,380 less in societal costs at 
follow-up. 
 
4.3.5 Component costs  
 
Analyses were undertaken to determine if any of the individual services that were key 
components of overall costs were associated with non-adherence. These analyses may help 
determine which, if any, particular types of services used by people with schizophrenia were 
strongly impacted by non-adherence. The services deemed to be most influencial on total 
costs, both in terms of the number of users of the service and the costs incurred, were 
inpatient visits, community-based day services and informal care. Within each of these, a 
significant number of individuals in the sample did not use the service and therefore, two-part 
models were used. Recall that the first part of the two-part model uses a logistic regression 
model to assess factors for their association with whether or not the service was used and the 
second part uses a GLM to assess factors for their association with the costs incurred within 
the subsample of individuals who used the service. 
 
  
132 
Predicted societal costs, QUATRO study
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Inpatient stays 
 
The logistic regression model found that individuals who lived alone were less likely to have 
had an inpatient stay as compared to those who lived with others. None of the other individual 
characteristics considered was significantly associated with having had an inpatient stay (see 
Table 4.9). The model correctly predicted whether or not inpatient stays had occurred for 65% 
of cases. The link test p-value for this model was 0.2976 suggesting that the model was not 
misspecified, and the likelihood ratio, Pearson’s and Hosmer-Lemeshow test p-values 
suggested acceptable goodness of fit. 
 
With respect to inpatient costs, the GLM model found that inpatient costs were not 
significantly associated with any of the factors considered. The interaction of treatment and 
non-adherence approached statistical significance (p=0.077), suggesting that the effect of non-
adherence on inpatient costs was different for those who received treatment compared to those 
who did not. There was a trend towards inpatient costs being significantly higher for this 
group (p=0.083). Thus for those not receiving the study intervention (or prior to receiving the 
intervention), the effect of non-adherence was not significant. Receipt of treatment was 
associated with a trend towards non-adherence being associated with higher costs. 
 
There was also a trend for ethnic minority respondents to have lower inpatient costs as 
compared to White European respondents (see Table 4.10; p=0.060). Because the factors 
considered did not appear to be associated with inpatient costs, predictions for case types 
comparing costs were not estimated. 
 
 
Community-based day services 
 
The next key group of services modelled were community-based day services. In a logistic 
regression model of whether or not these services were used, living alone and time on 
medication were significant (see Table 4.11). Individuals who lived alone were two times as 
likely to have used community-based day services as compared to those who lived with 
others.  
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Table 4.9: Logistic regression model of factors associated with use of inpatient services, 
QUATRO study 
 
 
Potentially associated factors N=770 
 
Odds ratio 95% Confidence Interval 
Treatment… 
…relative to no treatment 
0.93 0.55, 1.56 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
0.46*** 0.31, 0.68 
Non-adherent… 
…relative to adherent 
1.40 0.92, 2.15 
Intervention x Non-adherence interaction 1.02 0.39, 2.69 
Age (5 year increase in age) 0.99 0.90, 1.09 
Females… 
…relative to males 
0.97 0.69, 1.36 
Lives alone… 
…relative to lives with others 
0.67** 0.48, 0.94 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
1.69** 
4.69*** 
0.87 
1.02, 2.80 
2.71, 8.13 
0.51, 1.46 
Education – further or tertiary... 
...relative to primary, secondary or general 
1.05 0.74, 1.49 
Not White European… 
…relative to White European 
0.99 0.62, 1.58 
Number of years on medication 0.99 0.97, 1.01 
Link test p-value 0.2976 
Pearson’s chi-squared test p-value 0.2997 
Hosmer-Lemeshow chi-squared test p-value 0.2087 
Likelihood ratio chi-squared p-value 0.0001 
Percent correctly classified 66.18 
 
 
* p<0.10; ** p<0.05; *** p<0.01
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Table 4.10: Generalised linear model of factors associated with inpatient costs, QUATRO 
study 
 
 
Potentially associated factors N=291 
 
Coefficient 95% Confidence Interval 
Treatment… 
…relative to no treatment 
-0.033 -0.45, 0.38 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
-0.23 -0.58, 0.13 
Non-adherent… 
…relative to adherent 
-0.092 -0.49, 0.30 
Intervention x Non-adherence interaction 0.99* -0.15, 2.13 
Age – in 5 year increments 0.0051 -0.074, 0.085 
Females… 
…relative to males 
-0.20 -0.50, 0.10 
Lives alone… 
…relative to lives with others 
-0.14 -0.44, 0.16 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
1.07*** 
-0.24 
-0.41 
0.62, 1.51 
-0.74, 0.27 
-1.02, 0.21 
Education – further or tertiary... 
...relative to primary, secondary or general 
0.17 -0.17, 0.50 
Not White European… 
…relative to White European 
-0.38** -0.77, 0.0023 
Number of years on medication 0.0022 -0.018, 0.022 
Constant 9.93*** 9.24, 10.62 
Link function Log 
Distributional family Gamma 
 
 
* p<0.10; ** p<0.05; *** p<0.01
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Table 4.11: Logistic regression model of factors associated with use of community-based day 
services, QUATRO study 
 
 
Potentially associated factors N=770 
 
Odds ratio 95% Confidence Interval 
Treatment… 
…relative to no treatment group 
1.33 0.83, 2.12 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
1.03 0.71, 1.49 
Non-adherent… 
…relative to adherent 
0.86 0.57, 1.31 
Intervention x Non-adherence interaction 0.41* 0.16, 1.11 
Age (5 year increase in age) 1.04 0.95, 1.14 
Females… 
…relative to males 
1.05 0.76, 1.46 
Lives alone… 
…relative to lives with others 
2.06*** 1.49, 2.83 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
0.77 
0.95 
1.38 
0.47, 1.25 
0.56, 1.61 
0.84, 2.25 
Education – further or tertiary... 
...relative to primary, secondary or general 
0.88 0.63, 1.23 
Not White European… 
…relative to White European 
1.20 0.76, 1.91 
Number of years on medication 1.02* 1.00, 1.04 
Link test p-value 0.4232 
Pearson’s chi-squared test p-value 0.3207 
Hosmer-Lemeshow chi-squared test p-value 0.6205 
Likelihood ratio chi-squared p-value 0.0001 
Percent correctly classified 61.46 
 
 
* p<0.10; ** p<0.05; *** p<0.01 
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Also, the greater the number of years on medication, the greater the probability of having used 
community-based day services. This model correctly predicted 61% of cases and the link test 
suggested that the model was not misspecified. The likelihood ratio, Pearson’s and Hosmer-
Lemeshow test p-values suggested acceptable goodness-of-fit. 
 
The interaction between treatment and non-adherence in this model approached statistical 
significance (p=0.080). If the effect of non-adherence is estimated seperately for those who 
received the study intervention, the odds of using community-based day services are 
significantly lower for those within this group who were non-adherent as compared to those 
who did adhere. 
 
Among those who used community-based day services, the GLM model found that non-
adherence was associated with the costs incurred. That is, community-based day service use 
costs were significantly lower for those deemed non-adherent as compared to those who did 
adhere to their medication (see Table 4.12). Additionally, women incurred less costs than men 
and those with a tertiary or further education incurred greater costs as compared to those 
without this level of education.  
 
Again the interaction term approached significance (p=0.075) suggesting that the effect of 
non-adherence differed according to whether or not the study intervention was received. 
Separate estimation of the effect of non-adherence on community-based day service use costs 
for those who received the study intervention found this effect to not be significantly different 
from zero (p=0.424). 
 
Graphicallly, the effects of non-adherence and the other significant variables are illustrated in 
Figure 4.3. Relative to the base case (male, age 45, of White European ethnicity, without 
tertiary or further education, resident in London, adheres to medication, lives with others, 
randomised to adherence education and on medication for six years), follow-up community-
based day service use costs were halved if the base case was altered to be that of an individual 
non-adherent to medication. An increase in costs of approximately €600 was predicted if the 
base case was altered to be an individual living alone.  
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Table 4.12: Generalised linear model of factors associated with cost of community-based day 
services, QUATRO study 
 
 
Potentially associated factors N=282 
 
Coefficient 95% Confidence Interval 
Treatment… 
…relative to no treatment 
-0.87** -1.55, -0.18 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
-0.076 -0.65, 0.50 
Non-adherent… 
…relative to adherent 
-0.72** -1.37, -0.078 
Intervention x Non-adherence interaction 1.12* -0.11, 2.34 
Age – in 5 year increments 0.13 -0.039, 0.30 
Females… 
…relative to males 
-0.66** -1.22, -0.11 
Lives alone… 
…relative to lives with others 
0.26 -0.31, 0.82 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
0.51 
0.52 
-0.36 
-0.23, 1.24 
-0.74, 1.78 
-1.12, 0.40 
Education – further or tertiary... 
...relative to primary, secondary or general 
0.71** 0.11, 1.32 
Not White European… 
…relative to White European 
0.016 -0.63, 0.66 
Number of years on medication -0.021 -0.052, 0.011 
Constant 7.72*** 6.38, 9.07 
Link function Log 
Distributional family Gamma 
 
Net effect of non-adherence if adjusted is 0.44 (-0.64, 1.52) 
 
* p<0.10; ** p<0.05; *** p<0.01 
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Predicted cost of community-based day services, QUATRO study
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Informal care costs 
 
The final key cost component to be analysed were informal care costs. The logistic regression 
model found that among individual characteristics, living with others was associated with 
receipt of informal care as would be expected (see Table 4.13). Those who lived alone were 
30% less likely to receive informal care. The link test suggested this model was adequately 
specified. The model correctly classified 59% of cases. The Pearson’s, Hosmer-Lemeshow 
and likelihood ratio test p-values all suggested adequate goodness-of-fit. 
 
The GLM on informal care costs did not find non-adherence to be significanly associated with 
informal care costs amongst those who received informal care (see Table 4.14). These costs 
were associated with age and gender. The association with age was negative. That is, within 
the sample of recipients of informal care, as age increased, the informal care costs declined. 
With respect to the other significant effect, women had greater informal care costs than men. 
 
Figure 4.4 graphically illustrates the impact of the significant effects on informal care receipt 
and costs relative to a base case. The base case chosen was the same as in Figure 4.3. That is, 
of a man, age 45, of White European ethnicity, without tertiary or further education, resident 
in London, who adheres to medication, lives with others, allocated to adherence education and 
on medication for six years. The model predicted the informal care costs for the base case to 
be €3,250. Altering the base case to that of someone who lives alone was associated with a 
€1,000 reduction in the predicted cost of informal care. If the characteristics of the base case 
are altered such that the case is of a 30 year old, the predicted costs would increase by just 
under €1,200. A €4,100 increase in predicted informal care costs was associated with the 
effect of changing the base case to that of a woman as opposed to a man.  
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Table 4.13: Logistic regression model of factors associated with receipt of informal care, 
QUATRO study 
 
 
Potentially associated factors N=768 
 
Odds ratio 95% Confidence Interval 
Treatment… 
…relative to no treatment group 
0.96 0.60, 1.54 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
0.57*** 0.40, 0.82 
Non-adherent… 
…relative to adherent 
1.16 0.77, 1.75 
Intervention x Non-adherence interaction 1.18 0.50, 2.78 
Age (5 year increase in age) 1.05 0.97, 1.15 
Females… 
…relative to males 
1.19 0.86, 1.63 
Lives alone… 
…relative to lives with others 
0.70** 0.51, 0.96 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
0.54** 
1.11 
0.89 
0.33, 0.87 
0.67, 1.84 
0.55, 1.42 
Education – further or tertiary... 
...relative to primary, secondary or general 
1.05 0.76, 1.47 
Not White European… 
…relative to White European 
0.91 0.58, 1.44 
Number of years on medication 1.00 0.98, 1.02 
Link test p-value 0.2414 
Pearson’s chi-squared test p-value 0.3790 
Hosmer-Lemeshow chi-squared test p-value 0.6395 
Likelihood ratio chi-squared p-value 0.0001 
Percent correctly classified 58.9 
 
 
* p<0.10; ** p<0.05; *** p<0.01 
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Table 4.14: Generalised linear model of factors associated with cost of informal care, 
QUATRO study 
 
 
Potentially associated factors N=326 
 
Coefficient 95% Confidence  Interval 
Treatment… 
…relative to no treatment group 
-0.25 -1.03, 0.53 
Time 1(follow-up)… 
…relative to Time 0 (baseline) 
0.51* -0.049, 1.08 
Non-adherent… 
…relative to adherent 
-0.15 -0.42, 0.13 
Intervention x Non-adherence interaction -0.018 -1.12, 1.08 
Age – in 5 year increments -0.13*** -0.21, -0.042 
Females… 
…relative to males 
0.77*** 0.46, 1.07 
Lives alone… 
…relative to lives with others 
-0.19 -0.46, 0.078 
Amsterdam (The Netherlands)… 
Leipzig (Germany)… 
Verona (Italy)... 
...relative to London (UK) 
-1.38*** 
-0.086 
-0.10 
-1.75, -1.01 
-0.61, 0.43 
-0.50, 0.29 
Education – further or tertiary... 
...relative to primary, secondary or general 
0.21 -0.096, 0.51 
Not White European… 
…relative to White European 
-0.14 -0.48, 0.20 
Number of years on medication 0.0062 -0.013, 0.025 
Constant 9.82*** 9.12, 10.51 
Link function Log 
Distributional family Inverse Gaussian 
 
 
* p<0.10; ** p<0.05; *** p<0.01 
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Predicted cost of informal care, QUATRO study
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4.3.6 Sensitivity analyses 
 
Estimates from previous studies are that between 25% and 80% of schizophrenia patients do 
not adhere to their medication as prescribed (Battaglia 2001; Conley and Kelly 2001). Cramer 
and Rosenheck (1999), in a systematic review, found the mean rate of non-adherence among 
patients with psychoses to be 42%. The rate of non-adherence in the QUATRO study was at 
the low end, ranging from 11% to 49% across sites. Given that the rate of non-adherence was 
markedly lower in Amsterdam (11%) relative to the three other sites, sensitivity analyses were 
conducted to determine the effect of excluding the patients from Amsterdam to see how this 
would impact the study results.  
 
In the model of societal costs, excluding the Amsterdam sample the effect of non-adherence 
increases but remains statistically insignificant (see Table 4.15; p=0.115). Also, as in the 
primary results, in the model of health and social care costs which excluded observations from 
Amsterdam, the effect of non-adherence did not achieve statistical significance (p=0.246). 
The interaction between treatment and non-adherence was statistically significant in this 
model at the 0.05 level. While the effect of non-adherence was not significant when the study 
intervention is not received, amongst recipients there was a significant positive association 
between non-adherence and inpatient costs (p=0.021). 
 
The association between non-adherence and the probability of use of community-based day 
services differs by receipt of the study intervention when the Amsterdam sample is excluded 
from the analyses. When the intervention was received there was a significantly lower 
probability of use of these services (p=0.004). At the same time, amongst those not receiving 
the study intervention non-adherence was associated with significantly lower community-
based day service use costs (p=0.028). These costs were not associated with non-adherence 
amongst recipients of the study intervention. Additionally, excluding the Amsterdam sample 
resulted in there being a significant negative association between non-adherence and informal 
care costs. 
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Table 4.15: Results of sensitivity analysis on effect of non-adherence on primary outcomes, 
QUATRO study - Excluding observations from Amsterdam § 
 
 
 Outcome Coefficient 95% Confidence 
Interval 
 
 
Excluding Amsterdam sample 
 
Non-adherence 
 
 
Health and 
social care costs 
-0.16 -0.44, 0.11 
Treatment x Non-
adherence interaction 
0.56 -0.17, 1.29 
Non-adherence 
 
 
Societal costs 
-0.19 -0.43, 0.047 
Treatment x Non-
adherence interaction 
0.57 -0.034, 1.18 
Non-adherence 
 
 
Inpatient visits 
1.43 0.90, 2.27 
Treatment x Non-
adherence interaction 
1.23 0.43, 3.55 
Non-adherence 
 
 
Inpatient costs 
-0.11 -0.52, 0.31 
Treatment x Non-
adherence interaction 
1.29** 0.13, 2.46 
Non-adherence 
 
Use of 
community-
based day 
services 
0.81 0.52, 1.26 
Treatment x Non-
adherence interaction 
0.28** 0.095, 0.84 
Non-adherence 
 
Cost of 
community-
based day 
services 
-0.72** -1.37, -0.078 
Treatment x Non-
adherence interaction 
1.17* -0.11, 2.34 
Non-adherence 
 
Use of informal 
care 
1.21 0.78, 1.87 
Treatment x Non-
adherence interaction 
1.17 0.47, 2.91 
Non-adherence 
 
Cost of informal 
care 
-0.36** -0.71, -0.015 
Treatment x Non-
adherence interaction 
0.65 -0.43, 1.72 
 
* p<0.10; ** p<0.05; *** p<0.01 
 
 
§All other effects are included in these models but are not listed here. 
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Another sensitivity analysis was undertaken to determine the impact of the choice of threshold 
in the Morisky score used to determine non-adherence. Shalansky (2004) suggests using other 
choices of a threshold score so as to trade off between the sensitivity and positive predictive 
value of the scale in detecting ‘true’ non-adherent patients. Sensitivity analyses were 
conducted to determine if using a threshold score of 3 on the Morisky score to define non-
adherence would have an impact on the results. That is, individuals were deemed non-
adherent if they reported that in the past three months they had at some point either forgotten 
to take medication, were careless about taking medication, had at some point stopped taking 
medication once they felt better, or had at some point stopped taking medication because it 
made them feel worse.  
 
Using the lower threshold level suggested that 52.8% of the sample were non-adherent at 
baseline. For all of the outcomes analysed the effect of non-adherence remained statistically 
non-significant (see Table 4.16). Thus, the higher threshold did not alter the results of the 
primary analyses.  
 
 
4.4 Discussion 
 
The results of the analyses set out in this chapter suggest that non-adherence does not have a 
significant impact on the health and social care or societal costs incurred in schizophrenia 
patients. This finding is not consistent with analyses in the previous chapter that looked at 
factors associated with use of health and social care services which included residential  
costs. For subsamples of the data, there was evidence of non-adherence being associated with 
higher inpatient costs. For some subsamples there was evidence that non-adherence was 
associated with lower community-based day service use costs when these costs were incurred. 
While the samples and settings of the PMS 1993/4 and QUATRO studies differ markedly, the 
results suggest that the contribution to costs of non-adherence may be relevant for some 
services. This is consistent with the results observed by Gilmer et al (2004). They found that 
while total costs were actually lower for those individuals who did not adhere to their 
medication, hospital costs were significantly higher for the non-adherent group.  
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Table 4.16: Results of sensitivity analysis on effect of non-adherence on primary outcomes, 
QUATRO study - Lower threshold to define non-adherence § 
 
 
 Outcome Coefficient 95% Confidence 
Interval 
 
 
Lower threshold used to define non-adherence 
 
Non-adherence 
 
 
Health and 
social care costs 
-0.057 -0.35, 0.24 
Treatment x Non-
adherence interaction 
0.16 -0.35, 0.67 
Non-adherence 
 
 
Societal costs 
-0.072 -0.33, 0.18 
Treatment x Non-
adherence interaction 
0.033 -0.44, 0.50 
Non-adherence 
 
Inpatient visits 1.14 0.78, 1.67 
Treatment x Non-
adherence interaction 
1.23 0.55, 2.73 
Non-adherence 
 
Inpatient costs -0.16 -0.54, 0.22 
Treatment x Non-
adherence interaction 
0.24 -0.51, 0.99 
Non-adherence 
 
Use of 
community-
based day 
services 
0.83 0.56, 1.22 
Treatment x Non-
adherence interaction 
0.65 0.31, 1.36 
Non-adherence 
 
Cost of 
community-
based day 
services 
-0.016 -0.77, 0.74 
Treatment x Non-
adherence interaction 
-0.090 -1.16, 0.98 
Non-adherence 
 
Use of informal 
care 
1.07 0.74, 1.54 
Treatment x Non-
adherence interaction 
0.98 0.47, 2.03 
Non-adherence 
 
Cost of informal 
care 
-0.14 -0.45, 0.17 
Treatment x Non-
adherence interaction 
-0.78 -1.75, 0.20 
 
* p<0.10; ** p<0.05; *** p<0.01 
 
 
§All other effects are included in these models but are not listed here. 
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One consideration as to why non-adherence was not significant in predicting health and social 
care or societal costs in the QUATRO study was that the sample for this study was made up 
of patients deemed to be clinically unstable in the year prior to the start of the study. Indeed, a 
hospital inpatient stay in the year prior to the study was one of the criteria for individuals to 
be considered for inclusion in the study. These patients were likely to be less functional than a 
general schizophrenia sample. However, this was also an inclusion criterion in the study by 
Gilmer et al (2004) which observed no statistically significant difference in total treatment 
costs between adherent, partially adherent and non-adherenct individuals, but significantly 
higher hospitalisation costs for the non-adherent group. Relative to the 1993/4 PMS sample, 
when a comparable index of non-adherence was used for the QUATRO sample (Morisky 
score of 3 or below), the latter were, at baseline, more likely to be non-adherent and had been 
on medication for longer, potentially reflecting greater severity of illness. The QUATRO 
sample was also more ethnically diverse and had higher educational attainment, on average, 
as compared to the 1993/4 PMS sample.  
 
Another consideration is whether or not the sample in the QUATRO study was large enough 
to detect meaningful differences in costs with sufficient power. The sample size calculation 
performed for this study was based on the primary clinical outcome of the main study, the SF-
36 mental component summary score (Gray, Leese et al. 2006). Retrospective estimation of 
the power of this study for the service use outcomes (and by extension costs) is difficult as 
these outcomes typically have high variability leading to under estimation of power (Gray, 
Marshall et al. 1997). Based on the standard error observed in the analysis of health and social 
care costs, the sample size of the study was sufficient to observe a 44% difference in costs 
with 80% power. How much of a change in costs this represents depends on where on the 
distribution of costs it is applied. At the 10th percentile, a change of 44% is less than the 
difference between the 10th and 5th percentile. At the 90th percentile, a 44% change would 
reflect the difference from the 90% to the 76th percentile. With respect to societal costs, the 
sample size of the study was sufficient to observe a 38% difference in costs with 80% power. 
 
Previous studies that have examined the relationship between non-adherence and health care 
costs have focussed on hospitalisation costs. Svarstad et al (2001) found non-adherers, that is 
those whose claims data indicated a three month gap in claims for medication, were 
significantly more likely to have been rehopsitalised and incurred significantly higher 
inpatient costs. Weiden et al (2004) observed that gaps in medication therapy, based on 
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prescription claims, were positively correlated with risk of hospitalisation  In the PMS 
analysis there was a trend towards an association between inpatient visits and non-adherence 
being significant, but this was the case in the QUATRO analysis only for those patients who 
received the study intervention.  
 
Non-adherence was associated with lower community-based day service costs (when these 
services were used) in the QUATRO study. In the analysis of the PMS 1993/4 sample, visits 
to patients by community-based health and social care professions were positively associated 
with non-adherence. If it is accepted that non-adherence to medication will result in 
resumption or exacerbation of symptoms in patients taking antipsychotics, the point of contact 
for non-adherent patients will depend on how long they wait before seeking health and social 
care help, the way services are organised in their area and the ease with which they are able to 
access the services they seek out. If non-adherent patients do not seek health or social care 
support as their symptoms increase in severity, the effects of non-adherence may be observed 
in the wider societal services such as the criminal justice system. My results suggest that 
community care professionals may be the primary source of care for non-adherent individuals 
who require services. Use of community-based day services appears to associated with a 
greater degree of acceptance of medication (based on adherence and length of time on 
medication). 
 
The observed lower health and social care and societal costs experienced by those patients 
living alone may reflect the role that co-resident family and friends play in identifying and 
encouraging those individuals with schizophrenia to access the available services. However, 
those living alone were significantly more likely to use community-based day services. 
Community-based day services are the services most likely to be substituted with informal 
care. This suggests that informal care acts as a substitute for community-based day services 
but as a complement to other health and social care services. Because these effects were 
present after accounting for non-adherence in the model, it would indicate that the impact of 
co-resident family or friends was not affecting costs solely through reduced rates of non-
adherence. These results were not observed in the earlier analyses of PMS data. 
 
Also contradictory to the earlier analyses is the direction of the association between ethnicity 
and costs. The PMS analysis did not find a significant difference in total health and social care 
costs between non-Whites and Whites, though non-Whites had significantly higher inpatient 
  
150 
costs and were significantly less likely to use external services. Analysis of the QUATRO 
data indicated that sample subjects who were not White European had lower health and social 
care costs (at a level that approached statistical significance) and significantly lower societal 
costs. There was also a trend for those not White European to have incurred lower inpatient 
costs when inpatient services were used. More than one interpretation of these contradictory 
findings is possible, although further information would be required to conclude definitively. 
It may be that the two ethnic minority subsamples differed quite significantly in the two 
studies. The PMS data compared all non-Whites to Whites while the QUATRO study 
compared White Europeans with other ethnicities. Also, the settings of the two studies differ 
appreciably. The effect of ethnicity observed in a study of British patients would be expected 
to differ from this effect as estimated in a study including individuals from other countries. It 
should be noted, however, that in the QUATRO study, only the London (46.7%) and 
Amsterdam (56.0%) samples included ethnic minority patients. Further difference on the 
ethnic mix of the non-White samples could exist. Minority ethnic groups were not sampled in 
sufficient numbers to determine wether the mix of ethnicities were similar in the two studies. 
The difficulty with making conclusions regarding the impact of ethnicity is that like the PMS 
and QUATRO studies, few studies are sufficiently large to sample from ethnic minorities with 
schizophrenia in sufficient numbers.  
 
The analysis of the PMS data identified associations between length of time on medication 
and the use of external services and day activity services. In the QUATRO analysis a 
significant positive association was found between length of time on medication and use of 
community-based day services. These results suggest that familiarity with medical treatment 
allows patients to feel more comfortable with use of community-based services. These results 
may also, in part, reflect greater stability in the treatment of patients over the course of their 
illness. That is, patients may become more able to rely on community services as opposed to 
inpatient or outpatient services. Another conclusion may be warranted, however, as the 
QUATRO study sampled unstable patients so one would expect that familiarity with 
medication in this group to be poor and unrepresentative of stability of their medication 
regime. 
 
 
  
151 
4.4.1 Limitations 
 
There are several aspects of the QUATRO study that may limit the strength of the conclusions 
drawn from these data. Firstly, the sample in the QUATRO study was relatively small, both 
overall and within each site. The results may not be generalisable to the populations within 
each site and across sites. 
 
The use of a multi-centre, cross-country sample has some advantages, but may also lead to 
problems and uncertainty. There are many challenges to such a study design as survey 
instruments have to be translated and in costing services uncertainty is likely given that 
services are delivered in different ways across sites and unit costs for services are not always 
available (Patel 2006). With regards to differences in unit costs across countries, a sudy by 
Heider et al (2009), which followed samples of schizophrenia patients in France, Germany 
and the UK for two years, found that while differences existed in the costs for individual 
services, the total adjusted costs of health services were less variable than the unit costs. 
 
Because the Morisky scale is basing non-adherence assessment on self-reporting, it runs the 
risk of underestimating non-adherence. As discussed in chapter 2, however, self-assessment 
of non-adherence is the method most widely used in studies of schizophrenia patients 
(Velligan, Lam et al. 2006) and few studies corroborate self-reported adherence with pill 
counts or physiological data (Zygmunt, Olfson et al. 2002). More fundamentally, comparisons 
across studies are difficult because the definitions of what constitutes adherence, the period 
over which it is assessed and the sample of patients on whom it is assessed, vary widely 
across studies.  
 
The QUATRO study data is also lacking information that would be beneficial in the 
interpretation of the nature of the relationship between non-adherence to medication in 
schizophrenia and service use costs. The prior analysis of PMS data adjusted for some factors 
that were not considered in the analysis of the QUATRO data because they were not available 
in the dataset. These were general health status, whether or not co-morbidity was present 
(based on the CIS-R score), self-reported use of illegal drugs and self-reported alcohol abuse. 
However, none of these factors were statistically significant in the model of total health and 
social care costs in the previous analyses. The PMS analysis observed an association between 
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drug abuse and lower costs of external service use. Unfortunately, because the QUATRO 
study did not collect data on illegal drug use this association could not be tested for in the 
current analysis.  
 
Another important omission is data on the type of antipsychotics prescribed to the patients in 
the study. Without this information it is not possible to determine if certain prescribed 
antipsychotics are more cost inducing than others, or in fact if the general class of the 
antipsyhchotic, ‘typical’ or ‘atypical’ impacts on costs. Evidence to date suggests that 
adherence rates are similar across the different generation of antipsychotics and across 
different specific medications. Gilmer et al (2004) found no difference in adherence rates 
between those treated with the atypical antipsychotics risperidone, olanzapine and quetiapine 
and those treated with typical antipsychotics and refers to two other studies where similar 
results were found. They do not, however, compare service use costs across medications. 
There may be other effects of the type or class of antipsychotic prescribed that may impact on 
costs. For example, it could be the case that a particular medication was better than others in 
preventing weight gain which did not impact on adherence rates but did reduce costs incurred 
from illness due to the gain in weight. For this reason, it is not possible to say that had data on 
the type or class of drug been included in the QUATRO study, this would have had a direct 
impact on the interpretation of the effect of non-adherence in this study. Also, as mentioned 
earlier, the reason for not including the cost of treatment in the measure of costs was that is 
would be in effect replicating a difference in the treatment and control groups that is 
determined by the inclusion of a treatment effect in the model. 
 
Finally, while longitudinal, the duration of the QUATRO study is still quite short relative to a 
lifetime of schizophrenia and the (probable) long-term impacts of non-adherence. That is, 
some of the negative impacts of non-adherence might not be observed within the one year 
over which patients were followed in this study or if changes in service use have occurred, 
these changes may persist for longer than this length of time. 
 
Despite these limitations the analysis of the QUATRO study data was helpful in assessing the 
relationship between non-adherence and costs. Unlike previous literature that has tended to 
estimate this association using cross-sectional data, the longitudinal element of this study 
allows for estimates to take account of changes over time. The longitudinal nature of the 
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study, the robust method of assessing adherence and the detailed information on service use 
data made it the best available source for examining these associations. 
 
 
4.5 Summary 
 
The QUATRO study, a randomised control trial assessing the efficacy of an adherence 
therapy intervention in individuals with schizophrenia, provided longitudinal data from which 
to analyse the relationship between non-adherence and service use costs. The dataset included 
thorough information from which health and social care service use costs were estimated, as 
well as criminal justice and informal care costs. The sum of these costs was taken as an 
approximation of societal costs. 
 
Non-adherence was not found to be associated with either health and social care service use 
costs or societal costs, but for subsamples of individuals was significantly associated with 
higher inpatient costs and lower community-based day service costs. The significance of non-
adherence may have been underestimated as the sample was made up of clinically unstable 
patients. The service use patterns of these individuals may not be representative of a broader 
range of patients with schizophrenia. Also, the sample of the QUATRO study may not have 
been large enough to observe meaningful differences in costs with adequate power. Further, 
the duration of the QUATRO study – one year – may not have been sufficiently long to 
observe the long-term effects of non-adherence. 
 
Living alone was associated with significantly lower health and social care and societal 
costs.This may reflect the importance of support from family and friends in the lives of people 
with schizophrenia in encouraging them to seek out services and providing informal care. The 
associations between ethnicity and a lower probability of use of community services and a 
greater probability of inpatient visits found in analysis of the 1993/4 PMS institutions sample 
were not observed in this dataset. 
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Chapter 5 
Associations between medication non-adherence and resource use and costs for 
people taking medication for depression – analysis of the Psychiatric Morbidity 
Survey 2000 
 
 
5.1 Background 
 
Given that some illnesses are more debilitating than others, it follows that attitudes towards 
medication are likely to vary widely across illnesses. Furthermore, the side effects of 
medications differ widely across medication types and these differences are reflected in 
varying rates of non-adherence to medication across different illnesses. In trying to 
understand the impact of non-adherence to medication on service use and service use costs in 
patients with schizophrenia it is important, therefore, to consider how the associations differ 
from those that would be observed in a different illness population. To do this, I have chosen 
to look at patients with another mental illness, depression.  
 
The UK Office of National Statistics (2008) estimates that the prevalence of treated 
depression in the UK was 5% in 1998 and the World Health Organization estimated that 
major depression will carry the second highest disease burden by 2020 (Murray and Lopez 
1996). 
 
The incidence of depression is higher than that for schizophrenia although the actual 
medication cost per patient is lower due to the lower unit cost the of medications taken. The  
Health and Social Care Information Centre (2009) reported the average net ingredient cost per 
prescription in England in 2008 to be £34.55 for drugs used in psychosis and related disorders 
and £6.88 for antidepressants.  
 
Estimates of non-adherence rates in depression are comparable to those in schizophrenia. In a 
study conducted in California in the US, Venturini et al (1999) retrospectively studied the 
pharmacy claims data of 942 patients and determined that over a six month period only 13% 
of patients completed an adequate course of treatment with selective serotonin reuptake 
inhibitors (SSRIs). Adequate treatment was defined as the average daily dose exceeding 90% 
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of the minimum therapeutic dose. Another US-based study, relying on automated pharmacy 
data and reviewing medical records, observed that among 155 patients newly prescribed 
antidepressants, 28% stopped their medication in the first month and by the third month 44% 
had stopped taking their medication (Lin, Korff et al. 1995). Cantrell et al (2006) conducted a 
retrospective study of patients starting treatment on SSRIs for depression or anxiety using a 
large US managed care database which included data for approximately 23,000 patients and 
observed a 57% rate of non-adherence.  
 
The prevalence and burden of illness of depression and the non-adherence rates of patients 
prescribed medication for this illness are good reasons to use patients with this illness as a 
comparator to those with schizophrenia in assessing the impact of non-adherence to 
medication. Both illnesses are likely to affect a patient’s insight into their illness, a factor 
thought to impact on non-adherence. Also, the medications for both schizophrenia and 
depression have significant (but different) side effects.  
 
Side effects vary according to the type of antidepressant prescribed. Those associated with 
selective serotonin reuptake inhibitors are nausea, diarrhoea, agitation, headaches, loss of 
libido, erectile dysfunction and failure to reach orgasm. The side effects associated with 
tricyclic antidepressants include dry mouth, blurred vision, drowsiness, dizziness, tremors, 
skin rash, weight gain or loss and sexual dysfunction. Monoamine oxidase inhibitors are less 
likely to have associated side effects in of themselves but are associated with very adverse 
effects, such as heart attack and stroke, when interacted with certain foods or other 
medications (NICE 2007). 
 
Here the focus is on depression, but many patients with a diagnosis of anxiety will also be 
prescribed anti-depressants. The primary analyses will include both groups as there is high 
comorbidity for anxiety and depression. Within the Psychiatric Morbidity Survey (PMS) 
2000, mixed anxiety and depressive disorder was the most prevalent neurotic disorder 
observed (Singleton, Bumpstead et al. 2001).  
 
Data from the PMS 2000 of adults living in private households was used to examine the 
factors associated with non-adherence and the relationship between non-adherence and the 
use of formal services and the resulting cost of these services, amongst patients taking 
antidepressants. The previous PMS of adults in institutions (1994) was used to examine these 
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associations amongst patients taking antipsychotic medication (chapter 4). While the two 
PMS surveys were conducted 6-7 years apart, the questionnaires used were very similar and 
the benefit of comparing across similar data on individual characteristics and health and social 
care service use outweighs limitations due to the few differences in how the data were 
collected.  
 
Thus the aims of the analyses of the PMS 2000 were to estimate the rate at which treatment 
with medication was discontinued in patients with depression; to assess the impact of this 
non-adherence to depression medication on how resources were used and at what cost. These 
results are compared to the results observed for patients taking antipsychotic medication in the 
concluding chapter.   
 
 
5.2 Methods 
 
5.2.1 The Psychiatric Morbidity Survey 2000 sample 
 
The PMS 2000 was a cross-sectional survey covering people aged 16 to 74 living in private 
households in England, Wales and Scotland. It was a repeat of the 1993 survey of adults 
living in private households with some modifications. The age range of the first survey was 
18 to 65 and the PMS 2000 included measures of personality disorder and intellectual 
functioning (Singleton, Bumpstead et al. 2001). The PMS 2000 surveys included structural 
assessment and screening instruments to determine if mental disorders were present and if so, 
the severity of illness. Additionally, data on service use, risk factors for mental disorders and 
socio-demographic status were collected. A subsample of individuals was selected to 
undertake a second-stage interview to assess for psychosis and personality disorders. 
Interviews took place between March and September 2000. 
 
The sampling frame of the survey was the postcode address file (Royal Mail 2009) and the 
primary sampling units were postal sectors. From the over 9000 postal sectors in Britain, 438 
were selected with a probability proportional to the number of addresses within the sector. 
Within each postal sector, 36 addresses were selected, and if the household included 1 or 
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more persons aged 16 to 74 the Kish grid method (Kish 1965) was used to systematically 
select one person in each household to be interviewed for the survey. 
 
The selection of individuals to include in the analyses was as follows. To minimize 
differences between the 1993/94 PMS and the PMS 2000, analyses were restricted to those 
between 16 and 65 years of age. Various data in the PMS 2000 can be used to identify 
patients with depression and determine the severity of the illness. A relevant sample was 
identified as those patients that were prescribed antidepressants at the time of the survey.  
 
5.2.2 Variable definitions 
 
With respect to non-adherence, as in the 1993/4 PMS surveys, the PMS 2000 survey relied on 
self-reported information. Patients were asked if they ever do not take the medication they 
have been prescribed for mental illness (and if they ever take more than the stated dose). Data 
was also gathered on the reason for the non-adherence and the time since the last interruption 
of their medication taking. The wording of these questions was identical to that used in the 
1993/4 PMS surveys.  
 
The variables included in the modelling were the same as used in the analysis of non-
adherence to antipsychotics: age, sex, ethnicity, education, general level of health, illness 
severity, previous experience of side effects, inpatient contact for mental health reasons in the 
past year, self-reported drug abuse, self-reported alcohol abuse, social support, and familiarity 
with medication. Derived variables produced by the primary data collection team, and used in 
the main report, were the source of some indices used in my analyses (Singleton, Bumpstead 
et al. 2001). As in the 1993/4 PMS, data on ethnicity was collected in nine categories, but for 
the purpose of the analyses was collapsed into White and non-White due to the small number 
of respondents in each of the individual non-White classifications. The education variable was 
collapsed from five categories to three. The first category combined those with a degree, 
teaching, Higher National Diploma, nursing or A Level qualification. The second category 
includes those with GCSE or equivalent education and the third included those with no 
qualifications.  
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The index of drug dependency was the derived variable provided in the dataset (Singleton, 
Bumpstead et al. 2001). This variable took the value of one if the respondent reported 
dependency on any drug and zero if they did not. A variable indication alcohol abuse was also 
taken from the derived variables. This variable took a value of one, indicating a drinking 
problem, if the respondent had a combined score of eight or more on the ten drinking audit 
questions included in the survey. 
 
Levels of general health were reported by patients on a five-point scale which was collapsed 
to three levels: very good/good; average; and poor/very poor as some of the original 
categories had relatively few observations. The wording of the question in the survey relating 
to general health was the same as in the earlier PMS studies though in the PMS 2000 this 
question was part of the SF-12 instrument. As previously, prevalence of symptoms relating to 
and severity of neurosis was based on results from the Revised Clinical Interview Schedule 
(CIS-R), a standardised instrument used to assess the prevalence and severity of symptoms in 
minor psychiatric disorders (Lewis, Pelosi et al. 1992). Support from an adult with whom the 
patient feels close was based on the question: ‘How many adults who live/are staying here 
with you do you feel close to?’ 
 
The course of treatment for patients taking antidepressants is typically shorter than that for 
patients taking antipsychotics. The NICE (2007) guidelines for the treatment of depression 
states that: 
 
 “Antidepressants should be continued for at least six months after remission 
of an episode of depression, because this greatly reduces the risk of relapse. 
Patients who have had two or more depressive episodes in the recent past, and 
who have experienced significant functional impairment during the episodes, 
should be advised to continue antidepressants for two years.”  
 
For this reason, consideration was given for changing the definition used to assess medication 
familiarity from two years, as used in the analysis of non-adherence to antipsychotics, to a 
period of one year for antidepressants. Examination of the PMS 2000 data suggested that a 
substantial proportion of patients reported taking antidepressants for 2 years of more (39.8%), 
so the decision was taken to use this period in defining medical familiarity. 
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5.2.3 Costing service use, benefits and absenteeism 
 
The potential economic consequences of non-adherence that were analysed were the cost of 
health and social care services, costs to the state and the cost of time off work due to illness. 
This is a wider group of costs considered than in the analyses of non-adherence in 
antipsychotics. The additional cost outcomes were analysed because previous literature 
looking at the impact of non-adherence on costs in patients taking antidepressants suggested 
that these wider costs were substantial in this patient population. 
 
A list of benefits included in the analysis, along with the individual health and social care 
services included, appears in Table 5.1. With respect to GP visits, survey respondents were 
asked if they had visited their GP in the past year and if these visits related to a physical or 
psychological problem. The number of visits in the past year was not requested. Respondents 
were also asked the number of times they had visited their GP in the past 2 weeks. Because 
the 2 weeks prior to the survey were not necessarily representative of GP service use in the 
past year, a decision was made to use the information on whether or not they had visited their 
GP in the past year. To account for the fact that the number of visits were not recorded, those 
that visited their GP for a physical problem were assumed to have made 2 such visits in the 
past year and likewise, those that reported that they had visited their GP for a psychological 
problem were assumed to have made 2 visits. That is, individuals who report having visited 
their GP for both physical and psychological problems would be assumed to have made 4 
visits in the past year. 
 
Health and social care costs were calculated by multiplying the frequency of use of each 
service by the estimated national average cost for the service. The unit costs were taken  
from the PSSRU Unit Costs of Health and Social Care for 2001 (Netten, Rees et al. 2001). 
These were the costs applied in costing the 1993/4 PMS surveys. The unit costs do not 
include qualification costs. Daily rates were applied for inpatient stays and included 
accommodation costs. A cost per visit was applied to A&E outpatient visits and community 
care services. An average length of time of one hour was assumed per visit and the unit cost 
relating to hourly patient contact time was used. For community mental health centre and 
sheltered workshop visits, the average length time of visits was estimated and an hourly unit  
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Table 5.1: Health and social care services and benefits included in analyses, PMS 2000 
 
Health  and 
social care 
services 
GP visits  
Hospital inpatient 
stays 
Secure/semi-secure or special hospital unit 
Acute psychiatric ward 
Rehabilitation or long-stay ward/facility 
A&E department or emergency ward 
General medical ward 
Hospital outpatient 
visits 
A&E department 
Psychiatric outpatient department 
Day activity services Community mental health centre 
Day activity centre 
Sheltered workshop 
Community services Community Psychiatrist 
Community Psychologist 
Community Psychiatric Nurse 
Community learning difficulty nurse 
Other nursing services 
Social worker 
Self-help/support group 
Home help/home care worker 
Outreach worker/family support 
 
Benefits  Income support 
Incapacity benefit 
Housing benefit 
Severe disablement allowance 
Disability living allowance 
 
 
 
 
cost applied. For day activity centre visits a sessional unit cost was applied with a session 
being either a morning, afternoon or evening. 
 
The unit cost for each service was multiplied by the total number of visits to that service to 
estimate the annual cost for that service. The data were then summed to estimate total health 
and social care costs. 
 
The survey asked patients to indicate which state benefits were received. The cost of each 
benefit was estimated from available sources. Data from the Department of Work and 
Pensions Resource Centre (2008) was the source for the average weekly amount of Income 
Support for the population under age 60 as of May 2001. This was the estimate closest to the 
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age range of the sample used in the analyses. This site was also the source for the average 
weekly amount of the Incapacity Benefit and Severe Disablement Allowance for the working 
age population as of May 2001. Because the earliest data available on the Disability Living 
Allowance benefit was May 2002, this amount was applied to the PMS 2000 rate of receipt of 
this benefit. These benefit amounts were multiplied by 52 to arrive at annual amounts and 
then summed to arrive at the total annual cost of benefits. The costs of benefits were added to 
health and social care costs to estimate total costs to the state. Absenteeism costs were 
estimated as the length of time off work for those in employment in the past year. The 
national annual salary was estimated from data summarised by the UK Office of National 
Statistics (2001). This source estimated the average weekly gross earnings for all employees. 
This amount was divided by five to arrive at average daily earnings. This amount was 
multiplied by the number of days taken off work as reported in the dataset.  
 
5.2.4 Statistical analyses 
 
The first primary analysis was a logistic regression model to identify the characteristics 
potentially related to non-adherence to medication. In this model, the outcome was the binary 
variable ‘Was the patient adherent or non-adherent to their prescribed medication at the time 
of the survey’. The other main analyses determined the factors associated with the cost of 
health and social care services, costs to the state and the costs of absenteeism.  
 
The methods appropriate for modelling costs were discussed in detail in chapter 2. Only a 
brief summary of the methods is provided here. For each outcome, if a significant proportion 
of the sample did not incur the cost, a two-part modelling process was undertaken (Mullahy 
1998). The first part was a model to determine which, if any, of the factors were associated 
with incurring the cost vs. not-incurring the cost. Here logistic regression was used. The 
second part was a model of the costs incurred for the subsample of those patients who did 
incur costs. The choice of regression model was made based on the distribution of costs. If 
there was not significant skewness in the data, an ordinary least-squares (OLS) regression 
model would be appropriate. If the costs were skewed, a GLM was fitted to the data.  
 
In each of the models with cost outcomes, different combinations of the explanatory variables 
were used in an attempt to take into account potential multicollinearity between non-
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adherence and those factors found to be associated with non-adherence in the sample. For the 
logistic regression models assessment of model fit was by the link test, the Pearson’s chi-
squared test, the Hosmer-Lemeshow test, the likelihood ratio test and the percentage of 
observations correctly predicted by the model. For the GLM model, a log link function was 
used and the Park test was employed to determine the appropriate distribution to apply to the 
data.  
 
Robust standard-errors were applied in all analyses. Factors achieving significance at the 0.05 
level were deemed statistically significant. The analysis was performed using the STATA data 
analysis software (STATA 2008). 
 
As in the analyses of non-adherence to antipsychotics, predicted costs were derived for 
hypothetical cases based on the modelling results. Again a bootstrapping algorithm, 
incorporating 1,000 repetitions, was used to estimate the confidence interval for predictions 
based on two-part models. The case types were plotted in histograms using EXCEL 
(Microsoft Corporation 2003) to illustrate the relative impact of changes to key variables. 
 
 
5.3 Results 
 
Initial interviews were completed of 8,800 individuals and over 600 people participated in the 
second stage interviews on psychosis and personality disorder (Singleton, Bumpstead et al. 
2001). A total of 412 individuals in the PMS 2000 met the criteria set out for inclusion in the 
analyses. That is, they were prescribed an antidepressant at the time of the survey and were 
below the age of 65. This sample can then be further classified according to the diagnostic 
criteria applied in the survey. Responses to the CIS-R and an algorithm based on the ICD-10 
diagnostic criteria were used (WHO 1992; Singleton, Bumpstead et al. 2001). Based on a 
hierarchical classification of diagnosis, 75 (18%) of the sample of individuals prescribed 
antidepressant medication were  classified as having severe or moderate depression as their 
primary illness and a further 80 (19%) as having mixed anxiety and depression as their 
primary illness. 
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The average age of the sample was 44 years of age and the sample was predominately female 
with only one in four of the sample being male (see Table 5.2). Within the sample, 164 
patients (39.8%) self-reported that they at times did not take their medication for depression 
as it was prescribed.  
 
Table 5.3 presents descriptive statistics for the cost components estimated from data on health 
and social care service receipt, receipt of benefit and the time off work due to illness amongst 
those in employment. As expected, the costs were highly skewed. In all categories of costs -  
except GP visits - less than 50% of the sample incurred costs. Inpatient stays accounted for 
the greatest proportion of the health and social care costs. Community care and day activity 
centre costs appeared quite large on first inspection, but a closer look at the data indicated that 
two observations contained what appeared to be outliers. 
 
 
Table 5.2: Demographic characteristics of analysis sample, PMS 2000  
 
 Taking antidepressants and 
under age 65 
(n=412) 
Age, years (mean (s.d.)) 44.4 (11.5) 
Male gender (%) 26.2 
Ethnicity: White (%) 97.3 
Education (%) 
    Completed secondary school or university 
    Some secondary school 
    No qualifications 
 
24.2 
35.0 
40.8 
General health (%) 
    Good 
    Average 
    Poor 
 
17.5 
27.9 
54.6 
Moderate or severe depression (%) 18.2 
Severity of neurosis: CIS-R score (mean (s.d.)) 16.4 (11.7) 
‘Yes’ responses to survey questions (%) 
    Mental health hospital stay 
    Drug misuse 
    Alcohol misuse 
    Has adult with whom patient 
       feels close 
    Two or more yrs on antidepressant medication                                               
 
1.2 
5.1 
21.3 
 
90.2 
39.8 
Self-reported non-adherence (n (%)) 164 (39.8) 
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Table 5.3: Distribution of costs among patients taking antidepressants, PMS 2000 
 
 Number 
of users 
Mean Standard 
Deviation 
Median Interquartile 
range 
Min Max 
GP 394 £49 £15 £60 £30-£60 £30 £60 
Outpatient 151 624 789 296 296-592 244 6,144 
Inpatient 31 4,025 6,878 1,694 484-5,049 242 35,640 
Community care and 
day activity centre 
81 2,720 8,191 456 114-2,018 5 52,963 
Community care and 
day activity centre * 
79 1,484 2,465 456 103-1,833 5 14,584 
Total HSC 402 1,140 4,533 60 60-420 30 55,201 
Total HSC * 400 882 2,674 60 60-404 30 35,700 
Benefits 209 5,687 2,750 5,441 2,825-7,001 11 12,603 
Cost to the state 
(benefits + HSC) 
 
406 
 
4,057 
 
6,104 
 
2,646 
 
60-7,031 
 
30 
 
60,594  
Cost to the state 
(benefits + HSC) * 
 
404 
 
3,777 
 
4,647 
 
2,646 
 
60-7,031 
 
30 
 
35,700  
Absenteeism 97 4,617 7,564 1,196 449-3,738 75 27,287 
 
* Excludes 2 outliers 
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The first outlier resulted from a recording of an average daily receipt of 11 hours of home care 
in the three months prior to the survey, along with two visits of 10 hours each from a nursing 
service and one visit of two hours with a support group. The annual cost of community 
services for this patient was estimated to be £50,140. The second outlier was a patient who 
reported receiving home help for an average of 12 hours per day in the three months prior to 
the survey. This patient’s annual cost of community services was estimated to be £52,960. 
These two potential outliers were kept in the primary analyses, but sensitivity analyses 
estimated results for models where these two observations were excluded. 
 
The mean annual total health and social care service use costs incurred was £1,100. This 
amount was substantially less than the mean annual cost of benefits which was just under 
£5,700. It should be noted, however, that only just over half of the sample were receiving 
benefits. The influence on the distribution of the two outlier cases was reflected in the large 
reduction in the standard deviation values when these cases were omitted. Of the total sample 
of 412 individuals, 185 (44.9%) were in employment. Of sample members in employment, 97 
(52.4%) had at least one day off for health reasons. The mean annual cost attributable to 
absenteeism was approximately £4,620.  
 
Table 5.4 presents the distribution of costs by age. The cost of benefits and absenteeism were 
evenly distributed across age ranges, but health and social care costs were higher among those 
in the middle of the age range. Health and social care costs were also higher for men than 
women (see Table 5.5). The cost of benefits also followed this pattern. 
 
With respect to the covariates included in the modelling, three individuals were missing data 
on ethnicity; three were missing data on their educational attainment; one was missing data on 
drug abuse; three were missing data on alcohol misuse; and three were missing data on the 
social support variable. Of the 412 individuals in the sample, 406 (98.5%) had complete data. 
Two were missing one variable only; one was missing two variables; and three were missing 
five variables. Due to the fact that so few patients were missing relevant data, and that the 
nature of the variables that had missing values could be interpreted as possibly being related 
to why the values were missing (e.g. embarrassment about alcohol abuse), multiple 
imputation was not performed. 
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Table 5.4: Distribution of costs by age, PMS 2000 
  
 
 N Health and 
social care 
Benefits Cost to the state 
(benefits + HSC) 
Absenteeism 
16 – 24 14 £282 2,960 3,242 214 
25 – 34 83 1,094 3,023 4,117 1,342 
35 – 44 108 1,470 2,356 3,826 1,100 
45 – 54 117 1,204 3,295 4,499 1,196 
55 – 64 90 711 2,847 3,558 831 
 
 
 
 
 
Table 5.5: Distribution of costs by sex, PMS 2000 
 
  
 Health and 
social care 
Benefits Cost to the state 
(benefits + HSC) 
Absenteeism 
Males 1,559 4,175 5,734 1,011 
Females 954 2,426 3,380   1,114 
 
 
 
 
 
As a result of these missing values, however, the data for the six individuals without complete 
data were excluded from analyses as the routines to run the models exclude cases with 
missing values on any of the included variables. To compare the excluded individuals with 
those included in the analyses, Wilcoxon rank sum tests were conducted for the continuous 
variables and Fisher’s Exact tests for the categorical variables (Fisher 1922). The Fisher’s 
Exact test was preferred to chi-squared test because of the small number (six) of observations 
within the group with incomplete data. 
 
The only variables where the six individuals without complete data differed from those with 
complete data were experience of side effects and the index of social support. A greater 
percentage of the respondents without complete data experienced side effects (33% versus 
6%; p=0.046) and a smaller percentage lived with an adult with whom they felt close (33% 
versus 91%; p=0.026). 
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5.3.1 Factors associated with non-adherence to antidepressants 
 
In a model assessing the association of patient-, medication- and environment-related factors 
on non-adherence to antidepressants, the effects of age, CIS-R score, length of time on 
medication and having experienced side effects were statistically significant (see Table 5.6). 
Each five-year increase in age reduced the probability of being non-adherent by 11%. Non-
adherence was significantly more likely for those patients who experienced a greater 
prevalence or severity of symptoms (CISR score >12). A five-unit increase in the CIS-R score 
increased the odds of being non-adherent by 16%. 
 
Greater familiarity with medication, based on having been prescribed anti-depressants for two 
years or more, was associated with 1.6 times the odds of reporting non-adherence as 
compared to those on medication for less than two years. Those who had experienced side 
effects with their antidepressant medication were over 15 times as likely to be non-adherent to 
this medication. The estimate of this effect was based on 23 patients who reported 
experiencing side effects.  
 
The link test p-value (0.968) of the square of the predicted value suggested that the model was 
not misspecified. The Pearson’s and Hosmer and Lemeshow chi-squared p-values (0.3131 and 
0.9108 respectively) were not significant, indicating acceptable goodness-of-fit, as did the 
statistical significance of the likelihood ratio chi-squared test. The percentage of observations 
correctly predicted by the model was 68.0%. 
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Table 5.6: Logistic regression model of factors associated with non-adherence to 
antidepressants, PMS 2000 
 
Variables N=406 
Odds-ratio 95% CI 
Age (5 year increase in age) 0.89** 0.79, 0.99 
Gender: 
   Male (n=106)… 
   …relative to Females (n=300) 
 
0.71 
 
0.42, 1.20 
Education: 
  Higher qualifications or A-levels (n=98)… 
  O-level  2 (n=142)…  
  …relative to below O-level qualifications (n=166) 
 
1.14 
1.33 
 
0.64, 2.04 
0.78, 2.27 
Health: 
  Average (n=114)… 
  Poor (n=220)… 
  …relative to good or very good (n=72) 
 
1.24 
1.22 
 
0.62, 2.49 
0.60, 2.48 
Prevalence/severity of neurosis: 
  CIS-R score 3 (five unit increase) 
 
1.16*** 
 
1.04, 1.29 
Had a hospital stay for a mental, nervous or 
emotional problem (n=5)… 
…relative to not having had hospital stay for a 
mental, nervous or emotional problem (n=401) 
 
0.14 
 
0.011, 1.69 
Experienced side effects (n=23)… 
…relative to not experiencing side effects (n=383) 
15.51*** 3.45, 69.80 
Ethnicity: 
  Non-White (n=11)… 
   …relative to White (n=395) 
 
2.86 
 
0.77, 10.67 
Two or more years on medication (n=161)… 
…relative to less than 2 years on medication 
(n=245) 
1.61** 1.01, 2.58 
Lives with an adult with whom feels close 
(n=368)… 
…relative to no does not live with an adult with 
whom feels close (n=38) 
0.84 0.39, 1.79 
Reports drug abuse (n=21)… 
…relative to no reported drug abuse (n=385) 
1.69 0.62, 4.61 
Reports alcohol abuse (n=86)… 
…relative to no reported alcohol abuse (n=320) 
1.53 0.89, 2.62 
Link test p-value 0.968 
Pearson’s chi-sqpared test p-value 0.3131 
Hosmer-Lemeshow chi-squared test p-value 0.9108 
Prob > LR chi-squared 0.0001 
Percent correctly classified 68.0 
 
 
* p≤0.10;  ** p≤0.05;  *** p≤ 0.01 
 
 
1The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic psychiatric 
disorder; higher scores indicate greater prevalence or severity of symptoms. 
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5.3.2 Health and Social Care costs 
 
As only ten patients did not incur any health or social care service use costs, rather than 
complete a two-step model for this dependent variable, these patients were included as they 
represented a relatively small portion of the sample (2.4%). The generalised linear model for 
this outcome employed a log link function and the Park test suggested a gamma distribution 
for this data. Health status, CIS-R score and length of time on medication were significantly 
associated with total health and social care costs (see Table 5.7). Those in average or poor 
health had higher health and social care costs than those in good health. Likewise, as the 
prevalence or severity of symptoms increased, higher health and social care costs were 
incurred. Having been on medication for two or more years was also associated with higher 
total health and social care costs as compared to having been on medication for less than two 
years. There was a trend towards non-adherence being associated with lower health and  
social care costs as compared to those who did adhere to their medication (p=0.083).  
 
Figure 5.1 illustrates the marginal increase in cost attributable to the significant effects in the 
model of health and social care costs. As a starting point, the predicted costs were calculated 
for an arbitrary case. This initial case was for a man, age 45, White, without O-Level 
academic qualifications, who had a low prevalence and severity of symptoms, had average 
general health, who adhered to his medication, did not misuse drugs or alcohol, had social 
contact with an adult with whom he felt close and had been on medication for 2 or more 
years. The effect of altering this case to that of an individual with poor health status as 
opposed to the average was a £4,300 increase in predicted health and social care costs. The 
costs attributed to altering the case to someone who did not adhere to his medication was a 
£100 decrease in the predicted costs relative to the base case. The high degree of uncertainty 
in these estimates is reflected in the wide confidence intervals. 
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Table 5.7: Generalised linear model of factors associated with health and social care costs, 
PMS 2000  
 
 
Independent variables N=406 
Coefficient 
 
95% CI 
Age 0.00017 -0.025, 0.026 
Male (n=108)… 
…relative to Female (n=304) 
0.19 
 
-0.33, 0.71 
Higher qualifications or A-levels (n=100)… 
O-levels (n=144)… 
…relative to below O-level qualifications (n=168) 
0.49* 
0.41 
-0.093, 1.07 
-0.20, 1.03 
Non-White (n=11)… 
…relative to White (n=401) 
-0.44 -1.54, 0.65 
Average general health (n=115)… 
Poor general health (n=225)… 
…relative to good general health (n=72) 
0.84*** 
1.77*** 
0.29, 1.38 
1.21, 2.33 
CIS-R score 1 0.037*** 0.015, 0.059 
Non-adherent (n=164)… 
…relative to adherent (n=248) 
-0.45* -0.96, 0.059 
Lives with adult with whom feels close (n=371)… 
 …relative to does not live with adult with whom feels 
close (n=41) 
0.16 -0.39, 0.71 
Reports illegal drug use (n=21)… 
…relative to non drug users (n=391) 
0.053 -0.92, 1.02 
Reports moderate or high alcohol dependence (n=87)… 
…relative to no alcohol dependence (n=325) 
0.72 -0.18, 1.62 
Two or more years on medication (n=164)… 
…relative to less than 2 years on medication (n=248) 
0.62** 
 
0.13, 1.11 
Constant 4.07*** 2.60, 5.54 
Link function Log 
Distributional family Gamma 
 
* p≤0.10;  ** p≤0.05;  *** p≤ 0.01 
 
 
 
1 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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Predicted health and social care costs, PMS 2000
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When the two observations thought to be potential outliers were excluded from the analysis of 
health and social care costs, the results were somewhat altered in that while the health status 
and severity of illness effects remained statistically significant, the effect of length of time on 
medication was no longer significant (p=0.134). In this model, non-adherence no longer 
approached statistical significance (p=0.275) and gender was significant (p=0.018) with males 
generating higher health and social care costs. When those variables found to be associated 
with non-adherence (age, CIS-R score, length of time on medication) were excluded from the 
model to take account of potential multicollinearity, there was no change in the significance 
of non-adherence. 
 
5.3.3 Costs to the state 
 
The costs of benefits paid to the patient were combined with the health and social care service 
use costs to arrive at costs to the state. Here, as with the previous model, a generalised linear 
model was estimated. In this model, a log link function was used and the Park test suggested a 
Poisson distribution underlying the data (see Table 5.8). As in the previous model, all cases 
with complete data contributed to the model estimation. Relative to those without 
qualifications, the respondents who achieved A-Level or university qualifications incurred 
lower costs to the state. There was also a significant association between general health status 
and these costs. As general health worsened, costs to the state increased. Similarly, as the 
prevalence and severity of neurosis symptoms increased, costs to the state also increased. 
Also, these costs were significantly higher for those who had been taking antidepressants for 
two or more years as compared to those who had been on medication for less than two years. 
The effect of non-adherence was not significant. 
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Table 5.8: Generalised linear model of factors associated with costs to the state (health and 
social care costs plus cost of benefits), PMS 2000 
 
 
Independent variables N=406 
Coefficient 
 
95% CI 
Age -0.014 -0.033, 0.0056 
Male (n=108)… 
…relative to Female (n=304) 
0.24 
 
-0.078, 0.55 
Higher qualifications or A-levels (n=100)… 
O-levels (n=144)… 
…relative to below O-level qualifications (n=168) 
-0.59*** 
-0.27 
-0.96, -0.22 
-0.69, 0.15 
Non-White (n=11)… 
…relative to White (n=401) 
0.21 -0.35, 0.77 
Average general health (n=115)… 
Poor general health (n=225)… 
…relative to good general health (n=72) 
0.74** 
1.29*** 
0.11, 1.37 
0.74, 1.84 
CIS-R score 1 0.014*** 0.0053, 0.024 
Non-adherent (n=164)… 
…relative to adherent (n=248) 
-0.13 -0.43, 0.17 
Lives with adult with whom feels close (n=371)… 
 …relative to does not live with adult with whom feels 
close (n=41) 
0.31* -0.052, 0.66 
Reports illegal drug use (n=21)… 
…relative to non drug users (n=391) 
0.034 -0.32, 0.39 
Reports moderate or high alcohol dependence (n=87)… 
…relative to no alcohol dependence (n=325) 
0.13 -0.37, 0.64 
Two or more years on medication (n=164)… 
…relative to less than 2 years on medication (n=248) 
0.40*** 
 
0.10, 0.70 
Constant 7.28*** 6.20, 8.37 
Link function Log 
Distributional family Poisson 
 
* p≤0.10;  ** p≤0.05;  *** p≤ 0.01 
 
 
 
 
1 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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Illustrations of the marginal effects of key variables appear in Figure 5.2. The initial case 
chosen for this model was that of a man, age 45, White, who had completed O-Levels, had 
low prevalence and severity of symptoms, was in very good general health, adhered to his 
antidepressant medication, did not misuse drugs or alcohol, had social contact with an adult 
with whom he felt close and was on antidepressants for less than two years. For this case the 
predicted costs to the state were £1,550. The effect of changing the case to a non-adherent 
patient reduced predicted costs by just under £200. The largest increase in the predicted costs 
occurred if the case was changed to someone in poor health or on medication for two or more 
years. In these cases the predicted costs increase by £2,750 and £770 respectively. If the 
highest level of educational qualifications was assumed, predicted costs to the state were £690 
less than those predicted for the initial reference case. 
 
When the model was run without the two potential outliers, the effects of education, health 
status, illness severity and length of time on medication remained statistically significant. In 
this model, age and gender were also significantly associated with costs to the state. As the 
age of patients increased the costs incurred by the state decreased. Also, the costs to the state 
were higher for male patients than for female patients. As in the analysis of health and social 
care costs, the potential multicollinearity between non-adherence and age, CIS-R score and 
length of time on medication did not appreciably alter the significance of non-adherence. 
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Predicted costs to the state, PMS 2000
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5.3.4 Cost of absenteeism 
 
The final outcome of interest was absenteeism costs. A sample of 185 respondents reported 
being in employment in the last year and were asked the number of days that they had been 
away from work due to ill health. The effect of ethnicity could not be included in the logistic 
regression analysis as the three ethnic minority respondents who reported being in 
employment in the last year had all experienced days off work due to ill health. That is, the 
index of the effect of being from an ethnic minority perfectly predicted having time off work. 
Thus it was not possible for the model to estimate the effect of ethnicity on whether or not 
someone had taken experienced time off work and the effect of ethnicity was excluded in this 
model. 
 
As would be expected, the model found that poor health was associated with having incurred 
absenteeism costs (see Table 5.9). Those with poor health were nearly five times as likely to 
have taken time off work for ill health as compared to those in excellent or good health. There 
was also a trend towards those with O-Level academic qualifications to have greater odds of 
having had a period of absence from work as compared to those without O-Level 
qualifications (p=0.065). 
 
The link test p-value (0.0.566) suggested the model was satisfactorily specified. The 
Pearson’s and Hosmer and Lemeshow chi-squared p-values (0.2586 and 0.2435 respectively) 
were not significant, indicating acceptable goodness of fit. The statistical significance of the 
likelihood ratio chi-squared test suggested that the model fit the data adequately (p=0.0195). 
The percentage of observations correctly predicted by the model was 64.3%.  
 
In the GLM run on those people with depression who did report days missed from work 
(n=99), the cost of absenteeism was modelled with a log link function and the Park test 
suggested a gamma distribution. Age, health status, severity of illness, alcohol abuse and non-
adherence were all statistically significantly associated with the cost of absenteeism (see 
Table 5.10). 
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Table 5.9: Logistic regression model on factors associated with having incurred absenteeism 
costs (amongst those in work), PMS 2000 
 
 
Independent variables N=182 
Odds Ratio 
(of using services) 
95% CI 
Age (5 year increase in age) 1.10 0.93, 1.29 
Male (n=108)… 
…relative to Female (n=304) 
0.75 
 
0.32, 1.76 
Higher qualifications or A-levels (n=62)… 
O-levels (n=72)… 
…relative to below O-level qualifications (n=48) 
1.31 
2.18* 
 
0.56, 3.05 
0.95, 4.97 
Non-White (n=0)… 
…relative to White (n=182) 
- - 
Average general health (n=72)… 
Poor general health (n=55)… 
…relative to good general health (n=55) 
1.30 
4.86*** 
0.59, 2.86 
1.83, 12.93 
Prevalence/severity of neurosis: CIS-R score 1 (five 
unit increase) 
 
0.97 
 
0.80, 1.18 
Non-adherent (n=68)… 
…relative to adherent (n=114) 
1.69 0.85, 3.39 
Lives with adult with whom feels close (n=164)… 
 …relative to does not live with adult with whom 
feels close (n=18) 
0.68 0.20, 2.30 
Reports illegal drug use (n=7)… 
…relative to non drug users (n=175) 
1.13 0.21, 5.96 
Reports moderate or high alcohol dependence 
(n=43)… 
…relative to no alcohol dependence (n=139) 
 
1.12 
 
0.51, 2.44 
Two or more years on medication (n=47)… 
…relative to less than 2 years on medication (n=135) 
0.60 0.28, 1.31 
Link test p-value 0.566 
Pearson’s chi-sqpared test p-value 0.2586 
Hosmer-Lemeshow chi-squared test p-value 0.2435 
Likelihood ration chi-squared p-value 0.0195 
Percent correctly classified 64.3% 
 
* p≤0.10;  ** p≤0.05;  *** p≤ 0.01 
 
 
 
 
1 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
  
179 
Table 5.10: Generalised linear model of factors associated with cost of absenteeism, PMS 
2000 
  
 
Independent variables N=99 
Coefficient 
 
95% CI 
Age 0.055*** 0.022, 0.088 
Male (n=18)… 
…relative to Female (n=81) 
0.056 
 
-0.50, 0.61 
Higher qualifications or A-levels (n=33)… 
O-levels (n=44)… 
…relative to below O-level qualifications (n=22) 
-0.057 
0.39 
-0.69, 0.58 
-0.24, 1.03 
Non-White (n=3)… 
…relative to White (n=96) 
-0.64* -1.35, 0.075 
Average general health (n=35)… 
Poor general health (n=41)… 
…relative to good general health (n=23) 
0.43 
1.42*** 
-0.26, 1.12 
0.62, 2.22 
CIS-R score 1 0.043*** 0.010, 0.077 
Non-adherent (n=43)… 
…relative to adherent (n=56) 
-0.57** -1.05, -0.089 
Lives with adult with whom feels close (n=88)... 
 …relative to does not live with adult with whom feels 
close (n=11) 
0.24 -0.69, 1.16 
Reports illegal drug use (n=4)… 
…relative to non drug users (n=95) 
-0.16 -1.08, 0.76 
Reports moderate or high alcohol dependence (n=25)... 
…relative to no alcohol dependence (n=74) 
-0.61** -1.23, -0.0031 
Two or more years on medication (n=22)… 
…relative to less than two years on medication (n=77) 
-0.66* 
 
-1.37, 0.045 
Constant 4.62*** 2.76, 6.48 
Link function Log 
Distributional family Gamma 
 
* p≤0.10;  ** p≤0.05;  *** p≤ 0.01 
 
 
 
 
 
1 The Revised Clinical Interview Schedule (CIS-R) is used to assess minor neurotic 
psychiatric disorder. Higher scores indicate greater prevalence/severity of symptoms. 
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Absenteeism costs increased as patients got older and were significantly greater for those in 
poor health as compared to those in good health. The cost of absenteeism were lower for those 
who reported alcohol abuse as compared to those who did not report alcohol abuse, and 
individuals who reported being non-adherent to medication also had lower absenteeism costs. 
There was also a positive relationship between absenteeism costs and the CIS-R score (which 
reflects prevalence and severity of symptoms).  
 
The effects of ethnicity and length of time on medication approached statistical significance 
(p=0.079 and p=0.066 respectively). The trend was for individuals from an ethnic minority to 
have lower absenteeism costs than their White counterparts. Recall, however, that this effect 
was estimated based on only three ethnic minority respondents. Those on medication for two 
or more years had lower absenteeism costs as compared to those on medication for less than 
two years. 
 
Figure 5.3 illustrates the impact of the significant effects on absenteeism costs. Due to the 
relatively small sample size, the bootstrap algorithm did not converge to a solution in several 
repetitions when the full list of variable was included in the models. To get around this 
problem, the models were altered to include only those variables found to be statistically 
significant in either the logistic regression on whether or not days off were taken due to ill 
health and the GLM on the amount of costs attributable to these lost days. A hypothetical base 
case of a 45 year old individual, without O-Level qualifications, in average health, who had a 
score of 10 on the CIS-R, adhered to medication and had been prescribed antidepressants for 
less than two years. The impact of relatively few observations on which to base the estimates 
of absenteeism costs was reflected in the wide confidence intervals around each of the 
estimates. As would be expected, poor general health had the greatest impact on increasing 
absenteeism costs. Relatively poor mental health, reflected in prevalence and severity of 
neurotic symptoms also significantly increased absenteeism costs. There was a trend for non-
adherence to increase the probability that a respondent had days off work due to ill health but 
to decrease the frequency of days off, and thus costs. On balance, non-adherence increased the 
estimate of annual absenteeism costs by over £750, suggesting that those in work are likely to 
feel good and able to cope without taking their medication. 
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5.4 Discussion 
 
The analysis of the PMS 2000 data, by incorporating costs associated with receipt of benefits 
and absenteeism costs, provides a very broad overview of the observable direct and indirect 
costs incurred by individuals prescribed antidepressant medication. It is noteworthy that the 
costs of both benefits and absenteeism were substantial and amongst those who incurred these 
costs, far outweigh health and social care service use costs. Few factors were found to be 
associated with non-adherence in the data. Analyses of costs found that non-adherence was 
significantly associated with absenteeism costs only, and this association was negative. The 
analyses also determined that two outliers have a substantial impact on some of the findings. 
There was a trend towards non-adherence being negatively associated with health and social 
care service use costs, but this trend disappeared when the potential outlier values were 
excluded from the analyses. 
 
5.4.1 Rate of non-adherence in individuals taking antidepressants 
 
The rate of non-adherence in this study was 40%. It was very difficult to determine from the 
literature if consistent estimates of the rate of non-adherence could be observed due to 
difference in settings, patient populations and methods use to assess adherence. A review of 
the literature on non-adherence in patients taking anti-depressants identified several large 
studies with widely differing rates of non-adherence for the time periods under study. Rates of 
non-adherence ranged from 35% to 70%. Within the PMS 2000 sample a large proportion of 
those taking antidepressants were judged to have mild or moderate depression. This contrasts 
with some of the previous studies in this area that have focussed on patients with severe 
depression or had a greater proportion of patients with severe depression. This may partly 
explain the relatively low prevalence of non-adherence to antidepressants in the PMS 2000 
data as compared to other studies. 
 
A large (n=4,312) US-based study estimated non-adherence rates for newly diagnosed, 
privately insured patients with major depression (Akincigil, Bowblis et al. 2007). The sample 
consisted of members of the general population who were enrolees in a large health care 
organisation operating in north-eastern US states. Assessment of adherence was based on 
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pharmacy refill records for the period from January 2003 to January 2005. The non-adherence 
rates were 49% in the first 16 weeks of treatment, increasing to 58% by week 33.  
 
Cantrell et al (2006) studied adherence to SSRI medication using medical and pharmacy 
claims data from a managed care database in the US covering 30 health plans and holding 
records of over 25 million persons across the US. This study included data for nearly 23,000 
individuals newly prescribed SSRIs during the period of July 2001 to June 2002. The 6-month 
adherence rate was approximately 57% and this estimate was consistent across varying 
methods of assessing adherence: length of therapy, medication possession ratio and a 
combination of the two. Olfson et al (2006) in a nationally representative US sample observed 
a 42% rate of non-adherence in the initial 30 days of treatment with an antidepressant and a 
72% rate of non-adherence after 90 days.  
 
Pampallona et al (2002), in a review of non-adherence in depression identified 32 studies 
published between 1973 and 1999. Fifty percent of these were US-based studies, ten were 
conducted in the UK, three in Canada and three in continental Europe. In total, these studies 
included over 10,000 patients, all of whom were diagnosed with depression. The range of 
rates of non-adherence was between 30% and 97% with a median of 63%. The methods used 
to assess adherence varied across studies. 
 
A literature review on medication compliance in psychiatric treatment identified ten articles 
which assess the rate of compliance for patients taking medication for depression (Cramer and 
Rosenheck 1998). The review was based on a MEDLINE search of literature published 
between 1975 and 1996. The methods of assessing adherence in these studies were primarily 
pill counts and lithium blood levels supplemented by patient interviews. Two of the articles 
included in the review were meta-analyses. The review found that the mean rate of non-
adherence across the studies was 37% and ranged from 10% to 60%. 
 
Using quite strict criteria to assess a patient as adherent (a combination of identifying 
detectable serum levels of study medication at all follow-up assessments, self-reported 
assurance and attendance at scheduled visits), a Swedish study found that 60% of patients 
with major depressive disorder were non-adherent to their medication in the first 24 weeks of 
treatment (von Knorring, Akerblad et al. 2006). 
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A small (n=107) UK-based cross-sectional study found the rate of self-reported non-
adherence to medication to be 35% for a sample of patients diagnosed with depression (Byng, 
Bury et al. 2007), while in a US sample of older patients with depression (based on secondary 
analysis of a prospective cohort study of participants from the (US) National Institute of 
Mental Health Clinical Research Center for the Study of Depression in Later Life), where 
self-reporting was used to asses non-adherence, approximately 28% of patients taking 
antidepressants reported being non-adherent in their medication taking (Bosworth, Voils et al. 
2008). The results of this study, along with the analyses of the PMS 2000, support the view 
that self-reported non-adherence rates will be lower than if more invasive methods are used in 
assessment. As discussed in chapter 4, however, in a large-population survey, all methods 
other than self-reporting would be extremely difficult to implement. The two studies above 
which based non-adherence rates on large populations were both US studies that 
retrospectively analysed claims data for large managed care organisations. 
 
5.4.2 Factors associated with non-adherence 
 
My analysis observed a very strong association between the experience of side effects and 
non-adherence to antidepressants. This association was not surprising given the range of side 
effects known to affect those prescribed antidepressants as detailed in the introduction to this 
chapter. 
  
In the literature reported in the previous section, rates of non-adherence to antidepressants 
were observed to increase over time. Just as the duration of a study is likely to impact on the 
rate of non-adherence, it may also influence results of analysis of the factors associated with 
non-adherence. Aikens et al (2005) postulate that in the period after commencing taking an 
antidepressant, non-adherence is related to the side effects and the perception that the 
medication prescribed is ineffective. In the longer-term non-adherence is likely to result from 
patients judging that they no longer need the medication or becoming less willing to continue 
tolerating previously acceptable side effects (e.g. sexual dysfunction) (Aikens, Nease et al. 
2005). Note, however, that for this theory to hold, patients must distinguish between what are 
intolerable side effects in the short and longer term. If this theory is true, it would explain the 
higher rates of non-adherence observed in the literature above which sampled newly 
diagnosed patients prescribed antidepressants for the first time. 
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Several empirical studies in the literature examine the associations between non-adherence 
and patient-, medication- and environment-related factors. A search of the literature found 
two review studies, although neither was a structured or systematic review. In the first, 
Nemeroff (2003) identified severe side effects/adverse events such as severe daytime 
sleepiness, anxiety and nausea to be consistently significant contributors to non-adherence in 
patients taking antidepressants. The method by which the studies cited in this review were 
identified was not stated by the author. 
 
The other review was a narrative review by Mitchell (2006)4. The author discusses the 
literature in support of, and opposing, the hypothesis that adherence behaviour is a form of 
self-medication. The method to identify the included studies is not stated. Key determinants 
of non-adherence for patients taking antidepressants, based on observed trends in the 
literature, were perceptions of stigma, concern about drugs, feeling better and side effects.  
 
Olfson et al (2006), using data from the US Medical Expenditure Panel Survey for 1996-
2001, observed associations between non-adherence to antidepressants and Hispanic ethnicity, 
lower educational attainment and low family income. They also observed that among patients 
who continued on antidepressant medication beyond the first 30 days, those treated with 
SSRIs were more likely to adhere to their medication than those treated with tricyclic 
antidepressants or other older antidepressants.  
 
The study by Akincigil et al (2007), described above, found that non-adherence was 
associated with younger age, alcohol or substance abuse, comorbid cardiovascular/metabolic 
conditions, use of older generation antidepressants and residence in lower-income 
neighbourhoods.  
 
In another US study conducted between December 1999 and May 2000, Bull et al (2002) 
surveyed people with major depression or depressive disorder who had recently started to take 
an SSRI antidepressant. In this study, patients were asked in a questionnaire if they had 
                                                 
4 A narrative review summarises primary studies from which conclusions may be interpreted. Results have a 
qualitative rather than a quantitative meaning. Kirkevold, M. (1997). "Integrative nursing research - an important 
strategy to further the development of nursing science and practice." Journal of Advanced Nursing 25: 977-984, 
Campbell Collaboration. (2001). "Campbell Collaboration guidelines."   Retrieved February 14, 2006, from 
www.campbellcollaboration.org.. 
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discontinued treatment. Thus, the outcome was a more severe interruption of medication 
taking beyond non-adherence. The authors found that communication about adverse events, 
regular visits to a physician, lack of experience of adverse events and being married 
significantly reduced the probability of discontinuing SSRI medication in the first 3 months. 
 
In a small US-based study of patients prescribed antidepressants for greater than 11-weeks 
(defined as being in a maintenance phase of medication treatment) adherence was assessed 
with two forms of self-reported information (Aikens, Nease et al. 2005). Firstly, the first three 
items from the Brief Medication Questionnaire were used to measure the percentage of their 
medication adhered to in the preceding two weeks. Secondly, general adherence was assessed 
using the Morisky scale. This study found that a composite score that takes into account the 
relative weight of perceptions about the necessity of medication and the concerns about 
medication, derived from the Beliefs About Medication scale, was found to be statistically 
significantly associated with non-adherence in multivariate regression analyses that accounted 
for depression severity, treatment duration and social desirability bias (the tendency to answer 
questionnaires in the socially acceptable direction). 
 
Loh et al (2007) conducted a survey in Germany of general practitioners and patients with 
depression in which they collected data at baseline and after six to eight weeks to, among 
other things, determine if patient participation in decision-making was associated with 
treatment adherence. Adherence was assessed based on response to a question put to both the 
GP’s and the patients at the six to eight week visits, asking them to rate adherence on a 5-
point scale. Using structured equation modelling, the authors concluded that an association 
between self-reported adherence and patient participation in shared treatment decision-making 
did exist. This result was observed after accounting for the severity of the patients’ 
depression. 
 
5.4.3 Association between non-adherence and service use and costs 
 
Few studies were identified which analysed the associations between non-adherence to 
antidepressants and service use and the costs associated with service use. Cantrell et al (2006) 
used claims data from a large US health plan database to conduct such a study. Patients were 
recipients of at least one prescription for an SSRI between July 2001 and June 2002. The 
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authors produced three indices of non-adherence: one based on the medication possession 
ratio (MPR), another based on the length of therapy (LOT), and a third that combined MPR 
and LOT data. The results were that patients judged to be adherent to their medication 
incurred lower medical costs (this did not include prescribing costs). The difference in 
medical costs between adherent and non-adherent patients was approximately $450. When the 
cost of medication was included, the difference between adherent and non-adherent patients 
was not statistically significant. 
 
von Knorring et al (2006), in an analysis conducted in Sweden between June 1999 and 
February 2003, costed health services and time off work due to illness in patients with major 
depression. In this study, patients were deemed to be adherent if they had detectable serum 
levels of medication, self-reported that they had taken medication as prescribed, and attended 
scheduled visits. The authors did not observe any differences in total costs incurred after two 
years between adherent and non-adherent patients. Inpatient costs were significantly higher 
for non-adherent patients. The average total cost per patient over the 2 years of the study was 
just under €39,000. Indirect costs were estimated at just below €34,000.  
 
In a large study using pharmacy and medical claims data from a pharmacy benefit and 
medical management company in the US, adherence was defined as having 70% or greater 
supply of pills supplied over a 180 day follow-up period and the economic outcomes analysed 
were pharmacy cost charges, medical charges (depression and non-depression related 
physician, emergency room, hospital, laboratory and any other medical charges) and total 
healthcare (combined pharmacy and medical) charges (White, Vanderplas et al. 2003). Non-
adherence was found to be associated with significantly lower medical charges as compared 
to adherent patients, though total healthcare charges were not significantly different between 
adherent and non-adherent patients. The difference in total medical costs for the follow-up 
period was approximately US$1,300. 
 
Apart from the von Knorring work, few previous studies have assessed associations between 
non-adherence to antidepressants and non-health care costs. No studies were identified which 
used costs to the state as an outcome in assessing the potential impact of non-adherence. It 
could be argued that there is no theoretical basis for hypothesising that non-adherence would 
impact on costs to the state, but given that non-medical costs incurred by individuals with 
depression often greatly exceed their medical costs, it is helpful to contextualise the impact of 
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non-adherence from the wider perspective of costs to the state. Layard et al (2007) estimated 
that the average, per person, economic savings to the UK Exchequer of treating patients with 
depression and/or anxiety in reduced incapacity benefit, income support, housing benefit, 
council tax benefit and recovered employment taxes would be three times the medical costs 
saved. Similarly, Bosmans et al (2007), in a cost-effectiveness analysis of a pharmacy based 
coaching programme to improve adherence to antidepressants, estimated that the average 
indirect costs of absenteeism for the non-intervention group were €2,249 while the direct 
medical costs for this sample were €711. The data for this study were collected in 2000 and 
2001, with costs adjusted to 2002 values.  
 
5.4.4 Other factors associated with service use and costs 
 
Amongst the other factors assessed in the models, those found to be significantly associated 
with health and social care costs were related to the severity of illness. Self-reported poor 
health, higher CIS-R scores and greater length of time on medication were all significantly 
associated with these costs. Similarly, poorer health was, as would be expected, associated 
with higher absenteeism costs. Older individuals also incurred higher absenteeism costs, 
perhaps reflecting the fact that having been in the workforce for longer, they would have 
higher incomes than younger individuals and would thus have higher costs associated with 
time off work. This is consistent with the fact that the probability of having time off work is 
not significantly associated with age. Alcohol abuse was associated with lower absenteeism 
costs among those who took time off work but not the probability of taking time off work. 
This suggests that those individuals with moderate to high alcohol intake returned to work 
more quickly after time off.   
 
5.4.5 Limitations 
 
There were some limitations associated with using the PMS 2000 dataset for the analyses 
undertaken as this survey was not designed specifically to address the questions being asked 
in my analyses. These were much the same as discussed in chapter 4 in relation to the 1993/4 
PMS surveys: the inability to incorporate some potentially important factors that relate to 
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non-adherence, the fact that the data was cross-sectional and the resulting possibility that non-
adherence may be endogenous. 
 
As discussed in chapter 3, the source of endogeneity may be simultaneity or omitted variable 
bias. The inclusion of an index of medication familiarity reduced the likelihood of omitted 
variable bias as it is served as a proxy for the unobserved effects of the attitudes to medication 
and the patient’s insight into their illness. The potential for simultaneity between service use 
and non-adherence is arguably greater in the 2000 PMS sample of individuals taking 
antidepressants than in the 1993/4 PMS sample of individuals prescribed antipsychotics; this 
is because the overall pattern of service use suggested that the main health and social care 
services used by the antidepressants sample were outpatient and community services. It is in 
these services, which are usually regular contacts between patients and health providers, 
where reminders and encouragement of adherence are more likely (as compared to inpatient 
visits). Services that offer reminders and encouragement regarding medication taking, will 
however, have the effect of improving adherence, and would bias down the observed effect of 
non-adherence in the models.  
 
The theoretical models of non-adherence suggest key factors such as a patient’s attitude to 
their illness and their medication are key to understanding non-adherence. With respect to the 
data being cross-sectional, as with patients diagnosed with schizophrenia, the nature of the 
associations between illness, non-adherence and service use cannot be fully understood 
without being able to assess causality. For patients taking antidepressants the potential exists 
for their illness to impact on the ways in which they perceive medication and thus whether on 
not they adhere, while at the same time non-adherence is likely to make symptoms worse and 
thus may impact on the severity of illness which may in turn impact on the use of services. 
Previous studies have attempted to assess the impact of depression on adherence to 
medication (DiMatteo, Lepper et al. 2000; Wing, Phelan et al. 2002). 
 
The analysis of the impact of non-adherence on the cost of absenteeism was compromised by 
not being able to identify whether all time off work was directly related to an individual’s 
illness for which antidepressants were prescribed. In the survey, respondents were asked to 
report the number of days off work for all health- related reasons. It should be noted, 
however, that it has been shown that depression can trigger the onset of physical health issues 
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(Carroll, Cassidy et al. 2004). Thus it cannot be ruled out that while some health service use 
may not appear to be related to depression, this may in fact be the case. 
 
A further limitation pertains to the analysis of the cost of absenteeism. Absenteeism was taken 
as proxy of lost productivity, but the current literature suggests that estimates of lost 
productivity should also incorporate presenteeism. Sanderson and Andrews (2006) define 
presenteeism as ‘lost productivity arising from attending work while unwell’. These costs 
could not be captured from the PMS 2000 data. 
 
Donohue and Pincus (2007) conducted a literature review based on searches of MEDLINE 
and EMBASE between 1990 and July 2005 to assess whether the costs of depression 
treatment are offset by gains in worker productivity and/or reductions in other healthcare 
spending. Among their key findings are that suicide-related costs made up 6% of total societal 
costs of depression in 2000, that depression affected educational attainment, which lowers 
earning potential and that in addition to absenteeism, significant costs can be attributed to 
presenteeism – reduced productivity at work. The authors cite data from a study by Greenberg 
et al (2003) which estimated suicide-related costs of patients with depression in the US in 
2000 to be US$5,450million and presenteeism costs to be US$15,295million. As a percentage 
of total costs (direct health care, suicide-related and all workplace-related costs), presenteeism 
accounted for 18.4% of costs. Greenberg et al (2003) estimated suicide-related costs using a 
human capital framework based on the total number of suicides by age and gender in 2000, 
with the present value of lost lifetime earnings estimated assuming 60% of suicides were 
attributable to depression. They estimated presenteeism by assuming that 20% of time at work 
while suffering from a depression episode resulted in lost productivity. 
 
Finally, my analyses does not account for differences between antidepressant medications or 
between the classes of antidepressants. There is evidence that antidepressants differ in their 
effects on adherence to medication (MacGillivray, Arroll et al. 2003), presenteeism (Greener 
and Guest 2005) and total medical costs of treatment (Sheehan, Eaddy et al. 2005).  
 
The PMS 2000 was not designed to answer specific questions regarding patient behaviours 
and service use, but rather as a nationally representative survey of psychiatric morbidity in the 
British population. It uniquely offered a snapshot of the British household population and the 
relative prevalence and severity of mental illnesses. The PMS 2000 and the 1993/1994 PMS 
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surveys, taken together, offer comparable data from similar samples. The analyses undertaken 
sought to make use of these data, as best possible, to assess the associations between non-
adherence, patient-, treatment- and environment-related factors and a range of cost outcomes. 
As in the previous empirical chapters, robust statistical methods were used, increasing 
confidence in the associations reported. 
 
 
5.5 Summary 
 
The rate of non-adherence to antidepressants observed in my analysis of the PMS 2000 data 
was towards the low end of the range reported in the literature. This may be due to the 
assessment of non-adherence in the PMS relying on self-reported information, the smaller 
proportion of severely depressed and newly diagnosed patients in the sample relative to 
samples in previous literature. The relatively low rate of non-adherence observed may also 
reflect a bias for people who do not take their medication also not wanting to participate in 
surveys.  
 
An association was observed between greater prevalence or severity of symptoms and non-
adherence in the data. My results were consistent with the literature in finding a strong 
association between the experience of side effects and non-adherence to antidepressants. The 
literature also supports the finding that a positive association existed between length of time 
on medication and the probability of non-adherence. The literature suggests some potential 
reasons for this finding: that patients perceive that they no longer need medication or that they 
want to avoid side effects. 
 
Non-adherence to medication did not appear to be strongly associated with health and social 
care costs or, more widely, costs to the state amongst patients taking antidepressants. For 
those in work there was a trend towards non-adherence increasing the probability of having 
had to take time off from work due to ill health but the actual number of days missed were 
lower amongst non-adherent individuals. Few other studies have assessed the impact of non-
adherence on either health, social care or state costs of absenteeism costs. Some of these 
studies observe medical costs to be higher for non-adherent patients, although other results 
suggest a weak or opposite association.  
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Chapter 6 
Discussion and Conclusions 
 
 
6.1 Discussion of findings 
 
The aim of this thesis was to identify those factors associated with non-adherence to 
antipsychotic medication and to determine the extent to which non-adherence was associated 
with service use costs incurred by individuals taking antipsychotics. The findings for this 
patient population were compared to those from a sample of individuals taking 
antidepressants to determine if the previously observed relationships were present in another 
patient group. 
 
6.1.1 Factors associated with non-adherence 
 
In relation to factors associated with non-adherence, my hypotheses were that where non-
adherence to antipsychotic medication was driven by attitudinal factors, severity of illness and 
insight would be key factors, and where non-adherence was driven by external factors, social 
support, drug and/or alcohol abuse and the experience of side effects would be significant. 
 
Analysis of the 1993/4 PMS institutions sample indicated that non-adherence was associated 
with the type of institution the individual was in, their age, level of education, severity of 
illness, whether or not they had an alcohol abuse problem, whether or not they had had a 
recent inpatient stay and whether or not they experienced medication side effects. Individuals 
who were in residential care homes, supervised housing, group homes or hostels were more 
than twice as likely to not adhere to their antipsychotics as those in hospital. The association 
between age and the probability of non-adherence was negative. That is, within the sample, as 
age increased, the probability of non-adherence decreased. Those individuals who had higher 
education or A-level educational qualifications were more likely to not adhere as compared to 
those with the lowest level of educational attainment. Individuals whose illness was deemed 
more severe based on the presence and severity of neurosis, those that had recent inpatient 
stays, those who reported moderate or high alcohol dependency and those who reported 
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experiencing side effects were all more likely to not adhere to their medication. The 
significance of a recent inpatient stay was also observed in secondary analysis of the 1993/4 
PMS household and homeless samples. 
 
These findings were difficult to compare with previous research in this area because of 
inconsistency in methodologies across studies. In particular, the reviewed studies differed 
widely in the methods used to assess non-adherence, the factors considered and the length of 
time over which individuals were followed. Despite these differences, some consistent 
findings emerged which were also observed in my analyses. Among patient-related factors, 
age, level of education and illness severity were significantly associated with non-adherence 
in other studies. Additionally, several studies observed an association between substance 
abuse and non-adherence, though in some studies this was an association with illegal drug 
misuse as opposed to alcohol, the latter being the association observed in my analysis. The 
most consistent finding across this literature was the association between the experience of 
side effects and non-adherence.  
 
The effects of age, severity of illness and experience of side effects were also observed as 
significantly associated to non-adherence in analysis of individuals taking antidepressants in 
the PMS 2000. These findings were broadly consistent with results from other studies. 
Significant associations between non-adherence and socioeconomic factors, ethnicity and 
substance abuse have also been reported in the literature (Olfson, Marcus et al. 2006; 
Akincigil, Bowblis et al. 2007). In my analyses of the 1993-4 and 2000 PMS (chapters 3 and 
5), the effects associated with non-adherence in both samples were consistent in the direction 
of their association. This suggests that these individual- level factors are important to 
medication taking behaviour across mental illnesses. 
 
Some differences between the results do emerge, however. Neither an individual’s level of 
education, nor alcohol abuse (or substance abuse more widely) had a significant impact on 
non-adherence to antidepressants in the analysis of the PMS 2000, although these effects were 
found to be significant in other studies of individuals prescribed antidepressants. In the case 
of the effect of having had a recent inpatient stay, in the sample of individuals taking 
antidepressants this was associated with a greater likelihood to adhere to their medication as 
compared to the sample of individuals taking antipsychotics where it was associated with 
greater likelihood of non-adherence. Note, however, that the finding in the sample of those 
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taking antidepressants is based on a very small number of recent inpatients. Also, length of 
time on medication was significantly associated with non-adherence to antidepressants but not 
with non-adherence to antipsychotics. 
 
Where differences in the two sets of results occur, they suggest that there are particular 
aspects of the illness of psychosis or of antipsychotic medication that determine that certain 
factors influence medication taking behaviour in a way that differs from what occurs in 
patients taking antidepressants. For example, if it is assumed that individuals with higher 
educational attainment taking antipsychotics are more inclined to not take their medication 
because of the degree to which it inhibits their ability to function intellectually, at a level they 
feel they are capable of, this negative aspect does not appear to be associated with taking 
antidepressants.  
 
The significance of an inpatient stay on non-adherence to antipsychotics but not to 
antidepressants is likely due to the relative severity of illness in the samples studied. In the 
1993/4 PMS, approximately 15% of those included in the analysis sample had had an 
inpatient stay as compared to less than 2% of the sample of individuals taking antidepressant 
in the PMS 2000. If the rates of hospitalisation were similar in the two samples and having 
had an inpatient stay were still found to be significantly associated with non-adherence in the 
sample taking antipsychotics but not in the sample taking antidepressants, it would then be 
warranted to conclude that some aspect of the effects of acute illness warranting 
hospitalisation affects the subsequent medication taking behaviour of individuals with 
schizophrenia more that individuals with depression (e.g. disruption of therapeutic alliance). 
 
The rate of alcohol abuse was higher in those prescribed antidepressants in the PMS 2000 
compared to those prescribed antipsychotics in the 1993/4 PMS, but the effect of alcohol 
misuse was found to be associated with non-adherence in the latter group only. It is not 
obvious why alcohol abuse or substance abuse would be associated with non-adherence in one 
group of patients and not the other. The effect of alcohol or substance abuse was found to be 
associated with non-adherence to antidepressants by Akincigil et al (2007). 
 
These results support some of my hypothesis and not others. Severity of illness, alcohol abuse 
and the experience of side effects were found to be associated with non-adherence to 
antipsychotic medication. Other factors hypothesised to be significant – the patient’s level of 
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insight (proxied by their length of time on medication) and social support - were not found to 
be significant. 
 
To gain further understanding of the findings from the empirical results it is also relevant to 
see how well they relate to theoretical models that attempt to describe medication taking 
behaviour. These models were reviewed in Chapter 1. Typically, theoretical models 
developed to understand medication taking behaviours focus on preventative behaviours and 
the behaviours relating to the initiation of treatment rather than the maintenance phase of 
treatment, which is the focus of my analysis. Despite this, my findings, and those of the 
literature looking at factors associated with non-adherence in individuals taking 
antipsychotics support some of the models reviewed.  
 
Perhaps the most often cited theoretical model for explaining medication taking behaviour is 
the Health Belief Model (HBM). This model suggests health behaviours are determined by 
the interaction of personal beliefs and perceived susceptibility, severity, benefits and barriers 
of the behaviour. Budd et al (1996) conducted a study of the impact of the HBM in 
schizophrenia patients in Wales comparing 20 patients who had presented for, and accepted, 
depot antipsychotic medication at all scheduled appointments over the year prior to the study 
(compliers) with 20 patients who had failed to attend and/or accept medication for one-third 
or more of all scheduled appointments over the same period (non-compliers). The constructs 
of the HBM were evaluated using a Health Beliefs Questionnaire (Champion 1984; Pan and 
Tantam 1989). The authors found scores on the susceptibility subscale had the greatest 
discriminatory power in distinguishing compliers from non-compliers. Scores on the severity 
and benefits subscales were significant in distinguishing between the two groups when tested 
in separate analyses, but were not significant when added to a model that already contained 
the susceptibility subscale. 
 
The concept of susceptibility is consistent with the assumption that those with higher 
educational attainment are more likely not to adhere because they perceive the effects of the 
medication act as a barrier to functioning at a level they feel they are capable of. More highly 
educated individuals may also feel less susceptible to the consequences of non-adherence. The 
Self-Medication Hypothesis is, like the concept of susceptibility in the Health Belief Model, 
supported by the significance of educational attainment if one assumes that the more educated 
an individual is, the more likely they are to perceive that they have a good understanding of 
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their illness and do not need to take medication. The Self-Medication Hypothesis suggests 
that individuals intentionally and rationally decide to start, adjust or stop prescribed 
medication according to perceived health needs based the information they are given and their 
understanding of their condition (Mitchell 2007). It may be the case that more educated 
individuals are inclined to rationalise not taking their medication and for this to be an 
intentional choice. 
 
With respect to severity of illness, it is likely to be the case that, across illnesses, individuals 
whose symptoms are less severe will exhibit greater internal locus of control at the initial 
stage of treatment. That is, less severe symptoms may allow them to make the connection 
between taking medication and relieving symptoms. However, individuals experiencing more 
severe symptoms, particularly in psychotic illness where diminished cognitive function is one 
of the potential symptoms, may find it more difficult to perceive that they have the power, 
through adherence, to relieve symptoms. Where internal locus of control does not exist, 
patients may benefit from identifying their physicians as an external locus of control. This 
may account for the finding in the literature that a positive therapeutic alliance between 
patients and their physicians improves adherence in patients taking antipsychotics (Weiss, 
Smith et al. 2002; Rittmannsberger, Pachinger et al. 2004; McCann, Boardman et al. 2008). 
 
The Self-Regulatory Model of illness does not point to specific patient-, medication- or 
environment-related factors being related to non-adherence in patients taking antipsychotics, 
but does reflect the likely dynamic nature of medication taking behaviour present in 
individuals taking this medication. It proposes a dynamic flow between the three stages of 
self-regulation – representation of the illness, development and implementation of a plan to 
cope with the illness and evaluation of the coping mechanism. Perhaps the most likely 
representation of this model in empirical findings is the significance of side effects. An 
individual in the stage of evaluating their coping mechanism (taking the medication), on 
experiencing side effects, may reflect that their coping mechanism is ineffective and become 
non-adherent to seek to develop a new plan for coping with their symptoms.  
 
Interpretations of the applicability of empirical findings to the available theoretical models is 
difficult but may be enhanced by qualitative research methods. Using concept mapping, 
Kikkert et al (2006) identified five themes that encompass the factors that affect adherence: 
medication efficacy, external factors (such as patient support and therapeutic alliance), 
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insight, side effects and attitudes towards medication. The authors point out that the 
importance placed on each of these factors may differ substantionally between patients, carers 
and health professions. I will return to this point in my discussion of the implications of my 
findings for research. 
 
6.1.2 The association between non-adherence and service use costs 
 
The main hypothesis of my thesis was that non-adherence to medication in individuals taking 
antipsychotics, in addition to its impacts on clinical outcomes, is likely to lead to higher 
service use and costs. This hypothesis was put forward by researchers previously. Gilmer et al 
(2004) suggested that awareness and acknowledgement of the high service use costs that can 
be attributed to non-adherence in patients with schizophrenia might act as an incentive to 
locate resources to improve adherence in patients with this illness. 
 
My empirical findings support this hypothesis for some key health and social care services. In 
a nationally representative sample of patients taking antipsychotics, non-adherence was 
associated with greater likelihood of use of community-based health and social care 
professionals. Also, a trend towards significance was observed between non-adherence and 
the use of inpatient services and the total cost of health and social care services. Additional 
analysis of a randomised control trial sample observed no significant association between 
non-adherence and either health and social care or societal costs, but a significant association 
between non-adherence and lower community-based day service costs. The sample size for 
this study was chosen based on having adequate power to observe meaningful differences on 
the clinical outcomes and as such, may have been under-powered in relation to measuring 
differences in costs.  
 
My analyses also suggest that the relationships between non-adherence and service use and 
costs are specific to individuals taking antipsychotics and are likely to vary substantially for 
individuals taking other medications. My analysis of the PMS 2000 found a trend towards 
non-adherence being associated with lower health and social care service use costs in 
individuals taking antidepressants. There was a trend for non-adherence to be associated with 
absence from work in this group, although the costs attributed to time off work were 
significantly lower amongst those who did not adhere to their medication. 
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To date, few other studies have empirically modelled the effect of non-adherence on costs 
across a wide range of services. Previous studies have found an association between non-
adherence to antipsychotics and hospitalisations and their related costs (Weiden and Olfson 
1995; Svarstad, Shireman et al. 2001; Weiden, Kozma et al. 2004). These studies have 
observed a significant association between non-adherence and inpatient visits and their costs, 
confirming the trend observed in my analysis of the 1993/4 PMS. Loosbrock et al (2003) 
observed an association between non-adherence and total health care costs; however Eaddy et 
al (2005) did not observe this association although they did observe inpatient costs to be 
higher amongst individuals deemed partially compliant with their medication as compared to 
those who were overly compliant. Note that Eaddy et al (2005) included only inpatient, 
outpatient and physician costs in their definition of total costs. 
 
Only two studies were identified that assessed the relationship between non-adherence and 
service use and costs in patients taking antidepressants. von Knorring et al (2006) found an 
association between non-adherence and inpatient costs, and White et al (2003) observed an 
association with medical charges (physician, emergency room, hospital, laboratory and any 
other medical charges) but not with total health care costs. As I did, von Knorring et al (2006) 
looked at absenteeism costs in their analysis and also did not observe a difference in these 
costs by adherence status. 
 
My findings and previous literature suggest that non-adherence is associated with service use 
in individuals taking antipsychotics in a way that is different from patients with another 
mental illness. In particular, there was some evidence that inpatient and community-based 
services were more burdened by non-adherence than other services. Increased total health and 
social care costs associated with non-adherence were observed in the literature and while not 
conclusively supported by my analysis, there is a trend towards this observation as well in my 
analysis of the 1993/4 PMS. Further analysis in this area is warranted to corroborate these 
findings. Analysis of societal cost data suggests no differences in these costs by adherence 
status. It is the case, however, that my analysis and that of von Knorring et al (2006) only 
looked at a limited portion of the indirect costs associated with schizophrenia. 
 
Putting these results in context, there are certain aspects of the illness of schizophrenia that 
may impact on the strength of my findings and findings from the literature. There is an issue 
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that some individuals go untreated. Data from the 2000 PMS booster sample of individuals 
living in private households suggests that a substantial number of individuals who potentially 
have psychosis go untreated. Brugha et al (2005) found that of adults interviewed in 1993 and 
found to probably have functional psychosis, only 34% were prescribed medication for their 
psychosis. Data from the PMS 2000 found that this rate had increased to 57% in 2000 
(Brugha, Bebbington et al. 2004). This suggests that a large proportion of individuals with 
psychosis, many of whom will likely have schizophrenia, are untreated and in all probability 
will make demands on health, social care or other services. If some of these individuals go 
untreated because of difficulties adhering to medication, the estimated costs associated with 
non-adherence obtained by survey individuals who are taking medication will underestimate 
these costs. 
 
Another issue is the difficulty associated with obtaining data on homeless individuals. The 
1993/4 PMS included a survey of the homeless population and while non-adherence was not 
associated with total health and social care costs within this group (based on a very simple 
analysis), the sample was very small, and more importantly, the lack of service use in a 
homeless population may reflect unmet need. 
 
A third issue that may impact upon the results is that the nature of sampling for surveys may 
mean that those individuals that are less likely to adhere to medication are also less likely to 
participate in a survey if approached to do so. All of these factors suggest that findings from 
empirical analysis are likely to underestimate the service use and costs associated with non-
adherence to antipsychotics. 
 
6.1.3 Other factors associated with service use and costs in patients taking antipsychotics 
 
Of the other factors included in the modelling of service use and costs, none were found to be 
significant in both the 1993/4 PMS and QUATRO study analyses. Higher severity of 
symptoms was associated with higher external services (i.e. community-based visits by health 
and social care professionals), while longer length of time on medication was associated with 
greater probability of use of community-based day services. Length of time on medication in 
the QUATRO study is difficult to interpret because the sample was chosen from patients with 
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an unstable illness, but may relate to severity of illness which was not included in the 
QUATRO analyses. 
 
The finding that non-White respondents in the 1993/4 PMS were less likely to use external 
services but, on average, had a greater number of inpatient visits was not confirmed by the 
QUATRO analyses. In the latter study, non-White European respondents were no more likely 
to use inpatient services than White Europeans and incurred lower inpatient costs when 
inpatient visits occurred. The fact that the QUATRO study sampled across countries makes it 
unlikely that commonalities in the patterns of service use by ethnic minority individuals 
would be observed.  
 
The theoretical models presented in chapter 1 describe the current understanding of 
medication-taking decision-making, but to the extent that these theories can be thought of 
more broadly to describe decisions on all aspects of an individual’s health, they offer insight 
into the potential pattern for non-White individuals to forgo health and social care services in 
the community with the apparent impact of requiring inpatient services when their mental 
well-being deteriorates. This pattern of decision-making about when to access services is 
consistent with the Health Belief Model. It suggests that non-White individuals may have 
different views as to the benefits of community-based health and social care services and 
perceive there to be barriers to accessing these services. Other research in this area also 
supports this application of the Health Belief Model, identifying perception of illness severity, 
reliance on informal support networks, a lack of trust and the perception that the providers of 
community psychiatric care lack cultural awareness and understanding as key reasons why 
non-White individuals are less likely to access community-based services (National Centre for 
Social Research 2002; The Sainsbury Centre for Mental Health 2002; National Institute for 
Mental Health in England 2003). 
 
Severity of illness appeared to be strongly associated with total health and social care costs in 
individuals taking antidepressants. This was not the case in the analysis of patients taking 
antipsychotics identified in the 1993/4 PMS which included an index to represent this effect.   
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6.2 Limitations 
 
The analyses conducted in this thesis rely on the best available data on a cross-section of 
individuals taking medication for whom information was collected on adherence to 
medication and use of health, social care and other services. As this was secondary analysis, it 
is important to note that none of these data were collected for this purpose directly and as 
such, have some limitations with respect to addressing my particular research questions. The 
discussion above identifies some aspects of the samples that may have made it more difficult 
to observe consistent results.  
 
None of the datasets contained information on all of the factors found to be potentially 
associated with non-adherence in a review of the literature. With respect to the analysis of 
non-adherence to antipsychotics, the 1993/4 PMS and QUATRO samples differed in their 
settings. Had consistent results been observed across the two samples the results could be 
deemed more generalisable. However, the differences in the samples make it less likely to 
observe consistent results.  
 
The fact that prescribing patterns are constantly changing imposes a further limitation on 
these analyses. These changes may have an impact on the nature of the relationship between 
previously observed factors affecting adherence and the relationship between non-adherence 
and costs. Despite these limitations, however, it is my feeling that this thesis provides 
important information on these relationships. 
 
 
6.3 Policy Implications 
 
My research has implications for policies that relate to patients, the health care system and 
future research in this area. I will first discuss the policies affecting individual patients, and 
then implications for the wider health care system.  
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6.3.1 Implications for patients  
 
The empirical analyses within this thesis have important implications for patients. They 
illustrate that for a nationally representative sample, the rate of non-adherence was in line 
with those estimated in the literature from local studies and reviews. Given the rates at which 
patients report not adhering to their medication, there is a significant shortfall in the clinical 
benefits that could be available to patients.  
 
Factors associated with non-adherence in my analyses are consistent with some of the 
previous findings within the literature. These results aid in corroborating previous findings, 
with the benefit that the analyses include data drawn from a nationally representative study. 
Also, by comparing the results for non-adherence to antipsychotics with those of non-
adherence to antidepressants, for a similar population, the analyses shed light on which of the 
factors associated with non-adherence are particular to patients prescribed antipsychotics. 
That is, in addition to those factors that are likely to be associated with non-adherence across 
illnesses, such as the experience of side effects, there are those factors, such as substance 
abuse, that are more likely to be associated with non-adherence in patients experiencing 
psychosis. This information could potentially be used to help clinical staff to identify those 
patients most likely to benefit from interventions to improve adherence in patients taking 
antipsychotics, and to ensure that potential interventions are designed and delivered in such a 
way as to be targeted at those individuals most at risk of not adhering to their medication. 
 
A range of interventions have been developed to improve medication adherence in patients 
with schizophrenia. These are primarily psychosocial interventions such as educational 
approaches, skills training, group therapy, family interventions, cognitive treatments, 
behavioural modification techniques or some combination of these (Byerly, Nakonezny et al. 
2007). The evidence to date, while not entirely consistent, suggests that those interventions 
that are intensive, supportive, have a problem-solving element and include the family 
members of patients are most effective in improving adherence. Hudson et al (2008) found 
that in a trial of a practical, patient-tailored intervention to identify and develop strategies to 
overcome barriers to medication adherence, patients who received the intervention were less 
likely to be non-adherent at the 6-month study assessment. Note, however, that evidence in 
my results, and other literature, throw up the likely challenge of intervening with difficult-to-
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reach populations such as the homeless and those with a dependency on illegal drugs. For 
example, a focus on family- involvement strategies to improve adherence would not address 
the needs of homeless individuals. The availability of long-acting injectable antipsychotic 
medications does, however, allow physicians to identify those patients not attending 
appointments and therefore not receiving their medication. Depot antipsychotic medication 
has become an option for treating difficult-to-reach patients. 
 
My analyses did not estimate adherence rates for the range of antipsychotic drugs, as the  
datasets used did not identify the particular medication prescribed for each individual. Were 
this information available, it would be possible to determine to what extent non-adherence 
rates, and the factors related to adherence, differed by medication. A study by Gianfrancesco 
et al (2006) observed that in a comparison of antipsychotics on rates of adherence, where 
adherence was measured by medication possession ratio, use of the atypical antipsychotic 
quetiapine was associated with better adherence than use of two other atypical antipsychotics 
– risperidone and olanzapine. 
 
6.3.2 Implications for the health care system 
 
The current National Institute of Clinical Excellence guidance (NICE 2009) on treatment for 
patients with schizophrenia calls for medication choices to be made collaboratively by the 
person using services and healthcare professionals after the person using services has been 
informed of the benefits and side-effects of each drug and has had a chance to discuss this 
information. The guidance also calls for the views of carers to be considered if the service 
user agrees, and for the use of alcohol, tobacco, prescription and non-prescription medication 
and illicit drugs to be discussed so that the service user is aware that these will possibly 
interfere with the therapeutic effects of prescribed medication and psychological treatments. 
Specific guidance on treating patients from ethnic minorities was also provided. The current 
guidance is a revision of guidance published in 2002 which recommended atypical 
antipsychotics as the first-choice for pharmacological treatment (NICE 2002). 
 
The new guidance, therefore, addresses some key factors found to be associated with non-
adherence as corroborated by my findings, in particular, emphasising the role of carers and 
family members in successful management of the illness, the potentially adverse impact that 
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illicit drug use can have on therapeutic effects and issues around service provision to 
individuals from ethnic minorities.  
 
My findings confirmed the importance of carers and family members and suggest that the 
guidance could go further to address the needs of those individuals who live alone and/or are 
not in contact with family members. With respect to individuals with schizophrenia from 
ethnic minorities, it is highly likely that the observed pattern of service use which substitutes 
inpatient visits for community-based services reflects the fact that these individuals are only 
accessing services when their illness has progressed to become more severe. Further analysis 
is warranted to determine if the changes in the guidelines in England have the desired effect 
of eliminating patterns of service use that appear to be based on an individual’s ethnicity. 
 
The NICE guidance refers explicitly to non-adherence in recommending that service users are 
made aware of the high risk of relapse if they discontinue their medication and that depot 
injectable antipsychotic medication should be offered to people with schizophrenia when 
avoiding non-adherence is a clinical priority. 
 
The guidance recommend that the psychological therapy and psychosocial interventions that 
should be offered to people with schizophrenia are cognitive behavioural therapy, family 
intervention (where families live with or are in close contact with the service user) and art 
therapy. These interventions are recommended on the basis that they are beneficial in 
reducing symptoms, risk of relapse or rehospitalisation or improve the quality of life of 
people with schizophrenia, as opposed to the specific consideration of improving adherence. 
However, while their impact on adherence was not the primary consideration, it is possible 
that they may improve adherence. The one intervention assessed by NICE that was 
specifically designed to improve adherence was not recommended on the grounds that trials 
of its clinical effectiveness did not consistently show improvement in adherence as a result of 
the intervention. Counselling and supportive psychotherapy and social skills training were 
also not recommended. 
 
The results presented in my thesis suggest that the impact of non-adherence varied across the 
types of services used by individuals with schizophrenia. These results were not consistent, 
however, across the two studies assessing service use costs in individuals prescribed 
antipsychotics. Analysis of a sample of individuals taking antidepressants suggested that the 
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cost implications of non-adherence were not significant in this group of service users. Thus 
while adherence interventions may not be generally beneficial across illnesses, they have the 
potential to be beneficial for people taking antipsychotics.  
 
If further evidence supported the finding that use of community-based services was associated 
with non-adherence, then encouraging health professionals working in this sector to provide 
information and practical tools to help individuals adhere to their medication may have the 
best outcomes for reducing non-adherence rates. As an example, Gray et al (2004) observed 
that medication management training given to community mental health nurses was effective 
in improving adherence in patients with schizophrenia.  
 
Some common results do exist when hospital and outpatient services are contrasted with 
community services. In both studies, having social support was associated with an increased 
probability of having had an inpatient stay. This may be interpreted as evidence for the 
importance of monitoring individuals in secondary care without social support so as to ensure 
that the signs of symptom severity requiring an inpatient stay are adequately monitored. 
Alternatively, this result may reflect the need for community services to better support those 
living with individuals with schizophrenia. Another consistent finding was the significance of 
medication familiarity, as indexed by length of time on medication, in association with the use 
of community services. This suggests the need for newly diagnosed patients to be encouraged 
to access these services.  
 
6.3.3 Implications for research 
 
Having analysed data as to the factors associated with non-adherence, I believe that it would 
be beneficial to have a better understanding of the reasons behind the medication taking 
behaviour of individuals. This information would be helpful for assessing theoretical models 
to explain non-adherence to medication. There have been some qualitative research on the 
reasons individuals with schizophrenia give for not taking their medication. Löffler et al 
(2003) conducted a survey in Leipzig in Germany of schizophrenia patients receiving 
inpatient, day care or outpatient treatment. The patients were asked for their reasons for 
compliance and non-compliance with medication using the Rating of Medication Influences 
(ROMI) scale (Weiden, Rapkin et al. 1994). The reasons most often given were to avoid side-
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effects of medication, no perceived benefit of the medication and lack of insight into the 
necessity of medication. Similar findings were observed in a study by Rosa et al  (2005) in 
Brazil who interviewed outpatients diagnosed with schizophrenia.  
 
Löffler et al (2003) went further and assessed the correlation between patient-related factors 
and responses given regarding reasons for non-adherence. Men were significantly less likely 
to report fear of stigmatisation as a reason for non-adherence, older patients were less likely to 
consider distress from side effects as a cause for non-adherence and patients with more severe 
symptoms were more likely to give denial of the illness and a fear of stigma as reasons for 
non-adherence. Also, patients who had had an inpatient stay in the previous six months were 
more likely to report that lack of recovery or improvement was a reason for non-adherence. 
These results suggest that the Health Belief Model is relevant to explaining the underlying 
reasons for non-adherence in individuals taking antipsychotics. The authors of this study also 
found that the subjective reasons for non-adherence were stable over time (Löffler, Killian et 
al. 2003). 
 
Pound et al (2005) used meta-ethnography to synthesis qualitative research into the 
experiences of individuals with regards to their medicine taking. Reviewing studies from 
1992 to 2001, they found two qualitative studies of individuals taking antipsychotics, both of 
which suggested that individuals weigh up the positives and negatives of their medication 
when making decisions on how they take medicines (Rogers, Day et al. 1998; Usher 2001). 
The benefits reported were reduced symptoms, improved ability to deal with symptoms and 
reduced risk of relapse. These were weighed up against physical and psychological adverse 
effects and the stigma and discrimination associated with taking antipsychotics. The studies 
also found that people taking antipsychotics felt pressure from relatives and health professions 
to take their medication and that adherence was necessary for them to be tolerated in their 
communities. Pound et al (2005) concluded that individuals are generally reluctant to take 
medicine and prefer to minimise medicine intake; the authors suggest that the focus of 
improving medication taking behaviour should be on developing safer medicines. Weiden 
(2007) makes a similar suggestion by pointing out that non-adherence may be brought about 
for some patients by a lack of efficacy of their medication, which exacerbates symptoms 
which in turn interfere with an individual’s medication taking behaviour.  
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The theoretical models of medication taking behaviour are of benefit to the extent that they 
can be used in allowing individuals with schizophrenia and their health professionals to work 
towards making their illness more manageable. While theoretical approaches are of value for 
understanding an individual patient’s medication-taking behaviour, the constraints of clinical 
practice mean that it may be difficult to assess the theoretical underpinnings of non-adherence 
at an individual level and make it difficult to determine individually-specific methods for 
improving adherence (Zygmunt, Olfson et al. 2002). Weiden (2007) proposes a flexible 
approach to applying adherence theory in individuals taking antipsychotics that may lead to 
an enhanced range of potential therapeutic interventions to limit the effects of non-adherence. 
This approach distinguishes adherence attitudes from adherence behaviour and points out that 
each needs to be assessed and managed to improve medication taking behaviour. 
 
In addition to the valuable information that can be gained in future from qualitative research, 
how best to incorporate the impact of non-adherence in quantitative analysis needs to be 
addressed. One issue is how best to standardise the measurement and reporting of adherence. 
Cramer et al (2008) propose that adherence should be reported in studies as the percentage of 
dosages missed in a particular period of time. This continuous measure would reflect the 
severity of non-adherence and would avoid situations where different cut-points indicating 
non-adherence are used across studies. They suggest that in prospective studies, the 
percentage of dosages missed would be available from electronic monitoring and in 
retrospective studies the medication possession ratio would provide the necessary information 
to allow for this index to be calculated. Electronic monitoring and the medicine possession 
ratio methods, however, are not without limitations and are unlikely to be feasible in large 
surveys. Hughes et al (2001) have recommended using a measure of non-adherence, such as 
the therapeutic coverage achieved and relating it to changes in outcome at different levels of 
exposure over time. This would take into account the timing of missed dosages, which may be 
important to the effectiveness of the medication. 
 
Another important question is how best can cost-effectiveness analysis (CEA) take account of 
longer term outcomes which will reflect the true impact of non-adherence to medication? In a 
review of literature evaluating both costs and clinical outcomes in schizophrenia, none of the 
trials used for CEA evaluated costs and effects beyond the first year of treatment (Basu 2004). 
The fact that these trials were funded by pharmaceutical companies and employed methods 
that would meet marketing regulatory requirements only meant that it would be impractical 
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for them to take a long-term perspective, in part due to the costs involved. Long-term studies 
incur substantial costs in following patients and in data collection. Moreover, studies 
involving schizophrenia patients have very high sample attrition (Verhoeven, Van der Heijden 
et al. 2005; Vickar, North et al. 2009). These costs may be warranted, however, given that 
short-term studies do not address effects and costs that appear in the longer term, when the 
impacts of non-adherence may realised, especially in a chronic illness such as schizophrenia. 
 
Historically, analyses of randomised control trials to assess clinical effectiveness have 
adopted intention-to-treat analysis when participants do not receive the intervention or course 
of treatment to which they were randomised. Thus those individuals who do not adhere to 
their treatment would contribute outcome data towards the group to which they were 
assigned. This approach requires two important assumptions to be made (White 2005). 
Firstly, that the benefit of treatment is the same for all individuals, regardless of whether they 
are more or less likely to adhere to their medication. Secondly, that the difference in costs 
between the treatment and control group depends only on the difference in intervention costs. 
The latter assumption can not be made in drug trials where there are cost implications of non-
adherence. Cost-effectiveness evaluations of drug therapies should include sensitivity analysis 
to determine if realistic rates of non-adherence have a bearing on the outcome of the 
evaluation (Hughes, Bagust et al. 2001). Note that while the focus here is not on the clinical 
consequences on non-adherence, these too are important. 
 
Table 6.1 is a subset of part of Table II in Hughes et al (2001). The original table attempts to 
categorise drug-disease pairs according to the sensitivity of their cost-effectiveness ratios to 
changes in adherence taking into account the nature of the disease and the severity of the 
consequences of non-adherence. The table estimates these impacts for a range of illnesses 
including psychosis and depression. The economic consequences are represented as £ (least 
costly), ££ or £££ (most costly) which are hypothesised costs per quality-adjusted life-year 
(QALY) per percentage decrease in drug regimen non-adherence or premature treatment 
discontinuation. These, however, are only estimates. Information on the frequency of missed 
dosages would be necessary to determine the effects on the pharmacodynamic interaction of a 
drug with the disease process it was prescribed for. This is partly reflected in the perceived 
impact of non-adherence relative to premature discontinuation of medication for a potentially 
fatal disease such as hypertension. 
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Table 6.1: Examples of the clinical consequence of noncompliance estimated according to 
hypothesised costs per quality-adjusted life-year per percentage decrease in drug regimen 
 
 
Disease Drug treatment Drug regimen 
noncompliance 
Premature discontinuation 
Clinical 
consequences 
£/QALY/% Clinical 
consequences 
£/QALY/% 
Psychosis Antipsychotics Extended 
duration of 
symptoms 
££ Increased risk 
of suicide 
££ 
Depression Antidepressants Relapse of 
depression 
££ Discontinuation 
syndrome 
££ 
Osteoporosis Bisphosphonates Decreased 
bone density 
£ Increased risk 
of fractures 
££ 
Hypertension Diuretics Increased 
blood 
pressure 
£ Increased risk 
of 
cardiovascular 
events 
£££ 
Heart failure Diuretics Acute fluid 
retention 
£££ Increased risk 
of 
cardiovascular 
events 
£££ 
 
Source: Hughes et al 2001b 
 
 
 
 
A variety of modelling techniques have been employed in the recent literature to deal with the 
methodological difficulties in observing the long-term economic consequences of non-
adherence. The three main techniques used are decision-analysis or decision trees, Markov 
models and Discrete Event Simulation (DES). In decision-analysis models there is a ‘root’  
decision from which branches extend, representing different events or secondary decisions. 
Each branch has associated with it a probability of the event it relates to occurring. To reflect 
non-adherence, levels of adherence can be branches within a decision tree, each assigned a 
probability. Cost and effect consequences of each branch are typically represented at the end 
point of each sequence of branches. The weighted average of outcomes can then be calculated 
to arrive at the average effect and/or cost of each branch of the decision tree. Decision-
analysis models usually attempt to model a limited number of outcomes for the average 
patient. Attempting to incorporate variability across patients would require analysing the 
model with different event probabilities or building separate branches for different subgroups 
(Heeg, Damen et al. 2008). Similarly, decision-analysis models are also constrained by not 
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modelling variability in patient characteristics over time. To incorporate variability over time, 
the model would require branches for each time period, exponentially increasing the number 
of branches.  
 
A Markov model is a repeated decision tree in which events are modelled as transitions from 
one health state to another over time (Heeg, Damen et al. 2008). As in decision-analysis, 
Markov models become very complex when made to account for subgroups of patients. This 
method of modelling is also constrained by the assumption that the probability of an event is 
not affected by previous occurrences of the event. This assumption does not hold in 
schizophrenia where the risk of relapse or non-adherence is not independent of previously 
experienced relapses, so micro-simulation Markov models have been developed to simulate 
individual patient histories over time (Heeg, Damen et al. 2008). 
 
Discrete Event Simulation Models represent the dynamic behaviour of a system. They are 
able to represent multiple factors in a model simultaneously (Heeg, Buskens et al. 2005). 
Time-independent parameters, such as sex, can be assigned a probability distribution and 
time-dependent variables, such as adherence or non-adherence, are simulated as part of 
patient histories. This feature of DES models allows them to assess outcomes over longer-
term time horizons. Data for a large number of individuals can be run through the model to 
arrive at aggregate clinical outcomes and costs. 
 
Each of the modelling approaches require data from the literature or expert opinion as to the 
probability of events such as non-adherence and the clinical and cost consequences of these 
events. Typically, sensitivity analyses are run to determine the impact of varying the 
probability of non-adherence. The results produced in this thesis could be used to contribute 
estimates of the cost consequences on non-adherence to such model.  
 
Hughes et al (2007) conducted a review of pharmacoeconomic evaluations published between 
1997 and 2005 that included non-adherence in the evaluation process and found no 
consistency in the modelling techniques used. The authors note that Health Technology 
Assessment bodies have not published consensus guidelines on the use of these techniques. 
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6.4 Conclusions 
 
The impact of non-adherence on health, social care and the wider societal costs is difficult to 
assess for practical and methodological reasons. Analyses of nationally representative samples 
of individuals prescribed antipsychotics and antidepressants suggest that younger age, illness 
severity and the experience of side-effects are common causes of non-adherence in mental 
illness. Substance abuse is an additional factor associated with non-adherence in patients 
taking antipsychotics. 
 
Community-based services were found to be used more by individuals with interruptions in 
their antipsychotic medication. In this group there may also be additional costs in 
hospitalisations and overall health and social care services attributable to non-adherence. 
Benefits to patients may be accrued by enabling health and social care professionals, 
particularly those working in the community, to encourage medication adherence in 
individuals with schizophrenia and to provide information on new interventions that are cost-
effective in improving adherence.    
 
The datasets used in my analyses were the best available sources of data at the time of my 
analyses. Further analysis in this area is warranted. At the level of the individual, qualitative 
research methods may contribute to our understanding of the reasons why some people with 
schizophrenia choose not to take their medication. More long-term studies are needed to 
determine the clinical, economic and personal consequences of non-adherence. Greater 
standardisaton of the way in which non-adherence is assessed in these studies would be 
beneficial. The data provided from these studies will be particularly useful in assessments of 
the long-term cost-effectiveness of new medicines and therapies to treat schizophrenia. 
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APPENDIX 1 
Results of literature search for empirical studies looking at factors associated with non-adherence in schizophrenia 
 
 
Author, date Country Sample 
size 
Sample Adherence 
assessment 
Study 
time 
period 
Factors associated with 
non-adherence 
Factors not associated 
with non-adherence 
Swartz et al, 2001 US 258 Outpatients with 
psychosis 
Self-reported, 
family, case-
manager 
1 year Involuntary outpatient 
commitment, African-
American ethnicity, substance 
abuse, low GAF score 
Age, urban v rural, sex, 
marital status, income, 
education, social 
support, homelessness, 
victim of crime, Brief 
Symptom Inventory 
score, insight into 
illness, prior psychotic 
hospitalisation 
Trauer et al, 2000 Australia 218 Outpatients with 
psychosis 
Self-report, 
physician, case-
manager 
1 month  Insight into illness 
Weiss et al, 2002 US 162 Ambulatory with 
psychosis 
Therapist Time to 
non-adh. 
or end of 
study 
Low GAF score, substance 
abuse, poor working alliance 
with therapist 
Demographic factors, 
illness history 
Ruscher et al, 1997 Canada 148 Inpatients and 
outpatients with 
psychosis 
Self-report 6 months High educational attainment, 
currently an inpatient 
Class of antipsychotic, 
sex, age, marital status,  
diagnosis, number of 
previous admissions, 
length of 
hospitalisation 
Rittmannsberger et al, 
2004 
Austria 95 Outpatients with 
psychosis 
Self-report 1 month Low GAF score, irregular 
contact with treating 
psychiatrist, increased age  
 
 
GAF – Global Assessment of Functioning (measures social, psychological and occupational functioning 
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Author, date Country Sample 
size 
Sample Adherence 
assessment 
Study 
time 
period 
Factors associated with 
non-adherence 
Factors not associated 
with non-adherence 
Grunebaum et al, 
2001 
US 74 Residents of supported 
housing with psychosis 
Self-report 1 month Lack of medical supervision, 
negative view of psychiatric 
medicines, low GAF score 
Class of antipsychotic, 
medication regime 
complexity 
Kampman, 2002 Finland 59 Inpatient and outpatient 
with first-onset psychosis 
Self-report 3 months Side effects, male, lack of 
social acitivities, low PANSS 
positive symptoms subscale 
score, high PANSS total 
score, younger age 
 
Ziguras et al, 2001 Australia 168 Outpatients with 
psychosis 
Case-managers’ 
report 
 Poor cooperation with staff, 
poor insight, problems with 
impulse control, less ability to 
manage finances, case-
manager from different ethnic 
background 
Age, sex, receipt of 
depot medication, size 
of social network, drug 
or alcohol abuse, 
medication dose, 
thought disorder 
Coldham et al, 2002 Canada 200 Outpatients with first-
episode psychosis 
Medical records 
(reviewed by 
study first 
author) 
1 year Positive symptoms, substance 
abuse, low insight, younger 
age, younger age at onset of 
illness, lack of family support 
 
Hudson et al, 2004 US 153 Inpatients and outpatients 
with schizophrenia 
Self-report and 
medical records 
30 days Lower level of education, 
substance abuse, high PANSS 
total score, barriers to taking 
medication (e.g. stigma), 
adverse drug reactions, 
forgetfulness, lack of social 
support 
Age, sex, marital 
status, ethnicity, 
premorbid functioning, 
SF-36 score, Barnes 
Akathisia Scale score 
Owen et al, 1996 US 135 Inpatients with 
schizophrenia 
Self-report with 
input from 
family and health 
professionals 
30 days Substance abuse Living arrangements 
 
PANSS – Positive and Negative Syndrome Scale (measures schizophrenia symptom severity) 
SF-36 – Short Form 36 (measures health state) 
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Author, date Country Sample 
size 
Sample Adherence 
assessment 
Study 
time 
period 
Factors associated with 
non-adherence 
Factors not associated 
with non-adherence 
Holzinger et al, 2002 Germany 77 Inpatients or day hospital 
patients with 
schizophrenia 
Self-report, 
family 
1 month Quality of helping alliance, 
delusion of grandiosity, 
attitude towards antipsychotic 
drugs 
Perceptions of mental 
illness and prognosis 
Rettenbacher et al, 
2004 
Austria 61 Schizophrenia 
outpatients with recent 
inpatient stay 
Self-report and 
plasma levels of 
antipsychotic 
3 months Positive effect of drugs on 
illness, psychiatrist’s inquery 
into drug taking, 
psychological side effects 
PANSS subscales 
Weiden et al, 2004 US 239 Outpatients with 
schizophrenia 
Self-report Week of 
missed 
medication 
(if ever 
missed) 
obesity Sex, class of 
antipsychotic, 
satisfaction with 
psychiatrist, length of 
time on medication, 
general well-being, 
attitude to medication 
Valenstein et al, 2004 US 63,214 Inpatients and 
outpatients with 
schizophrenia 
Medication 
possession ratio 
1 year African-American ethnicity, 
younger age, low dose 
Class of antipsychotic 
Robinson et al, 2002 US 112 Inpatients and 
outpatients with 
schizophrenia 
Self-report, 
family, health 
professionals 
1 year Poor premorbid cognitive 
ability 
Demographics 
characteristics, 
premorbid social 
functioning, time to 
start of treatment, 
diagnosis, illness 
severity, presence of 
motor side effects, 
family attitudes 
Hunt et al, 2002 Australia 99 Schizophrenia patients 
requiring acute or crisis 
care 
Medical records 4 years Substance abuse  
 
PANSS – Positive and Negative Syndrome Scale (measures schizophrenia symptom severity) 
 
 229 
Author, date Country Sample 
size 
Sample Adherence 
assessment 
Study 
time 
period 
Factors associated with 
non-adherence 
Factors not associated 
with non-adherence 
Kamali et al, 2001 Ireland 87 Inpatients with 
schizophrenia suffering 
acute relapse 
Self-report, 
family, mental 
health 
professionals 
1 month Substance abuse, negative 
subjective response to 
medication, lack of insight 
Age, sex duration of 
illness, dosage of 
medication 
Novak-Grubic et al, 
2002 
Slovenia 56 Outpatients with 
schizophrenia after first 
episode 
Self-report, 
family 
1 year Poor insight, positive 
symptoms at admission, 
diagnosis 
Socio-demographics 
characteristics, severity 
of extra-pyramidal 
symptoms, class of 
antipsychotic, attitude 
towards hospitalisation, 
length of hospital stay  
Diaz et al, 2004 US 50 Individuals with 
schizophrenia in a 
community mental health 
centre 
Medication 
Event 
Monitoring 
System 
3 months Male, dose frequency Class of antipsychotic, 
Barnes Akathisia Scale 
Liraud et al, 2001 France 45 Inpatients with 
schizophrenia 
Self-report, 
medical records 
1 year Sensation-seeking Impulsivity, 
experience-seeking 
Donohue et al, 2001 Ireland 32 Inpatients with 
schizophrenia 
Clinical rating 
following 
interview 
3 months Attitude to medication, 
PANSS activation and 
composite subscales, poor 
memory 
Age, sex, time since 
diagnosis, level of 
education, living 
arrangements, 
schizophrenia subtype, 
substance abuse 
Lambert et al, 2004 Germany 213 Inpatients with 
schizophrenia prescribed 
first-generation 
(‘typicals’) 
antipsychotics 
Self-report, 
medical records 
1 month Negative attitude towards 
antipsychotics, side effects 
Age, sex, level of 
education, age at onset 
of illness, length of 
illness, medication 
dosage, number of 
prior admissions, 
psychopathology, 
duration of untreated 
psychosis 
 
PANSS – Positive and Negative Syndrome Scale (measures schizophrenia symptom severity) 
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Author, date Country Sample 
size 
Sample Adherence 
assessment 
Study 
time 
period 
Factors associated with non-
adherence 
Factors not associated 
with non-adherence 
Olfson et al, 2000 US 213 Outpatients with 
schizophrenia within 3 
months of an inpatient 
stay 
Self-report 3 months Substance abuse, prior non-
adherence, family refusal to 
participate in treatment, poor 
involvement in treatment 
class of antipsychotic, 
symptom severity 
Becker et al, 2007 US 10,330 Outpatients with 
schizophrenia 
Frequency of 
refills 
2 years Younger age, female, Non-
White ethnicity, prescribed 
first-generation (‘typical’) 
antipsychotic, substance 
abuse 
 
Asher-Svanum et al, 
2006 
US 1,579 Inpatients and outpatients 
with schizophrenia 
Self-report and 
medical records 
3 years Prior non-adherence, drug 
and alcohol abuse, prior 
treatment with 
antidepressants, medication-
related cognitive impairment 
 
Valenstein et al, 2006 US 33,760 Inpatients and outpatients 
with schizophrenia 
Medication 
possession ratio 
4 years Younger age, African-
American or Hispanic 
ethnicity, substance abuse, 
psychiatric hospitalisation, 
low dosage of medication, 
prescribed first-generation 
(‘typical’) antipsychotic 
Sex 
Yen et al, 2005 Taiwan 74 Outpatients with 
schizophrenia 
Medication 
Adherence 
Behaviour Scale 
score based on 
patient interview, 
family 
1 year Religious belief, non-
adherence at baseline 
Sex, marital status, 
occupation 
 
PANSS – Positive and Negative Syndrome Scale (measures schizophrenia symptom severity) 
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Author, date Country Sample 
size 
Sample Adherence 
assessment 
Study 
time 
period 
Factors associated with non-
adherence 
Factors not associated 
with non-adherence 
McCann et al, 2008 Australia 81 Outpatients with 
schizophrenia 
Factors 
Influencing 
Neuroleptic 
Medication 
Taking Scale 
based on patient 
interview 
 Younger age, side effects, 
poor access to psychiatrists 
Living arrangements, 
level of insight, stigma 
experienced, alcohol 
abuse, social support, 
access to case-manager 
and GP 
Cooper et al, 2007 Canada 4,495 Outpatients with 
schizophrenia 
Medical records 1 year Low intensity treatment, 
initiated on olanzapnie, 
prescribed first generation 
(‘typical’) antipsychotics, low 
comorbidity index, substance 
abuse, younger age, not on 
welfare or income support 
 
Karow et al, 2007 Germany 2,414 Inpatients and outpatients 
with schizophrenia 
Self-report , 
physician 
1 year Severity of positive 
symptoms, lack of 
improvement in positive 
symptoms 
Negative, depressive 
and cognitive 
symptoms, 
improvement in 
negative, depressive 
and cognitive 
symptoms, 
improvement in side 
effects 
de Haan et al, 2007  The 
Netherlands 
119 Inpatients and outpatients 
with schizophrenia 
Self-report, 
health 
professionals 
5 years Hostility and 
uncooperativeness, 
involuntary admission 
Subjective well-being, 
ROMI scale score, 
insight, PANSS score 
Perkins et al, 2008 US and 
Canada 
234 Inpatients and outpatients 
with schizophrenia (first 
episode) 
Self-report, 
physician 
1 year Substance abuse, comorbid 
depression, Black ethnicity, 
higher cognitive performance 
 Duration of illness, 
side effects 
 
PANSS – Positive and Negative Syndrome Scale (measures schizophrenia symptom severity) 
ROMI – Rating of Medication Influences Scale (measures reasons patients give for taking or not taking their medication) 
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Author, date Country Sample 
size 
Sample Adherence 
assessment 
Study 
time 
period 
Factors associated with non-
adherence 
Factors not associated 
with non-adherence 
Klingberg et al, 2008 Germany 108 Inpatients and 
outpatients with 
schizophrenia 
Physician 1 year Lack of trust in medication, 
lack of insight 
Problem solving 
ability, socio-
demographic factors, 
comorbidity, age at 
onset of illness, 
PANSS score, class of 
antipsychotic, number 
or severity of side 
effects, social contact 
Kamali et al, 2006 Ireland 100 Inpatient with psychosis 
(first episode) 
Self-report 6 months Positive symptom score, drug 
and alcohol abuse, lack of 
insight 
Age, sex, negative 
symptom score, 
voluntary versus 
involuntary admission 
Janssen et al, 2006 Germany 670 Inpatients with psychosis Self-report, 
health 
professionals  
Length of 
admission 
Substance abuse, history of 
aggressive behaviour, 
involuntary admission, lower 
level of education, PANSS 
negative symptom score, 
PANSS paranoid/belligerence 
score 
Household 
composition, 
employment status, 
side effects, class of 
antipsychotic 
Ramirex Garcia et al, 
2006 
US 30 Outpatients with 
schizophrenia 
Patient records, 
physician, family 
9 months Instrumental support from 
family 
Emotional support, 
criticism, emotional 
under-involvement 
Perkins et al, 2006 US 254 Inpatients and 
outpatients with 
schizophrenia 
Pill counts 2 years Low belief in need for 
treatment, low belief in 
benefit of medication, 
clinically-rated akathisia no 
weight gain, inpatient, low 
improvement in positive 
symptoms 
Age, negative aspects 
of medication, social 
support, duration of 
illness, ethnicity, 
neurocognitive 
function, PANSS score 
improvement, 
marijuana use 
PANSS – Positive and Negative Syndrome Scale (measures schizophrenia symptom severity) 
ROMI – Rating of Medication Influences Scale (measures reasons patients give for taking or not taking their medication) 
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Author, date Country Sample 
size 
Sample Adherence 
assessment 
Study 
time 
period 
Factors associated with 
non-adherence 
Factors not associated 
with non-adherence 
Lecomte et al, 2008 Canada 147 Outpatients with 
schizophrenia 
Self-report Cross-
sectional 
Positive symptoms, witnessed 
violence as a child, 
agreeableness 
Neurosis, negative 
symptoms, insight, 
drug and alcohol abuse 
Heinrichs et al 2008 Canada 147 Outpatient with 
schizophrenia 
Medical 
Management 
Ability 
Assessment 
Cross-
sectional 
Cognitive function  
Mutsatsa et al, 2003 UK 101 Inpatients and outpatients 
with schizophrenia 
Health 
professionals 
12 weeks Insight, negative attitude 
towards medication 
Drug and alcohol 
abuse, side effects, 
severity of illness 
Jeste et al, 2003 US 110 Outpatients with 
schizophrenia 
Medical 
Management 
Ability 
Assessment 
Cross-
sectional 
Cognitive function Age, sex, level of 
education, living 
arrangements, 
symptom severity, 
attitude towards 
medication 
 
PANSS – Positive and Negative Syndrome Scale (measures schizophrenia symptom severity) 
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APPENDIX 2 
Patterns of, and factors associated with, atypical and typical antipsychotic 
prescribing by general practitioners in the UK during the 1990s 
 
 
 
 
Introduction 
 
The development of atypical (or second generation) antipsychotics has offered people with 
schizophrenia a potentially more effective and less damaging set of treatment options. 
Atypical antipsychotics are more expensive than the earlier class of antipsychotics (which are 
no longer patented), but are argued to be more effective in alleviating symptoms of the illness 
and to be associated with fewer side-effects (Leucht et al. 1999; Sartorius et al. 2002; 
Sartorius et al. 2003). By reducing side-effects, for example, atypical antipsychotics may 
reduce non-adherence to medication, which significantly increases the probability of relapse 
into an acute schizophrenic episode (Weiden and Olfson 1995), and in turn pushes up 
treatment and support costs (Almond et al. 2004). Thus, support for prescribing of atypical 
antipsychotics, relative to typical antipsychotics, in treating patients with schizophrenia, has 
also been made on cost-effectiveness grounds (Davis et al. 2003; Hudson et al. 2003), 
although the evidence is not unequivocal (Basu 2004; Duggan 2005). 
 
Data from IMS indicate that sales of antipsychotics in the United Kingdom increased ten-fold 
between 1996 and 2002, a trend matched in a number of other European countries (IMS 
Health 2003). The introduction and uptake of atypical antispychotics has been the primary 
reason. A number of local studies of prescribing patterns in primary care in the UK show 
rapid increases in the use of atypical antipsychotics. For example, between 1994 and 1997, a 
28% growth in prescriptions in Scotland was observed (Stark et al. 2000); between 1996/7 
and 2000/1, there was a six-fold increase in the volume of atypical antipsychotics prescribed 
in the West Midlands (Ashcroft et al. 2002); and for a similar period there was a twenty-fold 
rise in expenditure on atypicals in Greater Manchester (Hayhurst et al. 2003). In July 2002, 
the National Institute for Clinical Excellence (NICE) published guidance favouring the use of 
atypical antipsychotics as a first line treatment for patients with schizophrenia (NICE 2002), 
which may be expected to further boost growth (Walley 2004).  
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Overall, the percentage of mental health drugs prescribed by general practitioners in England 
accounted for by antipsychotics has increased only slightly since 1998 to about 10%. 
However, they represent more than 21% of spending on mental health drugs in primary care, a 
proportion that has grown from approximately 12% in 1998 (source: Prescribing analysis and 
cross tabulation data). The rise in spending is entirely due to switching from low price typical 
antipsychotics to the more expensive atypical antipsychotics (despite inflation-adjusted prices 
for the latter having dropped over time). 
 
Using national data on primary care prescribing, Kaye et al (2003) calculated that 
antipsychotic use increased from 10.5 people per 1000 population in 1991 to 12.2 per 1000 in 
2000, with most of the increase – and indeed most of the use – to treat non-prescribing of 
atypical antipsychotics in the treatment of schizophrenia. My analysis, like that by Kaye et al, 
is based on the General Practice Research Database (GPRD). Importantly, the GPRD allows 
us to follow people with schizophrenia and schizoaffective disorder over a number of years in 
order to assess changes in the prescription of atypical antipsychotics over time and – a 
particular focus of my work – to explore some of the individual characteristics associated with 
these changes. 
 
 
Methods 
 
General Practice Research Database 
 
The GPRD is a computerised database of anonymised general practice patient records that 
commenced in 1987 and now contains over 30 million patient years of information. Currently, 
the database collects information on approximately 3 million patients: approximately 4.7% of the 
UK population. Data are provided by a cross-section of practices, across the UK. Information is 
recorded by GPs on demographics, medical diagnosis, all prescriptions, referrals to hospitals, 
hospital discharge reports where patients are referred to hospital for treatment, and treatment 
outcomes (crudely measured) (Wood and Coulson 2001). The GPRD is used for academic and 
policy-related research, and also by the United Kingdom Medicines and Healthcare products 
Regulatory Agency, primarily for better understanding of drug safety issues brought to its 
attention by GPs submitting adverse drug reaction reports. The quality and completeness of 
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these data for research have been confirmed by several validation studies (Walley and 
Mantgani 1997). 
 
As atypical antipsychotic medications were not prescribed in the UK before 1993, my study 
used data from 1st January 1993 through to 31st December 1999. A legal dispute between the 
data owners and the data vendors resulted in the rapid decline in the number of patients 
available in the database. For this reason, data for 2000 and 2001 are excluded. I did not look 
at later (post-2001) data because I chose to employ a panel design based on linking annual 
GPRD datasets from one year to the next. 
 
 
Schizophrenia and schizoaffective patients 
 
My inclusion criteria required a patient to have received at least one prescription for an 
antipsychotic medication, be enrolled in the General Practice Research Database for the entire 
year and have been diagnosed with schizophrenia or schizoaffective disorder prior to the 
beginning of that year. There were no other inclusion or exclusion criteria. 
 
Read codes (now simply called the Clinical Terms in the UK) provide the diagnostic 
classification used to identify patients with schizophrenia or schizoaffective disorder. The 
Read codes were introduced in the UK in 1986 to generate computer summaries of patient 
care in primary care. In the subsequent revision (Version 2), their structure was changed and 
based upon the International Classification of Diseases (ICD)-9 and OPCS-4, the 
Classification of Surgical Operations and Procedures. Schizophrenia disorders are identified 
by Read codes E100-106, E10y, E10z or Eu20; schizoaffective disorder by Read codes E107 
or Eu25. 
 
My identification of users of antipsychotic drugs was similar to the method employed by 
Kaye et al (2003). They too identified patients who had at least one prescription for an 
antipsychotic during the year. There are, however, important differences. They did not limit 
their analysis to schizophrenia and schizoaffective patients, and only used data from 270 
general practices that had an uninterrupted record of data contribution to the GPRD.  
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Antipsychotic drugs 
 
Medications are the most reliably recorded resource category in the GPRD given the separate 
and detailed prescription records in the database. The drug name (generic and method of 
administration), daily dose (mg, ml, etc.) and duration of therapy (days) of all prescriptions 
made by the GP are recorded in the database. The atypical antipsychotic medications 
observed in the dataset are: amisulpride, clozapine, olanzapine, quetiapine, remoxipride, 
risperidone, sertindole, and zotepine. These drugs were not all marketed for the full period 
under study here. The date of licensing for each of the drugs appears in Table 1. For 
comparison, Kaye et al (2003) identified patients who received a medication listed as an 
antipsychotic on the British National Formulary, but excluded from their analysis the use of 
clozapine, benperidol, sertindole, amisulipride and quetiapine on the basis that each of these 
drugs were prescribed to fewer than 1,000 patients during the study period. 
 
 
Linking of annual datasets 
 
I linked patients over time to allow panel analyses to be conducted (see below). Data for each 
year from 1993 to 1999 were sorted, and then merged on the unique patient number. This 
means that the number of observations per patient will vary, depending upon the number of 
years in which they met the inclusion criteria.  
 
 
Statistical analysis 
 
By linking annual datasets I created a longitudinal (also called panel) dataset which then 
allowed me to analyse changes over time. Longitudinal data designs of this kind are very 
helpful because they allow for separate estimation of the effects of differences between 
subjects, and of time-series or within-subject effects reflected in the changes within subjects 
over time. Panel data regression techniques allow one to take advantage of these different 
types of information. A panel logistic regression model was run in STATA (2001). A model 
was fitted to the data to determine factors influencing the choice between typical and atypical 
antipsychotics, with the dependent variable as positive if the patient received an atypical 
antipsychotic and negative if they did not.  
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Table 1: Licensing period of atypical antipsychotic medications observed in the GPRD dataset 
 
 
 
Drug name Year licensed If  withdrawn, 
Year 
Comments 
Amisulpride 1997   
Clozapine 1995   
Olanzapine 1996   
Quetiapine 1997   
Remoxipride 1986 1993 Withdrawn due to reports 
of aplastic anaemia1 
Risperidone 1993   
Sertindole 1996 1998 Withdrawn due to 
concerns about effects on 
the heart; Reinstated with 
restricted license in 2002 
requiring strict monitoring 
and guidelines of use2 
Zotepine 1998   
                                                 
1 Northern and Yorkshire Regional Drug and Therapeutics Centre. ‘The Use of Atypical Antipsychotics in the 
Management of Schizophrenia’ February 1998. Accessed on-line on 23 January 2006 at: 
http://www.nyrdtc.nhs.uk/docs/eva/atypical_antipsychotics.pdf 
2 Norfolk and Waveney Mental Health Partnership NHS Trust Pharmacy Medicine Information.  Accessed on-
line on 23 January 2006 at: http://www.nmhct.nhs.uk/pharmacy/dsertind.htm 
 242 
A random-effects model was employed because I assumed that while some omitted effects 
may be constant over time but vary between cases (e.g. the confidence of the patient in 
expressing a preference for atypical antipsychotics), others may be fixed between cases but 
vary over time (e.g. the relative price of atypicals to typical antipsychotics). Also, the STATA 
output includes a significance test of the proportion of the total variance in the data 
contributed by the panel-level variance component. If this test returns a finding of 
significance, this justifies the panel specification of the model which accounts for both the 
variability within patients over time, and the variability between patients. Significance levels 
at the 0.05 level or below were deemed statistically significant. 
 
 
Results 
 
Of patients with schizophrenia or schizoaffective disorder who contributed data in 1999, 
20.8% were prescribed an atypical antipsychotic during that year. At the start of the study 
period, atypical antipsychotic prescribing was much lower: 1.8% in 1993. Full data on the rate 
of atypical prescribing in each year of the study period appear in Table 2. At the beginning of 
this period, the most widely prescribed atypical antipsychotic was remoxipride (IMS Health 
2003b), but this drug was withdrawn in 1994 due to reports of aplastic anaemia (Northern and 
Yorkshire Regional Drug and Therapeutics Centre 1998). From 1994 to 1997, the atypical 
antipsychotic with the largest market share was risperidone, but in 1998 and 1999 it was 
overtaken by olanzapine as the most widely used atypical antipsychotic (IMS Health 2003b).  
 
A panel logistic regression model (random effects) was run on 4,391 patients in the database 
for 1993 to 1999 who had a diagnosis of schizophrenia or schizoaffective disorder and 
received at least one antipsychotic medication prescription in each year that they contributed 
data to my sample. Statistically significant associations were observed between choice of 
antipsychotic medication and three variables: age, having an inpatient stay in the previous 
year and having six or more primary care visits in the previous year (see Table 3). Older 
patients were less likely to be prescribed an atypical as compared to a typical antipsychotic. 
For every five-year difference in age the probability of being prescribed an atypical 
antipsychotic decreased by 15%. Patients who had an inpatient stay in the previous year were 
over 1.5 times as likely to receive atypical antipsychotics, as were patients who had visited 
their GP six or more times in the previous year. Gender and time since first diagnosis of 
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Table 2: Rate of atypical prescribing in general practice for patients with schizophrenia or 
schizoaffective disorder: 1993-1999 
 
Year Atypical antipsychotic prescribing among 
GPRD schizophrenia and schizoaffective 
patients prescribed antipsychotics 
N % 
1993 69 1.8 
1994 102 2.7 
1995 129 3.7 
1996 166 5.7 
1997 232 9.2 
1998 277 13.8 
1999 228 20.8 
 
 
Source: General Practice Research Database. 
 
 
 
Table 3: Panel logistic regression on GRPD data (1993-1999) looking at factors associated 
with receipt of atypical antipsychotics 
 
 
N = 4,391  
Average number of observations per subject = 3.3 
 
Wald chi-squared statistic = 78.71 
Prob > chi2 = 0.0000 
 
 Coefficient Odds ratio p-value 
Age – 5 year increase -0.1640 0.85 <0.001 
Sex – Male relative to female 0.2609 1.30 0.121 
Time since diagnosis of 
schizophrenia – 5 year increase 
0.0285 1.03 0.557 
Inpatient in the previous year 0.5206 1.68 <0.001 
6 or more GP visits 0.5165 1.68 <0.001 
Constant -4.3596   
Panel-level variance component 
(log of the standard deviation) 
 
2.2674 
 
0.1066 
 
Standard deviation 3.1072 0.1656  
Proportion of total variance 
contributed by the panel-level 
component 
 
0.7458 
 
0.0202 
 
 
Liklihood ration test of rho=0: chibar2(01) =  1258.70 Prob >= chibar2 = 0.000 
  
Note: random effects model with subject effect included. 
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schizophrenia or schizoaffective disorder were not associated with higher or lower odds of 
being prescribed an atypical antipsychotic.  
 
A test of the contribution to the model of having repeated observations from each patient 
suggests that the design of the model, which accounts for the fact that there is variability 
within patients over time and between patients, is justified. 
 
 
Discussion 
 
Trends in the rate of prescribing of atypical antipsychotics 
 
Within my primary care study sample, a tenfold increase in the rate of atypical antipsychotic 
prescribing was observed between 1993 and 1999. This rate of growth is comparable to UK 
data from other sources, although none appear to have looked at as wide a sample as I was 
able to examine in this paper. For example, a six-fold increase in retail sales of atypical 
antipsychotics was observed in IMS Health data for the period 1996 to 1999 (IMS Health 
2003). 
 
Local studies of prescribing have also found comparable growth rates, and have the advantage 
of looking at a more recent period. In the West Midlands between 1996/7 and 2000/1 there 
was a six-fold increase in the volume of atypical antipsychotics prescribed. The authors 
calculated defined daily dose at the health authority level by adjusting for differences in 
population size and age stratification (Ashcroft et al. 2002). 
 
Hayhurst et al (2003) observed greater increases in Greater Manchester over the same period 
(1996/7 to 2000/1), but these increases varied markedly across health authorities. For a three-
month period in 1999, the adjusted per capita expenditure on atypical antipsychotics ranged 
from less than £75 to over £500 and the variation between health authorities in per capita 
expenditure on atypical drugs was almost three times greater than the variation in per capita 
expenditure on typical antipsychotics.  
 
With regards to prescribing patterns subsequent to the data used in this study, data from the 
NHS Prescription Pricing Authority indicate that the rate of atypical antipsychotic prescribing 
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in General Practice in England has increased from 21.3% in June 2000 to 61.1% in June 2005 
(NHS Prescription Pricing Authority 2006). These data are not comparable to the GPRD data, 
however, as they include prescribing for indications other than schizophrenia and 
schizoaffective disorder and relate to rates in England only, as compared to the GPRD which 
incorporates data for all of the UK. 
 
 
Factors associated with atypical antipsychotics prescribing 
 
My analysis has been able to identify some significant correlates of prescription choice, 
notably age, previous inpatient stay and previous frequency of primary care consultation. 
 
 
Age 
 
The NICE guidelines issued in 2002 did not suggest that age should be taken into account in 
the prescription choice. The NICE guidelines do recommend that patients whose illness is 
stable on typical antipsychotics should not be switched to atypical antipsychotics. It is 
possible that older patients, having had their illness for a longer period of time (the age of 
onset of schizophrenia being almost always in early adulthood), are more likely to have been 
stabilised on a typical antipsychotic. My model tests for the effect of age separately from time 
since diagnosis, but this effect was not found to be statistically significant. One conclusion 
would thus be that other interpretations of the age effect are warranted. It is the case, however, 
that age and time since diagnosis are significantly correlated (r=0.49 in 1999; p<0.0001), so 
some degree of collinearity cannot be ruled out.  
 
It may be the case that more of the younger patients in the sample are newly diagnosed and 
are more likely to be receiving an initial prescription for atypical antipsychotics. For these 
patients, the NICE guidelines – which obviously postdate the period studied in this paper – 
suggest that atypical antipsychotics should be considered. Alternatively, this result may be 
due to GPs being more defensive in their prescribing to older patients. There have been 
concerns that atypical antipsychotics increase the risk of ischaemic stroke in patients with 
dementia (Wooltorton 2002), and while these concerns were not extended to patients with 
schizophrenia, it may be the case that clinical experience ahead of the formal issue of such 
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warnings affected the prescription choice for GPs prescribing for older patients (Percudani et 
al. 2005). Recent studies have subsequently found no statistically significant increased risk of 
ischaemic stroke for dementia patients taking atypical antipsychotics as compared to typical 
antipsychotics (Gill et al. 2005). 
 
There is also evidence that discrimination may affect the prescribing choice. Studies in the US 
have concluded that ethnic minority patients are less likely to be prescribed atypical 
antipsychotics relative to the general population (Valenti et al. 2003; Opolka et al. 2004). It 
may be the case that similar discrimination occurs against older schizophrenia and 
schizoaffective disorder patients. 
 
 
Inpatient stays in the previous 12 months 
 
The GPRD data indicate that over time, patients with recent inpatient stays were more likely 
to be prescribed atypical antipsychotics. If it is reasonable to assume that inpatient admission 
follows an exacerbation of symptoms, then it can be inferred from this result that, in line with 
the NICE guidance, patients with more severe illness, or whose illness has not been stabilised, 
are more likely to be prescribed atypical antipsychotics. Alternatively, this result may reflect a 
preference of prescribing atypical antipsychotics, for acute patients, by hospital-based 
psychiatrists. The prescription choice would then be continued by the patient’s GP once they 
were discharged from hospital. 
 
A US study by Duggan (2005), on individual patient Medicaid data, found a significant 
increase in the use of inpatient care in the days leading up to an initial prescription for an 
atypical antipsychotic. This suggests that patients were started on atypical antipsychotics as a 
consequence of their previous medication not preventing an acute episode. Therefore, this 
result is not likely to be due to comorbidity, but instead the result of the severity of symptoms 
present in an acute hospital setting. 
 
GP visits in the previous 12 months 
 
Evidence supporting the significance of comorbidity in the prescription choice can be found 
in my result that there is an increased likelihood of atypical prescribing among patients with 
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several recent visits to their GP. For some patients this may be for side-effects experienced as 
a result of their antipsychotic medication.  
 
The setting of care may also be a key factor in the prescription choice. Just as hospital 
psychiatrists may prescribe more atypical antipsychotics as they are often treating acutely ill 
patients, the prescribing of antipsychotics in primary care may be affected by a GP’s 
experiences. Mortimer (2003) suggests that where antipsychotics are prescribed in primary 
care, there may be a preference for using the older typical antipsychotics as GPs are more 
likely to be familiar with these drugs. As the GPRD data are primary care-based, there may be 
a bias in lower rates of atypical antipsychotic prescribing in these data. 
 
 
Significant findings from other studies 
 
Taylor et al (2000), in their study of inpatient prescribing, found an association between 
gender and the use of atypical antipsychotics. They found that men were more likely to 
receive atypical antipsychotics. This result was not substantiated by my analysis: I found no 
significant gender difference. 
 
In reaching treatment decisions, physicians are to some extent influenced by the extent of 
their postgraduate education, the views of local colleagues, staff shortages (encouraging, it 
has been argued, wider use of depot medications), pharmaceutical company advertising, the 
requests of patients and budgetary constraints (Hogman 1996; Bebbington 2001; Hayhurst et 
al. 2003; Walley 2004). For example, despite recommendations against either practice, there 
is evidence that for patients with severe symptoms, psychiatrists often prescribe excessive 
dosages or prescribe more than one antipsychotic (Taylor et al. 2000; Mortimer 2003; Paton et 
al. 2003). Further, there is evidence that in primary care, familiarity with the content of the 
National Service Frameworks in mental health is poor (Rogers et al. 2002). 
 
 
Limitations 
 
This study is potentially limited by the scope and content of the source of data. The GPRD 
includes prescribing data at the outpatient level only. This includes prescribing initiated by the 
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GP or by a specialist in an outpatient setting. The dataset does not include records of hospital 
inpatient prescribing, which may represent a sizeable proportion of antipsychotic prescribing. 
Data from IMS Health on sales of atypical antipsychotics in the United Kingdom indicate that 
in 2002 approximately 33% of prescriptions for atypical antipsychotics were made within 
hospitals (IMS Health 2003). 
 
The analysis of factors impacting on medication choice is limited by the lack of more detailed 
data on the characteristics of patients, and medical practitioners, included in the sample. It has 
been suggested by other UK studies that receipt of an atypical rather than a typical 
antipsychotic is linked to factors such as treatment history and risk of non-adherence 
(Hogman 1996; Mortimer 2003). 
 
 
 
Conclusions 
 
The trend of an increase in the rate of atypical antipsychotic prescribing in schizophrenia, as a 
percentage of all antipsychotic prescribing, is likely to continue, unless clear evidence is 
forthcoming that the side-effects attributable to atypical antipsychotics are more debilitating 
than those associated with typical antipsychotics (Bushe and Leonard 2004). Reductions in 
their real prices, relative to typical antipsychotics, seems likely to encourage GPs to prescribe 
atypical antipsychotics more frequently in preference to the older medications. What is not 
clear is if the rate of increase will be above what was observed prior to the introduction of the 
NICE guidelines. Those guidelines have been welcomed by psychiatrists and patients, the 
majority of whom appear to favour the use of atypical over typical antipsychotics in 
schizophrenia treatment (Patel et al. 2003; Rethink (formerly known as the National 
Schizophrenia Fellowship) 2005). Of course, atypical antipsychotics are not homogeneous in 
their efficacy or side-effect profiles, and so comparisons within the atypical class of 
antipsychotics would be a useful topic for further research. 
 
It is government policy in England to improve access to atypical antipsychotics, based on the 
evidence synthesis and consultations undertaken to inform the NICE review and guidance. 
Further evidence is needed to make more transparent the treatment choices being made by 
physicians. Variability in atypical prescribing rates, evidence of polypharmacy, and empirical 
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results such as those set out in this paper, indicating the use of non-need-based factors in 
antipsychotic drug choice, suggest that prescribing for schizophrenic patients retains elements 
of inconsistency and ambiguity. 
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